PL203554B1 - A streptogramin derivative from group A, a method for producing a streptogramin derivative from group A and a pharmaceutical composition containing a streptogramin derivative from group A - Google Patents

Description

DESCRIPTION OF THE INVENTION The present invention relates to a streptogramin derivative of the group A of the general formula: as well as its acid addition salts, which exhibit particularly interesting antimicrobial activity. The invention also relates to the process for the preparation of such derivatives and to the pharmaceutical compositions containing them. Among the known streptogramins, pristinamy tin (RP 7293) was isolated for the first time in 1955, an antibacterial agent of natural origin, produced by Streptomyces pristinaespiraiis. The pristinamycin commercially available under the name Pyostacine® consists mainly of pristinamycin II A bound to pristinamycin I A. Another antibacterial agent of the streptogramin class, virginiamycin, has been isolated from Streptomyces virginiae, ATS 13161 [Antibiotics and Chemotherapy, 5, 632 (1955)]. Virginiamycin (Staphylomycine®) consists mainly of M1 (VM1) factor bound to S factor (VS). Semisynthetic derivatives of streptogramins with the structure: in which n is 0 to 2, and are known from European patents EP 135,410 and EP 191662. From the international patent application No. WO 99/05165 there are known streptogram derivatives from group A with the general formula: in which R 1 represents the radical -NR'R "or -NR'OR" ", R 2 is hydrogen, methyl or ethyl, and the - - - bond is a single bond or a double bond and which are antibacterial agents. However, these derivatives do not show a particularly high level of activity, and besides, they do not always have the spectrum as broad as would be desired. It has now been found that the streptogramin derivatives from group A of general formula (I), in which: - R 1 is a halogen atom or an azide or thiocyanate radical, - R 2 is a hydrogen atom or a methyl or ethyl radical, - R 3 is a hydrogen atom or residues e of an aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic or heterocyclylaliphatic ester which may be substituted, and the - - - bond denotes a single bond (27R stereochemistry) or a double bond, and their salts, if any, they exhibit a particularly strong antimicrobial activity, either alone or in combination with a group B streptogramin derivative, and optionally also show a broad spectrum compared to the usual streptogramin spectrum. The subject of the invention is a streptogramin derivative from group A of the general formula: in which: - R 1 represents a halogen atom or an azide or thiocyanate radical, - R 2 represents a hydrogen atom or a methyl or ethyl radical, - R 3 represents a hydrogen atom or a R 3 'radical -CO, in which R 3 'is phenyl or phenylalkyl unsubstituted or substituted on the phenyl radical (by one or more radicals selected from alkyl, which optionally contains the radical NR'R ", in which the radicals R' and R" identical or different may be hydrogen atoms or alkyl radicals which may form together with the nitrogen atom to which they are bound, a saturated or unsaturated 3 to 8 membered heterocyclyl radical containing optionally another heteroatom selected from oxygen, sulfur or nitrogen, said heterocycle being itself substituted by one or more radicals (saturated or unsaturated alkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, aryl, heterocyclyl, 3 to 8-membered heterocyclylalkyl or -CH 2 -CO-NR'R ") or R 'and / or R" may be a hydroxyalkyl, phenyl, heterocyclylalkyl, saturated or unsaturated radical of 3 to 8 members, - CO-NR'R "" where NR'R "is either an alkyl or acyl substituted with NR'R" as defined above) or R 3 'may be selected from the phenyl or phenylalkyl radicals substituted by the phenyl radical by one or more radicals (selected from alkyl which may be substituted by an alkoxy or alkylthio radical which may itself optionally contain a carboxyl radical or a radical NR'R "as defined above, or selected from an acyloxy radical, which may be substituted with NR'R ", defined as above), or R 3 'may be selected from an alkyl or cycloalkyl radical, optionally substituted (by a carboxy radical , carboxyalkyldisulfanyl or via the radical NR'R ", -CH 2 -NR'R", -CO-NR'R ", or via the radical alkoxy ycarbonyl, alkoxy or alkyldisulfanyl optionally substituted with NR'R "or -CO-NR'R" "where NR'R" is defined as before), or R 3 'may be selected from saturated or unsaturated heterocyclyl radicals of 3 to 8 moieties optionally substituted (by alkyl or acyl optionally substituted by NR'R ") and a bond - - - denotes a single bond (stereochemistry 27R) or a bond by duality as well as its acid addition salts. Preferably - R 1 is a fluorine, chlorine, bromine or iodine atom or an azide or thiocyanate radical, - R 2 is a methyl radical, - R 3 is a hydrogen atom or a R 3 '-CO radical, in which R 3' is a phenyl or phenylalkyl unsubstituted or substituted on the phenyl radical (by one or more radicals selected from alkyl optionally containing the radical NR'R ", in which the radicals R 'and R", identical or different, may a being hydrogen atoms or alkyl radicals which can form together with the nitrogen atom to which they are bound a heterocyclyl radical, saturated or unsaturated, of 3 to 8 members, possibly containing another heteroatom selected from oxygen, sulfur or nitrogen, said heterocycle being itself substituted with one or more radicals (alkyl, hydroxyalkyl, alkoxyalkyl, alkoxycalrbonylalkyl, aryl, heterocyclyl, heterocyclylalkyl, saturated or unsaturated, 3 to 8 members or -CH 2 -CO-NR'R '') , or R 'and optionally R "hydroxyalkyl, phenyl, heterocyclylalkyl, saturated or unsaturated, 3 to 8 members, -CO-NR'R", where NR'R "is as previously defined, or alkyl or an acyl substituted with NR'R "as defined above, or R 3 'may be a phenyl radical substituted with one or more radicals (selected from alkyl which may be substituted with an alkoxy or an alkylthio radical) alone containing a carboxyl radical or a NR'R '' radical as defined above, or selected from acyloxy radicals which may be substituted with NR'R '', as defined above, or R 3 ' can be chosen from among alkyl or cycloalkyl radicals, optionally substituted (by a carboxylic, carboxylalkyldisulfanyl radical or by the radical NR'R ", CH 2 -R'R", -CO-NR'R "or by the radical alkoxycarbonyl, alkoxy or alkyldisulfanyl, optionally substituted with NR'R ", or -CO-NR'R", wherein NR'R "is as defined above), or R 3 'may be selected from heterocyclyl radicals, saturated or unsaturated, with 3 to 8 members optionally substituted (by alkyl or acyl optionally substituted by NR'R "" itself), it is understood that heterocycles are selected from among pyrrolidinyl, imidazolyl, pyridyl, piperidinyl, piperazinyl or morpholinyl, and - a bond - - - is a single bond (27R stereochemistry) or a double bond. Preferably the derivative is (16R) -16-deoxy-16-fluoropristinamycin IIB. Preferably the derivative is (16R) -16-deoxy-16-thiocyanatopristinamycin IIB. Preferably the derivative is (16R) -16-deoxy-16-chloropristinamycin IIB. Preferably the derivative is (16R) -16-azido-16-deoxypristinamycin IIB. Preferably the derivative is (16R) -16-deoxy-16-fluoropristinamycin IIB. The invention also relates to a process for the preparation of a streptogramin derivative from group A as defined above, which consists in halogenating, converting to azide or converting to thiocyanate a streptogramin derivative of the general formula: in which R 2 is defined as salt as before, the bond - - - means a single bond (27R stereochemistry) or a double bond, and the hydroxyl function of which in position 14 has been previously protected, and then removes the protecting radical and in the given case, in to obtain a streptogramin derivative from group A as defined above, wherein R 3 is other than hydrogen, introduces an aliphatic, cycloaliphatic, aromatic, aryl aliphatic, heterocyclic or heterocyclylaliphatic ester residue e which may be substituted with (R 3) and converted into an acid addition salt if necessary. It is preferable to work in the presence of an aminosulfur trifluoride or in the presence of sulfur tetrafluoride with a reagent such as a halide, nitride or thiocyanate tetraalkylammonium, trialkylammonium or trialalkylbenzylammonium or with the aid of a halide, nitride or an alkali metal, which has been optionally added with a cyclic ether. Preferably, in the case of fluorination, the work is carried out by the action of a fluorinating agent selected from sulfur fluoride, hexafluoropropyl diethylamine or N- (chloro-2-trifluoro-1,1,2-ethyl) diethylamine. Preferably, where appropriate, the esterification is carried out by reaction of the acid or a reactive derivative of the acid in the presence or absence of a coupling agent such as carbodiimide and a tertiary amine, and optionally a catalyst such as 4-N-dimethylaminopyridine. at a temperature of -40 to + 80 ° C, in an organic solvent such as an amide, pyridine, halogenated solvent or an ether. Preferably, the aminosulfur trifluoride can be selected from diethylaminosulfur trifluoride, bis (2-methoxyethyl) amino sulfur trifluoride or morpholino sulfur trifluoride. The invention also relates to a pharmaceutical composition comprising a streptogramin derivative from group A as defined above, either neat or in combination with at least one derivative of a streptogramin group B, in this case in the form of a salt, and / or in combination with one or more pharmaceutically acceptable diluents or adjuvants. Preferably, the streptogramin derivative from group B is selected from among the natural ingredients: pristinamycin IA, pristinamycin IB, pristinamycin IC, pristinamycin ID, pristinamycin IE, pristimycin IF, pristinamycin IG, virginiamycin S1, S3 or S4 or vernamycin B, or vernamycin S1, S3 or S4. , ethamycin or among the semisynthetic derivatives of the general formula: in which: 1) Rb, Rc, Re and Rf are hydrogen atoms, Rd is a hydrogen atom or a dimethylamino radical, and Ra is a radical of the structure -CH 2 R'a in which Ra is a pyrrolidinyl-3-thio, piperidyl-3 (or -4) -thio radical, which may be substituted by alkyl, alkyl substituted with 1 or 2 hydroxysulfonyl, alkylamino, dialkylamino groups (which can themselves and being c optionally substituted with mercapto or dialkylamino groups a) or substituted with 1 or 2 optionally substituted piperazine, morpholine, thiomorpholine, piperidine, pyrrolidinyl-1, piperidyl-2, -3, or -4 or pyrrolidinyl rings -2 or -3 (which may be substituted with alkyl) or Ra is a radical of structure = CHR'a where R'a is a group a pyrrolidinyl-3-amino, piperidinyl-3 (or -4) amino, pyrrolidinyl-3-oxy, piperidyl-3 (or -4) -oxy, piperidyl-3 (or -4) -thio which may be substituted with alkyl, or R'a is an alkylamino group, alkoxy or alkylthio, substituted with 1 or 2 hydroxysulfonyl, alkylamino, dialkylamino groups (themselves optionally substituted with dialkylamino) or with trialkylammonium, imidazolyl-4 or -5, or with 1 or 2 optionally substituted rings piperazine, morpholino, thiomorpholine, piperidino, pyrrolidinyl-1, piperidinyl-1, -3 or -4, or pyrrolidinyl-2 or -3 (which may be substituted with alkyl) or PL 203 554 B1 6 Ra is a quinuclidinyl-3 (or -4) thiomethyl radical or 2) Ra is a hydrogen atom, aa) or Rb, Re and Rf are hydrogen atoms, Rd is -NHCH 3 or -N (CH 3) 2, and Rc is a chlorine or bromine atom or is an alkenyl radical containing from 3 to 5 carbon atoms (if Rd is -N (CH 3) 2), b) or Rb, Rd, Re and Rf are a hydrogen atom, and Rc is halogen or an amino monoalkyl, aminodualkyl, alkoxy, trifluoromethyloxy, thioalkyl, C 1 -C 3 -alkyl or trihalomethyl radical, c) or Rb, Rc, Re and Rf are a hydrogen atom, and Rd is a halogen or a radical ethylamine, diethylamine or methylethylamine, alkoxy or trifluoromethyloxy, thioalkyl, C 1 -C 6 -alkyl, aryl or trihalomethyl, d) or Rb, Re and Rf denote a hydrogen atom and Rc is a halogen or amino monoalkyl radical or aminodualkyl, alkoxy or trifluoromethyloxy, thioalkyl, C 1 -C 3 -alkyl, and Rd is halogen or amino, amino-dialkyl or aminodualkyl, alkoxy or trifluoromethyloxy, thioalkyl, C 1 -C 3 -alkyl or trifluoromethyl, or Rd is halo) Re and Rf stand for a ato m hydrogen, and Rb and Rd represent a methyl radical, or moreover, among the semisynthetic derivatives of the general formula: in which: Y is a nitrogen atom or a radical = CR 3 -, R 1 is a hydrogen atom, up to 8 carbon atoms) alkenyl (2 to 8 carbon atoms), cycloalkyl (3 to 8 carbon atoms), saturated or unsaturated heterocyclyl (3 to 8 carbon atoms), phenyl, phenyl substituted (by one or more halogen atoms or by hydroxyl, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, alkylaminbwe or dialkylamino radicals) or the NR'R '' radical with R 'and R' ', identical or different, they can be hydrogen atoms or alkyl radicals (containing from 1 to 3 carbon atoms) or they can form, together with the nitrogen atom to which they are attached, a heterocyclic ring of 3 to 8 members, optionally containing another heteroatom selected from oxygen, sulfur or optionally e substituted nitrogen (via an alkyl radical, alkenyl (containing from 2 to 8 carbon atoms), cycloalkyl (containing from 3 to 6 carbon atoms), saturated or unsaturated heterocyclyl (containing 4 to 6 members), benzyl, phenyl or a substituted phenyl as defined above for R 1), or when Y is the radical = CR 3 -, R 1 may also be halogenomethyl, hydroxymethyl, alkoxymethyl, alkylthiomethyl in which the alkyl portion is optionally substituted with NR'R ", alkylsulfinylmethyl, alkylsulfonylmethyl, acyloxymethyl, benzoyloxymethyl, cyclopropylaminomethyl or - (CH 2) n NR'R" (where n is an integer from 1 to 4 and R ' and R '' are defined as above), or if R 3 is a hydrogen atom then R 1 can be either formyl, carboxyl, alkoxycarbonyl or - CONR'R ", where R 'and R" are defined as above, or when Y is a nitrogen atom, R 1 may also be a radical -XR °, where X is an oxygen or sulfur atom, the radical sulfinyl or sulfonyl or NH radical, and R ° is an alkyl radical (containing from 1 to 8 carbon atoms), cycloalkyl (containing from (containing from 3 to 6 carbon atoms), saturated or unsaturated heterocyclyl ( 3 to 8 members), heterocyclylmethyl (3 to 8 members), in which the heterocyclyl portion is attached to the methyl radical via an carbon atom, phenyl, phenyl substituted (by one or more halogen atoms or by hydroxyl radicals, alkyl, alkoxy, alkylthio, alkylsulfonyl, alkylsulfonyl, amine, alkylamino or dialkylamino) or the radical "(CH 2) n NR'R '' where R 'and R' 'are defined as above, and n is the number that an integer from 2 to 4, or if X is NH, then R ° may also be c a hydrogen atom, R 2 is a hydrogen atom or an alkyl radical (containing from 1 to 3 carbon atoms), R 3 represents a hydrogen atom or an alkyl, carboxy, alkoxycarbonyl or carbamoyl radical of the structure -CO-NR'R '', k where R 'and R' 'are defined as before, Ra is a methyl or ethyl radical, and Rb, Rc and Rd have the following meanings: 1) Rb and Rc are hydrogen atoms and Rd is a hydrogen atom or a methylamine radical or dimethylamino, 2) Rb is hydrogen, Rc is hydrogen, chlorine or bromine or is alkenyl (containing from 3 to 5 C atoms), and Rd is -NMe-R "", where R "" "denotes a radical; alkyl, hydroxyalkyl (containing from 2 to 4C) or alkenyl (containing from 2 to 8C) optionally substituted with phenyl, cycloalkylmethyl (containing from 3 to 6C in the cycloalkyl group), benzyl, benzyl substituted (with one or more halogen atoms or hydroxy, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amine, alkylamino or dialkylamino), heterocyclylmethyl or heterocyclylethyl radicals, in which the heterocyclyl part is saturated or unsaturated and contains from 5 to 6% 1 or 2 heteroatoms selected from sulfur, oxygen or nitrogen optionally substituted with an alkyl, alkenyl radical (containing from 2 to 8 carbon atoms), cycloalkyl (containing from 3 to 6 carbon atoms), saturated or unsaturated heterocyclyl (4- to 6-membered), phenyl, substituted phenyl as previously defined for R 1, or benzyl), or R "" is cyanomethyl or -CH 2 CORe, where either Re is - OR'e, where R'e is hydrogen, alkyl (having 2 to 6 carbon atoms), benzyl or heterocyclylmethyl where the heterocyclyl part is 5 or 6 members and 1 or 2 heteroatoms selected from sulfur, oxygen or nitrogen, or Re is an alkylamino, alkylmethylamino, heterocyclylamino or heterocyclylmethylamino radical in which the heterocyclyl portion is saturated and contains 5 or 6 units and 1 or 2 heteroatoms selected from sulfur, oxygen or nitrogen optionally substituted with an alkyl, benzyl or alkoxycarbonyl radical, 3) Rb is hydrogen, Rd is -NHCH 3 or -N (CH 3) 2 and Rc is chlorine or bromine or is an alkenyl radical (containing from 3 to 5 C) (if Rd is -N (CH 3) 2, 4) Rb and Rd are hydrogen atoms and Rc is halogen, or alkylamino or dialkylamino, alkoxy, trifluoromethoxy, thioalkyl, alkyl (containing from 1 to 6 C) or three ifluoro-comethyl, 5) Rb and Rc are hydrogen atoms, and Rd is halogen or ethylamine, diethylamine or methylethylamine, alkoxy or trifluoromethoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkyl (contain aces from 1 to 6 C), phenyl or trihalomethyl, 6) Rb is a hydrogen atom and Rc is a halogen atom, or an alkylamino or di-alkylamino, alkoxy or trifluoromethoxy, thioalkyl, alkyl (containing aces from 1 to 3 C) and Rd is a halogen atom or an amino radical, alkylamino or dialkylamino, alkoxy or trifluoromethoxy, thioalkyl, alkyl (containing from 1 to 6 C) or trihalomethyl, 7) Rc is hydrogen and Rb and Rd represent a methyl radical as well as their salts. According to the invention, when R 1 is halogen, it may be selected from fluorine, chlorine, bromine or iodine when the radical R 3 is an aliphatic, cycloaliphatic, aromatic, aryl aliphatic, heterocyclic or heterocyclylaliphatic ester residue e. which may be substituted, the latter may be chosen by way of example from the radicals R 3 '-CO-, in which R 3' is phenyl or phenylalkyl unsubstituted or substituted on the phenyl radical (by one or more radicals selected from alkyl optionally containing the radical NR'R ", in which the radicals R 'and R", identical or different, may be hydrogen atoms or alkyl radicals, which they can form, together with the nitrogen atom to which they are bound, a saturated or unsaturated heterocyclyl radical of 3 to 8 parts and possibly another heteroatom selected from oxygen, sulfur or nitrogen, said heterocycle being itself to be c substitute by one or more radicals (alkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, aryl, heterocyclyl, heterocyclylalkyl, saturated or unsaturated, with 3 to 8 members, or -CH 2 CO-NR'R " ), or R 'and optionally R "may be a saturated or unsaturated hydroxyalkyl, phenyl, heterocyclylalkyl radical, 3 to 8 members, -CO-NR'R", in which NR'R " is defined as before, either an alkyl or acyl substituted by NR'R "defined as above), or R '3 may be selected from a phenyl or phenylmethyl radical substituted on the phenyl radical by one or more the radicals (selected from alkyl which may be substituted by an alkoxy radical or an alkylthio radical which may itself contain a carboxyl radical or a radical NR'R "as defined above, or selected from acyloxy radicals which may be substituted with an NR'R '' radical as defined previously), or R '3 may be selected from an alkyl or cycloalkyl radical, optionally substituted (by a carboxyl, carboxyalkyl disulfanyl radical or by a radical NR'R ", -CH 2 -NR'R", -CO-NR'R' 'either by an acoxycarbonyl, alkoxy or alkylsulfanyl radical optionally substituted with NR'R "or -CO-NR'R", where NR'R "is defined as previously), or R 3' may be selected Among heterocyclyl radicals, saturated or unsaturated, 3 to 8 members, optionally substituted (by alkyl or acyl, themselves optionally substituted with NR'R "). In general formula (I), apart from the special mention, alkyl or acyl radicals or moieties are straight or branched and contain from 1 to 12 carbon atoms, heterocyclyl radicals being selected from among pyrrolidinyl, pyrrolyl , furyl, thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyrazanyl, pyrimidinyl, pyridazinyl, imidazolidinyl, aryl radicals can be selected especially from among optionally substituted phenyl, especially alkyl, phenyl groups alkoxy, halogen or -CH 2 OH - (CH 2) n NH 2 - (CH 2) n -NHalkyl or - (CH 2) n N (alkyl) 2. Streptogramin derivatives of general formula (I) can be obtained by halogenation, conversion to azide or conversion to thiocyanate of a streptogramin derivative by the general formula: where R2 is defined as before, and the bond is a single bond (stereochemistry 27R) or a double bond and in which the hydroxyl function in position 14 has previously been protected, followed by removal of the protecting radical and, if appropriate, to obtain a derivative of general formula (I), wherein R 3 is non-hydrogen, introducing an aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic or heterocyclylaliphatic ester residue which may be substituted for (R 3) by conventional methods which do not alter the rest of the molecule. Halogenation, azide or thiocyanate conversion reactions can be carried out in the presence of aminosulfur trifluoride (e.g. diethylaminosulfur trifluoride, bis (2-methoxyethyl) aminosulfur trifluoride (Deoxofluor), morpholinesulfur trifluoride) or alternatively sulfur tetrafluoride with a reagent such as a tetraalkylammonium halide, nitride or thiocyanate, trialkylbenzylammonium or trialkylphenylammonium or trialkylphenylammonium, or with an alkali metal halide, nitride or thiocyanate with the optional addition of a cyclic ether. Fluorination reactions can also be carried out by the action of a fluorinating agent, such as sulfur fluoride [for example, morpholino-sulfur trifluoride, sulfur tetrafluoride (J. Org. Chem, 40, 3808 (1975)), diethylaminosulfur trifluoride (Tetrahedron, 44, 2875 (1988)), bis (2-methoxyethyl) aminosulfur trifluoride (Dioxofluor®). The fluorination reactions can alternatively be carried out with a fluorinating agent such as hexafluoropropyl diethylamine (JP 2 039 546) or N- (2-chloro-1,1,2-trifluoroethyl) diethylamine. When a tetraalkylammonium halide, nitride or thiocyanate is used, the latter may be chosen, for example, from tetramethylammonium, tetraethylammonium, tetraethylammonium, tetra-butylammonium (e.g., tetra-n-butylammonium) halides, nitrides or thiocyanates (e.g. tetra-n-butylammonium). , tetrabutylmethylammonium, triethylmethylammonium, tetrabutylmethylammonium or trimethylpropylammonium. The reaction is carried out in an organic solvent such as a fluorinated solvent (for example dichloromethane, dichloroethane, chloroform) or in ether (for example tetrahydrofuran) at a temperature ranging from -78 to 40 ° C (preferably from 0 to 30 ° C). It is preferable to carry out the reaction under an argon or nitrogen atmosphere. It is understood that the use of a hydroxyl derivative with the (16S) configuration leads to the derivative with the (16R) configuration. The protection and de-protection of the hydroxyl radical in position 14 is carried out by conventional methods which have no effect on the rest of the molecule, in particular the methods described by T. IN. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis (2nd edition), A. Wiley - Interscience Publication (1991), or by McOmie, Protective Groups in Organic Chemistry, Plum Press (1973). For example, one works by protecting it with a trialkylsilyl, alkyl diphenylsilyl radical (for example t-butyldiphenylsilyl and t-butyldimethylsilyl) or allyl, which is put into place and removed as further described in the examples. Wherever it is required to obtain a product of general formula (I), in which R 3 is an aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic or heterocyclylaliphatic ester which may be substituted, the further esterification operation is carried out in the usual manner in some ways that do not change the rest of the part. More precisely, the esterification is carried out by reacting an acid or a reactive acid derivative (e.g., acid chloride, reactive ester, anhydride) in the presence or absence of an interfering agent such as a carbodiimide (e.g., dicyclohexylcarbodiimide), and a tertiary amine (a trialkylamine such as triethylamine or diisopropylethylamine or pyridine or a derivative thereof) and optionally a catalyst such as 4-N-dimethylaminopyridine at -40 to + 80 ° C in an organic solvent such as such as an amide (e.g. dimethylformamide or N-methyl-2-pyrrolidinone), pyridine, a halogenated solvent (e.g. dichloromethane, dichloroethane or chloroform) or an ether (tetrahydrofuran, dioxane, dimethoxyethane). It is understood that functional groups which may interfere with the reaction are first protected and then released after the reaction. The acid used or the reactive derivative of the acid is obtained as described in the examples hereinafter or in analogy to the methods described. The dihydroxy derivative of streptogramin from group A of the general formula (II) can be obtained by the method of selective reduction of the natural pristinamycin component of the general formula: where R 2 is defined as above, and the bond - - - denotes a bond single (27R stereochemistry) or double bond followed by separation of the 16S epimeric form. The reduction is preferably carried out in the presence of a reducing agent such as an alkali metal borohydride, for example sodium borohydride or sodium triacetoxyborohydride, in an organic solvent selected from among the fluorinated solvents (for example di-chloromethane, dichloroethane, , chloroform), tetrahydrofuran, acetic acid and alcohols such as methanol, ethanol or 2-propanol at -78 to 40 ° C. The separation of the 16R epomeric form and the 16S epimeric form is carried out by known methods. For example, separation of epimeric forms can be accomplished by chromatography, flash chromatography, high performance liquid chromatography (HPLC), or not on a chiral phase, or by vortex partition (CPC) chromatography starting from a mixture of 16R and 16S epimers, or the way of crystallization. (16S) -16-Hydroxypristinamycin II A can be obtained especially according to F. Le Goffic et al. , Eur. J. Med. , Chimica Therapeutica, Jan-Feb, 16 (1), 69-72 (1981). Pristinamycin derivatives of general formula (III) correspond respectively to pristinamycin IIA (PIIA), pristinamycin IIB (PIIB), pristinamycin IIC (PIIC), pristinamycin IID (PIID), pristinamycin IIF (PIIF) and pristinamycin IIG (PIIG), which are known constituents of natural pristinamycin. The components PIIF and PIIG are known from European Patent No. EP 614910. Pristinamycin IIC (PIIC) and pristinamycin IID (PIID) can be obtained as described by J. C. Barri cre et al. , Expert. Opin. Invest. Drugs, 3 (2), 115-31 (1994). The preparation and separation of the natural components of streptogramins from the group A (streptogramins of the general formula (III)) is carried out by fermentation and isolation of the components of the fermentation broth according to or analogously to the method described by J. Preud'homme et al. , Bull. Soc. Chim, Fr. , vol. 2, 585 (1968), or from EP 614910. Alternatively, the preparation of the natural ingredients of group A can be carried out by specific fermentation in the manner known from French Patent Specification No. FR 2 689 518. The streptogramin derivatives of general formula (I) can be purified, where appropriate, by physical methods such as crystallization, chromatography or CPC. Some streptogramin derivatives of general formula (I) can be converted into acid addition salts by known methods. As examples of addition salts with pharmaceutically acceptable acids, mention may be made of salts formed with mineral acids (hydrofluorides, hydrobromides, sulfates, nitrates, phosphates) or with organic acids (succinates, fumarates, tartrates, acetates, propionates, maleates, citrates, methanesulfonates, ethanesulfonates, phenylsulfonates, p-toluenesulfonates, isethionates, naphthalenesulfonates, or camphorsulfonates, or with substituted derivatives of these compounds). The streptogramin derivatives according to the present invention have both antibacterial properties and a tendency that synergize with the antibacterial activity of the streptogramin derivatives from group B. They are of particular interest, either alone or in combination, thanks to their strong activity. When they are associated with a component or derivative from group B of streptogramins, the latter can be selected depending on whether an orally or parenterally administered form is required, among the natural ingredients: pristinamycin, pristinamycin IB, pristinamycin IC, pristinamycin ID, pristinamycin IE, pristinamycin IF, pristinamycin IG, virginiamycin S1, S3 or S4, vernamycin B or C, etamycin or among semisynthetic derivatives such as are known from US 4,618,52799, US 5,729,882,799, US 5,729,882. , EP 772 630 or EP 770132, in particular streptogramin derivatives of the general formula: in which: 1. Rb, Rc, Re and Rf are hydrogen, Rd is a hydrogen atom or a dimethylamino radical, and Ra is a radical of the structure -CH 2 R'a, in which R'a is a pyrrolidinyl-3-thio group, piper- dynyl-3- (or -4) -thio, which may be alkyl-substituted, alkylthio substituted with 1 or 2 hydroxysulfonyl, alkylamino, dialkylamino (themselves optionally substituted with mercapto or dialkylamino) or substituted with 1 or 2 optionally substituted piperazine rings, morpholino, thiomorpholino, piperidinyl, pyrrolidinyl-1, piperidin-2, -3 or -4 or pyrrolidinyl-2 or -3 (which may be substituted with alkyl), or Ra is a radical of structure = CHR'a where R'a is a group a pyrrolidinyl-3-amino, piperidinyl-3 (or -4) amino, pyrrolidinyl-3-oxy, piperidyl- 3 (or -4) -oxy, piperidyl-3 (or -4) -thio which may be alkyl substituted or R'a is an alkylamino, alkyloxy or alkylthio group, substituted with by 1 or 2 hydroxysulfonyl, alkylamino, dialkylamino groups (themselves optionally substituted with dialkylamino) or by e trialkylammonium, imidazolyl-4 or -5, or by 1 or 2 optionally substituted piperazine rings, morpholino groups , thiomorpholino, piperidino, pyrrolidinyl-1, piperidinyl-1, -3 or -4, or pyrrolidinyl-1 or -3 (which may be substituted with alkyl), or Ra is a quinuclidinyl-3 (or -4) radical ) thiomethyl or 2. Ra is hydrogen, aa) or Rb, Re and Rf are hydrogen, Rd is -NHCH3 or, and Rc is chlorine or bromine, or is alkenyl with 3 to 5 carbon atoms (if Rd is -N (CH 3) 2. b) or Rb, Rd, Re and Rf are a hydrogen and Rc is halogen or amino monoalkyl, amino dialkyl, alkoxy, trifluoromethyloxy, thioalkyl, C 1 -C 3 -alkyl or trifluoroccomethyl, c) or Rb, Rc, Re and Rf are a hydrogen atom, and Rd is a halogen or an ethylamine, diethylamine or methylethylbamine, alkoxy or trifluoromethyloxy, C1-C6-thioalkyl, aryl or trifluoromethyl radical, d) or Rb, Re and Rf is a hydrogen atom, and Rc is halogen or amino-dialkyl or aminodualkyl, alkoxy or trifluoromethyloxy, thioalkyl, C 1 -C 3 -alkyl, and Rd is halogen or amino, amino-dialkyl or aminodualkyl, alkoxomethyl, or trifluoroalkyl radical , C 1 -C 6 -alkyl or trihalomethyl, e) or Rc, Re and Rf represent a hydrogen atom, and Rb and Rd represent a methyl radical, or moreover, among the semisynthetic derivatives of streptogramins from group B of the general formula: which m: Y is nitrogen or = CR 3 -, R 1 is hydrogen, alkyl (1 to 8 carbon atoms), alkenyl (2 to 8 carbon atoms) , cycloalkyl (containing from 3 to 8 carbon atoms), saturated or unsaturated heterocyclyl (containing from 3 to 8 members), phenyl, phenyl substituted (by one or more halogen atoms or by hydroxyl, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amine, alkylamino or dialkylamino) or the radical NR ', R' ', where R' and R '', identical or different, may be hydrogen atoms or alkyl radicals (containing from 1 to 3 carbon atoms) or may form, together with the nitrogen atom to which they are attached, a 3 to 8 membered heterocyclic ring, optionally containing another heteroatom selected from oxygen, sulfur or optionally substituted nitrogen (via an alkyl radical, alkenyl (containing from 2 to 8 carbon atoms), cycloalkyl (with 3 to 6 carbon atoms), saturated or unsaturated (4 to 6 membered) heterocyclyl, benzyl, phenyl or substituted phenyl as defined above for R 1), or when Y is the radical = CR 3 -, then R 1 may be halo methyl, hydroxymethyl, alkoxymethyl, alkylthiomethyl, the alkyl portion of which is optionally substituted with NR'R ", alkylsulfinylmethyl, alkylsulfonylmethyl, acyloxymethyl, benzoyloxymethyl, cyclopropylaminomethyl or - ( -N (CH 3) 2 NR'R "(where n is an integer from 1 to 4, a; R 'and R' 'are defined as above), or if R 3 is hydrogen then R 1 can be either formyl, carboxyl, alkyloxycarbonyl or -CONR'R ", where R' and R are defined as above, or when Y is a nitrogen atom, R 1 may also be the radical -XR °, where X is an oxygen or sulfur atom, a sulfinyl or sulfonyl radical, or an NH radical, and R ° is an alkyl radical (containing from 1 to 8 carbon atoms), cycloalkyl (containing from 3 to 6 carbon atoms), saturated or unsaturated heterocyclyl (3 to 8 members), heterocyclylmethyl (3 to 8 parts) anne), in which the heterocyclyl moiety is attached to the methyl radical through an atomic atom, phenyl, phenyl substituted (by one or more halogen atoms or by hydroxyl, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino radicals) , alkylamino or di-alkylamino) or the radical -N (CH 3) n NR'R '', where R 'and R' 'are defined as above, an oz is an integer from 2 to 4, or if X is NH, then R ° may also be c a hydrogen atom, R 2 is a hydrogen atom or an alkyl radical (containing from 1 to 3 carbon atoms), R 3 represents a hydrogen atom or an alkyl, carboxyl, alkyloxycarbonyl or carbamoyl radical of the structure -CO-NR'R "", where R 'and R "are as previously defined, Ra is a methyl or ethyl radical, and Rb, Rc and Rd have the following meanings: 1) Rb and Rc are hydrogen atoms, and Rd is a hydrogen atom or a methylamino radical, or (p dimethylamino, 2) Rb is a hydrogen atom, Rc is a hydrogen, chlorine or bromine atom or is a radical al - kenyl (containing from 3 to five C atoms), and Rd is the radical -NMe-R "", in which R "" is an alkyl, hydroxyalkyl radical (containing from 2 to 4 C) or alkenes (containing from 2 to 8 C) optionally substituted with phenyl, cycloalkylmethyl (containing from 3 to 6 C in the cycloalkyl group), benzyl, benzyl substituted (by one or more halogen or hydroxyl, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amine, alkylamino or dialkylamino radicals), heterocyclylmethyl or heterocyclylethyl in which some of the heterocyclyl is saturated or unsaturated and contains 5 to 6 parts lons and 1 or 2 heteroatoms selected from sulfur, oxygen or nitrogen optionally substituted with an alkyl, alkenyl radical (containing from 2 to 8 carbon atoms), cycloalkyl (containing from 3 to 6 carbon atoms), saturated or unsaturated rocyclyl (4 to 6 units), phenyl, substituted phenyl as previously defined for R 1, or benzyl), or R "" is cyanomethyl or -CH 2 CORe, where either Re is - OR'e wherein R'e is hydrogen, alkyl (having 2 to 6 carbon atoms), benzyl or heterocyclylmethyl wherein the heterocyclyl portion is 5 or 6 units and 1 or 2 heteroatoms selected from sulfur, oxygen or nitrogen, or Re is an alkylamino, alkylmethylamino, heterocyclylamino or heterocyclylmethylamino radical in which the heterocyclyl moiety is saturated and contains 5 or 6 units and 1 or 2 heteroatoms selected from sulfur, oxygen or nitrogen optionally substituted with an alkyl, benzyl or alkyloxycarbonyl radical, 3) Rb is a hydrogen atom, Rd is a -NHCH 3 or -N (CH 3) 2 radical, and Rc is a chlorine or bromine atom or is an alkenyl radical (containing aces from 3 to 5 C) (if Rd is -N (CH 3) 2) 4) Rb and Rd are hydrogen atoms and Rc is halogen, or alkylamino or dialkylamino, alkoxy, trifluoromethoxy, thioalkyl, alkyl ( containing from 1 to 6 C) or trifluoromethoxy, 5) Rb and Rc are hydrogen atoms, and Rd is a halogen atom or an ethylamine, diethylamine or methylethylamine, alkoxy or trifluoromethoxy, alkylthio, alkylsulfinyl, alkylsulfo radicals nyl, alkyl (containing from 1 to 6 C), phenyl or trihalomethyl, 6) Rb is a hydrogen atom, Rc is a halogen atom or an alkylamino or dialkylamino radical, alkoxy or trifluoromethoxy, thioalkyl, alkyl (containing aces 1 to 3 C) and Rd represents a halogen atom or an amino, alkylamino or dialkylamino radical, alkoxy or trifluoromethoxy, thioalkyl, alkyl (containing from 1 to 6 C) or trihalomethyl, 7) Rc is a hydrogen atom, and Rb and Rd are a methyl radical as well as their salts. It is also understood that the present invention also includes associations of derivatives according to the invention and streptogramins from group B. Derivatives from group B of streptogramins of structure (B) can be obtained by methods known in the international patent specification No. PCT / FR99 / 00409. The streptogramin derivatives according to the invention proved to be active in vitro against Staphylococcus au- reus 209 P at concentrations from 0.015 to 32 µ / ml, either alone or in combination with a derivative of group B, such as pristinamycin IB, and using ranging from 0.015 to 32 μg / ml on Staphylococcus aureus Schiclia (methicillin resistant), alone or in combination with pristinamycin IB, in vivo, and they produce synergies with the antimicrobial activity of pristinamycin IB against infections up to experimental mice on Staphylococcus ureus lP8203 at doses ranging from 5 to 150 mg / kg s.c. (DC 50) a; most of them are taken orally, at doses ranging from 30 to 150 mg / kg (DC 50). Finally, the products according to the invention are of particular interest due to their low toxicity. None of the products showed toxicity in mice at doses of 150 mg / kg on Staphylococcus aureus TP8203, twice daily, either subcutaneously or orally. Particularly interesting are the products of general formula (I) in which: R 1 represents a fluorine, chlorine, bromine or iodine atom or an azido or thiocyanate radical, R 2 represents a methyl radical, R 3 represents a hydrogen atom or a R 3'-CO radical - in which R 3 'is a phenyl or phenylalkyl unsubstituted or substituted on the phenyl radical (by one or more radicals selected from among alkyl optionally containing the radical NR'R ", in which R' and R" ", identical or different, they may be hydrogen atoms, or alkyl radicals may form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocyclyl radical of 3 to 8 members, possibly containing another heteroatom selected among oxygen, sulfur or nitrogen, said heterocycle itself being substituted by one or more radicals (alkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, aryl, heterocyclyl, 3 to 8 membered saturated or unsaturated heterocyclylalkyl alkyl) bo -CH 2 -CO-NR'R ''), or R 'and optionally R' 'may be a hydroxyalkyl radical, phenyl, 3 to 8 unsaturated heterocyclylalkyl, -CO-NR'R '' where NR'R 'is defined as previously, either an alkyl or acyl substituted by NR'R' 'as defined above), or R' 3 may be a phenyl radical substituted with one or more radicals (selected from alkyl which may be substituted with alkoxy or alkylthio radicals which themselves contain either a carboxyl radical or a NR'R '' radical as defined above, or selected from acyloxy groups which may be be substituted by NR'R '' defined as above), or R3 'may be selected from among alkyl or cycloalkyl radicals optionally substituted (by a carboxylic, carboxylalkyldisulfanyl radical or by a NR'R' 'radical , -CH 2 -NR'R ", -CO-NR'R" or by an alkoxycarbonyl, alkoxy or alkyldisulfanyl radical optionally substituted with pr with NR'R 'or -CO-NR'R' ', where NR'R' 'is defined as before) or R 3' may be selected from saturated or unsaturated heterocyclyl radicals by 3 up to 8 members, and optionally substituted (by alkyl or acyl, optionally themselves substituted by NR'R "", heterocycles being understood to be selected from among pyrrolidinyl, imidazolyl, pyridyl, piperidinyl, piper - zinyl or morpholinyl, and - a bond - - - denotes a single bond (stereochemistry 27R) or a double bond, as well as their salts, if any, and among these products in particular: - (16R) - 16-deoxy-16-fluoropristinamycin II B, PL 203 554 B1 14 - (16R) -16-deoxy-16-thiocyanatopristinamycin II B, - (16R) -16-deoxy-16-chloropristinamycin II B, - (16R) - 16-azido-16-deoxypristinamycin II B, - (16R) -16-deoxy-16-fluoropristinamycin II A. The invention is illustrated by the following non-limiting examples. In the following examples, the nomenclature 16-deoxypristinamycin IIA (or IIB) is the replacement of the ketone functionality at position 16 with 2 hydrogen atoms. As the chromatography progressed, all fractions were analyzed by thin layer chromatography (CCM) on Merck 60F254 silica plates. Fractions corresponding to the same spot in CCM are grouped and then concentrated to dryness under reduced pressure (30 ° C, 2.7 kPa). The residue thus obtained is analyzed by conventional spectroscopic techniques (NMR, IR, MS), which allows the identification of the expected product. Example 1 (16R) -16-Deoxy-16-fluoropristinamycin II B To 1.12 g of (16R) -16-deoxy-16-fluoro-14-O- (tert-butyldiphenylsilyl) pristinamycin II B in solution 10 cm 2 of tetrahydrofuran are added at a temperature of 20 ° C, under an argon atmosphere, 0.2 cm 3 of acetic acid and 0.6 g of tetra-n-butylammonium fluoride trihydrate. After 168 hours of stirring, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) to obtain 1 g of a brown oil which is purified by flash chromatography [eluent: dichloromethane / methanol / acetonitrile (90/5/5 ethical vol.)]. 0.3 g of (16R) -16-deoxy-16-fluoropristimycin is obtained as a light beige solid with a melting point of approximately 125 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.00 (d , J = 6.5Hz, 3H), 1.55-2.05 (m, 5H), 1.83 (s, 3H), 2.10-2.30 (m, 2H), 2.98 (m , 1H), 3.21 (m, 1H), 3.48 (m, 1H), 3.87 (m, 1H), 4.55 (m, 1H), 4.75-4.90 (m, 3H), 5.14 (reduced doublet, J HF = 48 Hz, 1H), 5.39 (d, J = 9 Hz, 1H), 5.71 (m, 1H), 5.82 (dd, J = 17 and 2Hz, 1H), 6.00 (m, 1H), 6.21 (d, J = 16Hz, 1H, 6.52 (dd, J = 17 and 5Hz, 1H), 8.12 (s, 1H) . (16R) -16-Desoxy-16-fluoro-14-O- (tert-butyldiphenylsilyl) pristinamycin II B can be prepared as follows: Up to 2 g of (16S) -16-hydroxy-14-O- ( tert-butyldiphenylsilyl) pristinamycin II B in a 50 ml solution of dichloromethane is slowly added at 20 ° C under an argon atmosphere of 0.464 ml of diethylaminosulfur trifluoride. After stirring for two hours, the reaction mixture is poured onto 100 cm 3 of a saturated aqueous solution of sodium hydrogen carbonate. The organic phase is decanted, washed twice with 100 cm 3 of water, dried over magnesium sulphate, filtered, and then concentrated to dryness under reduced pressure (2.7 kPa), obtaining 2.1 g of a solid substance a funnel with an ocher color, which is purified by flash chromatography (eluent: gradient dichloromethane / acetonitrile / methanol (100/0/0, 99 / 0.5 / 0.5, then 98/1/1 vol eto sabotage)]. 1.35 g of (16R) - -16-deoxy-16-fluoro-14-O- (tert-butyldiphenylsilyl) pristinamycin II B are obtained as a colorless solid with a melting point of about 116 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 0.99 (d, J = 6.5 Hz, 3H), 1.00-1 , 15 (m, 12H), 1.29 (s, 3H), 1.55-1.95 (m, 4H), 1.96 (m, 1H), 2.13 (m, 1H), 2. 24 (m, 1H), 2.76 (m, 1H), 2.85 (m, 1H), 3.03 (m, 1H), 3.39 (m, 1H), 3.80 (m, 1H ), 4.01 (m, 1H), 4.57 (m, 1H), 4.72 (m, 1H), 4.75-4.85 (m, 2H), 5.01 (reduced doublet, J HF = 48Hz, 1H), 5.38 (d, J = 9Hz, 1H), 5.50 (m, 1H), 5.81 (dd, J = 17 and 2Hz, 1H), 5.97 (m, 1H), 6.10 (d, J = 15.5 Hz, 1H), 6.49 (dd, J = 17 and 5 Hz, 1H), 7.30-7.50 (m, 6H), 7.63 ( broad d, J = 7 Hz, 2H), 7.68 (broad d, J = 7 Hz, 2H), 8.08 (s, 1H). (16S) -16-Hydroxy-14-O- (tert-butyldiphenylsilyl) pristinamycin II B can be obtained as follows: Up to 22 g of (16S) -16-hydroxypristinamycin II B in solution in 200 cm 3 of dichloromethane is added 29 ml of diisopropylethylamine, 43.2 ml of tert-butyldiphenylchlorosilane, and 1.01 g of 4-dimethylaminopyridine are dropwise at 20 ° C under argon. After stirring for 22 hours, the reaction mixture is poured onto 600 cm 3 of a saturated aqueous solution of sodium hydrogen carbonate. The organic phase is decanted and then extracted twice with 100 cm 3 of dichloromethane. The organic phases are collected, washed with 400 cm 3 of a saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa), obtaining 70.6 gg a fine orange oil which is stirred for 16 hours in 600 cm 3 of diisopropyl ether. After filtration and drying under reduced pressure (2.7 kPa) at 20 ° C, 28 g of (16S) -16-hydroxy-14-O- (tert-butyl-diphenylsilyl) pristinamycin II B are obtained in as a pink solid, m.p. 133 ° C (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.95 (d, J = 6.5 Hz, 3H), 1.00-1.05 (m, 9H), 1.08 (s, 9H ), 1.40-1.80 (m, 3H), 1.90-2.15 (m, 3H), 2.23 (broad d, J = 14Hz, 1H), 2.75 (m, 1H) , 2.83 (dd, J = 17 and 11Hz, 1H), 3.10 (dd, J = 17 and 2.5Hz, 1H), 3.25 (m, 1H), 3.60-3.75 ( m, 2H), 4.49 (m, 1H), 4.56 (m, 1H), 4.60-4.70 (m, 2H), 4.87 (m, 1H), 5.74 (dd , J = 17 and 2 Hz, 1H), 5.78 (d, J = 9 Hz, 1H), 5.95 (m, 1H), 6.04 (d, J = 16 Hz, 1H), 6.41 (dd , J = 17 and 4 Hz, 1H), 7.30-7.50 (m, 6H), 7.64 (dd, J = 7 and 1.5 Hz, 2H), 7.69 (dd, J = 7 and 1.5 Hz, 2H), 8.11 (s, 1H). (16S) -16-Hydroxypristinamycin II B can be obtained as follows: A suspension of 11.35 g of sodium borohydride in 550 cm 3 of dichloromethane is heated under reflux for 20 minutes and then added dropwise for about 30 minutes 68.6 cm 3 of acetic acid, then for about 45 minutes a solution (previously dried over sodium sulphate) of 52.75 g of pristinamycin II B in 230 cm 3 of dichloromethane. The reaction mixture is stirred for 4.5 hours under reflux and then for 16 hours at 20 ° C. Subsequently, 500 cm 3 of dichloromethane and 1500 cm 3 of water are added to the reaction mixture. The organic phase is decanted and the aqueous phase is extracted with 500 cm 3 of dichloromethane. The organic phases are combined and the pH is adjusted to 8 by slowly adding 1000 cm 3 of a saturated aqueous sodium hydrogen carbonate solution. The obtained organic phase is washed successively with 1000 cm 3 of water and 1000 cm 3 of an aqueous saturated solution of sodium chloride, and then mixed with 3S in charcoal, dried over sodium sulphate, filtered and concentrated to dryness under reduced pressure. - with (2.7 kPa) to give 50 g of a light yellow solid. 378 cm3 of 0.5M aqueous ammonium hydroxide solution are added to a solution of this solid in 900 cm 3 of dichloromethane at 20 ° C. After stirring for 16 hours at 20 ° C, the organic phase is poured off, washed with 1000 cm 3 of water and then with 1000 cm 3 of a saturated aqueous sodium chloride solution, dried over sodium sulphate, filtered and concentrated. under reduced pressure (2.7 kPa) to obtain 46 g of a light yellow solid, which was purified by flash chromatography [eluent: dichloromethane / methanol gradient (98/2 and 97/3 vol. )]. 31.68 g of (16S) -16-hydroxypristinamycin II B are obtained in the form of a crushed colorless solid with a melting point of approximately 131 DEG C. (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.02 (d, J = 6.5 Hz, 3H), 1.07 (d , J = 6.5Hz, 3H), 1.70-1.90 (m, 3H), 1.76 (s, 3H), 1.97 (m, 2H), 2.12 (m, 1H), 2.26 (broad d, J = 14.5Hz, 1H), 2.56 (d, J = 3Hz, 1H), 2.76 (m, 1H), 2.90 (dd, J = 16 and 10Hz, 1H), 3.08 (dd, J = 16 and 3Hz, 1H), 3.35 (m, 1H), 3.82 (m, 2H), 3.99 (d, J = 2.5Hz, 1H) , 4.40-4.55 (m, 2H), 4.65-4.75 (m, 2H), 5.03 (m, 1H), 5.65-5.85 (m, 3H), 6 . 01 (m, 1H), 6.21 (d, J = 16 Hz, 1H), 6.46 (dd, J = 17 and 5 Hz, 1H), 8.13 (s, 1H). Example 2 (16R) -16-Deoxy-16-fluoropristinamycin II B Up to 257 g (16R) -16-deoxy-16-fluoro-14-O- (tert-butyldimethylsilyl) pristinamycin II B in solution at 2500 cm 3 of dichloromethane are slowly added over 40 minutes at 40 ° C under argon to 970 cm 3 of triethylamine trifluorohydride. After two hours of stirring at 40 ° C, the reaction mixture is cooled to 8 ° C and then hydrolyzed by slowly adding 1940 cm 3 of water over 25 minutes. After 10 minutes of stirring, the organic and aqueous phases are decanted and the boundary layers are extracted with as much as 4000 cm3 of water and 1000 cm3 of dichloromethane. After mixing the two phases, the organic phases are decanted, the aqueous phases are combined and then extracted with up to 1000 cm 3 of dichloromethane. The organic phases are combined and added to 1500 cm 3 of water. The pH value of the aqueous phase is adjusted to 7 by a slow addition of 400 cm 3 of a saturated aqueous sodium hydrogen carbonate solution over 15 minutes at 10 ° C. The organic phase is decanted, diluted with 1500 cm 3 of ethyl acetate and then washed with 1000 cm 3 of water. The organic phase is decanted, the aqueous phase is extracted twice with 1500 cm 3 of ethyl acetate and then filtered through Celite® on a sintered glass filter. Celite® is rinsed 3 times with 400 cm 3 of ethyl acetate, the organic phases are combined, dried over sodium sulfate and then filtered through Celite® on a sintered glass filter. Celite® is rinsed 4 times with 800 cm 3 of ethyl acetate. The filtrate is concentrated to dryness under reduced pressure (2.7 kPa), and after drying to constant weight at 25 ° C, 218.5 g (16R) -16-deoxy-16-fluoropristinamycin II are obtained B in the form of a colorless crystalline powder with a melting point of approximately 133 ° C (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d, J = 6.5Hz, 3H), 1.55-2.05 (m, 5H), 1.83 (s, 3H), 2.10-2.30 (m, 2H), 2.76 (m, 1H), 2.98 (m, 1H), 3.21 (m, 1H), 3.48 (m, 1H), 3.87 (m, 1H), 4.07 (m , 1H), 4.55 (m, 1H), 4.75-4.90 (m, 3H), 5.14 (reduced doublet, J HF = 48Hz, 1H), 5.39 (d, J = 9Hz , 1H), 5.71 (m, 1H), 5.82 (dd, J = 17 and 2Hz, 1H), 6.00 (m, 1H), 6.21 (d, J = 16Hz, 1H), 6.52 (dd, J = 17 and 5 Hz, 1H), 8.12 (s, 1H). (16R) -16-Desoxy-16-fluoro-14-O- (tert-butyldimethylsilyl) pristinamycin II B can be obtained as follows: Proceeding analogously to the method described in example 1, but proceeding from ac with 22 g of (16S) - -16-hydroxy-14-O- (tert-butyldimethylsilyl) pristinamycin II B in solution in 500 cm 3 of dichloromethane, slowly added at 20 ° C under argon atmosphere 6.7 cm 3 of diethylaminosulfur trifluoride. After 4 hours of stirring and working up in an analogous manner to that in Example 1, 25 g of an orange oil are obtained, which is purified by flash chromatography [eluent: dichloromethane / methanol / acetonitrile gradient (100/0/0, 99 / 0.5 / 0.5 to 96/2/2 vol. Etical)]. 6.6 g of (16R) -16-deoxy-16-fluoro-14-O- (tert-butyldimethylsilyl) pristinamycin IIB are obtained as a light yellow solid, m.p. 128 DEG C. (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.04 (s, 3H), 0.07 (s, 3H), 0.89 (s, 9H), 0.96 (d, J = 6.5Hz, 3H), 0.99 (d, J = 6.5Hz, 3H), 1.50-2.05 (m, 5H), 1.79 (s, 3H), 2.10-2, 25 (m, 2H), 2.76 (m, 1H), 2.90 (m, 1H), 3.15 (m, 1H), 3.43 (m, 1H), 3.88 (m, 1H ), 4.09 (m, 1H), 4.59 (m, 1H), 4.75 (m, 1H), 4.79 (dd, J = 10 and 1.5Hz, 1H), 4.84 ( dd, J = 9 and 3 Hz, 1H), 5.12 (reduced doublet, J HF = 48 Hz, 1H), 5.34 (d, J = 9 Hz, 1H), 5.64 (m, 1H), 5, 82 (dd, J = 17 and 2Hz, 1H), 5.99 (m, 1H), 6.20 (d, J = 16Hz, 1H), 6.50 (dd, J = 17 and 5Hz, 1H), 8.09 (s, 1H). (16S) -16-Hydroxy-14-O- (tert-butyldimethylsilyl) pristinamycin II B can be obtained as follows: Up to 27 g of (16S) -16-hydroxypristinamycin II B (obtained as described in Example 1) in solution in 270 ml of dichloromethane, 44.4 ml of diisopropylethylamine and 39.6 ml of tert-butyldimethylchlorosilane in solution in 140 ml of dichloromethane are added at a temperature of 20 ° C. under an argon atmosphere. After stirring for 17 hours, the reaction mixture is washed 3 times with 300 cm 3 of water. The organic phase is dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) to obtain an orange oil which is purified by equilibrium chromatography [eluent: gradient dichloromethane / methanol / acetonitrile (100/0/0, 99 / 0.5 / 0.5 to 96/2/2 ethical v / v)]. 24 g of (16S) -16-hydroxy-14-O- (tert-butyldimethylsilyl) -pristinamycin II B are obtained as a light yellow solid, m.p. 139 DEG C. (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.05 (s, 3H), 0.10 (s, 3H), 0.91 (s, 9H), 0.96 (d, J = 6.5Hz, 3H), 1.02 (d, J = 6.5Hz, 3H), 1.06 (d, J = 6.5Hz, 3H), 1.70-2.05 (m, 5H), 1.71 (s, 3H), 2.12 (m, 1H), 2.31 (broad d, J = 14Hz, 1H), 2.70-2.80 (m, 1H), 2.80 (dd , J = 17 and 11Hz, 1H), 3.06 (dd, J = 17 and 2.5Hz, 1H), 3.30 (m, 1H), 3.79 (m, 2H), 4.47 (broad t, J = 10Hz, 1H), 4.52 (s, 1H), 4.54 (m, 1H), 4.65-4.75 (m, 2H), 4.99 (m, 1H), 5 , 69 (m, 1H), 5.76 (dd, J = 17 and 2 Hz, 1H), 5.78 (d, J = 9 Hz, 1H), 6.00 (m, 1H), 6.20 (d , J = 16 Hz, 1H), 6.43 (dd, J = 17 and 4 Hz, 1H), 8.12 (s, 1H). Example 3 (16R) -16-Deoxy-16-fluoropristinamycin II B To a suspension of 0.09 g of sodium para-toluenesulfinate in 6 cm 6 of dichloromethane is added at 0 ° C under an argon atmosphere of 0.5 cm 3 1N aqueous acid solution hydrochloric acid. After stirring for 15 minutes at 20 DEG C., the organic phase is decanted, dried over magnesium sulphate and filtered. 0.26 g of (16R) -14-O-allyl-16-deoxy-16-fluoropristinamycin IIB and 0.04 g of tetrakis (triphenylphosphine) palladium were added to the filtrate at 20 ° C under argon. After stirring for two hours, 0.01 g of triethylamine is added. After 30 minutes of additional stirring, the reaction mixture is concentrated to dryness and then purified by equilibrium chromatography [eluent: dichloromethane / methanol / acetonitrile (90/5/5 vol. Vol.)] To obtain 0, 2 g of (16R) -16-deoxy-16-fluoropristinamycin II B. (16R) -16-Desoxy-16-fluoro-14-O- (tert-butyldimethylsilyl) pristinamycin II B can be obtained as follows: Proceeding analogously to the method described in example 1, but proceeding from ac with 22 g of (16S) - -16-hydroxy-14-O- (tert-butyldimethylsilyl) pristinamycin II B in solution in 500 cm 3 of dichloromethane, slowly added at 20 ° C under argon atmosphere 6.7 cm 3 of diethylaminosulfur trifluoride. After 4 hours of stirring and working up in an analogous manner to that in Example 1, 25 g of an orange oil are obtained which is purified by flash chromatography [eluent: dichloromethane / methanol / acetonitrile gradient (100/0/0, 99 / 0.5 / 0.5 to 96/2/2 vol. Ethical)]. 6.6 g of (16R) -16-deoxy-16-fluoro-14-O- (tert-butyldimethylsilyl) pristinamycin IIB are obtained as a light yellow solid, m.p. 128 DEG C. (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.50-2.05 (m, 5H), 1.62 (d, J = 4Hz, 1H), 1.83 (s, 3H), 2.10-2 , 30 (m, 2H), 2.77 (m, 1H), 2.98 (m, 1H), 3.21 (m, 1H), 3.48 (m, 1H), 3.87 (m, 1H), 4.06 (m, 1H), 4.55 (m, 1H), 4.75-4.85 (m, 3H), 5.14 (reduced doublet, J HF = 48Hz, 1H), 5 , 39 (d, J = 9 Hz, 1H), 5.72 (m, 1H), 5.82 (dd, J = 16 and 2 Hz, 1H), 5.98 (m, 1H), 6.21 (d , J = 16 Hz, 1H), 6.51 (dd, J = 16 and 5 Hz, 1H), 8.11 (s, 1H). (16R) -14-O-Allyl-16-deoxy-16-fluoropristinamycin II B can be obtained as follows: Up to 0.8 g of (16S) -14-O-allyl-16-hydroxypristinamycin II B in In the solution in 25 cm 3 of dichloromethane, 0.28 cm 3 of diethylamino sulfur trifluoride in solution in 5 cm 3 of dichloromethane are added dropwise at 0 ° under argon. After stirring for 45 minutes at 0 ° C and then returning to 20 ° C, the reaction mixture is poured onto 70 cm 3 of a saturated aqueous sodium hydrogen carbonate solution at 0 ° C. The mixture obtained is extracted with 100 cm 3 of dichloromethane. The organic phase is washed successively with 70 cm 3 of a saturated aqueous sodium hydrogen carbonate solution and 70 cm 3 of a saturated aqueous sodium chloride solution and then dried over magnesium sulfate. After filtration and concentration to dryness under reduced pressure (2.7 kPa) at 20 ° C, 0.8 g of (16R) -14-O-allyl-16-deoxy-16-fluoropristinamycin II B is obtained in the form of a cream-colored solid. (16R) -16-Desoxy-16-fluoro-14-O- (tert-butyldimethylsilyl) pristinamycin II B can be obtained as follows: Proceeding analogously to the method described in example 1, but starting from 22 g of (16S) - -16-hydroxy-14-O- (tert-butyldimethylsilyl) pristinamycin II B in solution in 500 cm 3 of dichloromethane are added slowly at 20 ° C under argon 6.7 cm 3 diethylaminosulfur trifluoride. After 4 hours of stirring and working up in an analogous manner to that in Example 1, 25 g of an orange oil are obtained which is purified by flash chromatography [eluent: dichloromethane / methanol / acetonitrile gradient (100/0/0, 99/0, 5 / 0.5 to 96/2/2 ethical vol.)]. There are obtained 6.6 g of (16R) -16-deoxy-16-fluoro-14-O- (tert-butyldimethylsilyl) pristinamycin II B as a light yellow solid, m.p. 128 ° C (decomp. track). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.50-2.05 (m, 5H), 1.81 (s, 3H), 2.16 (m, 1H), 2.93 (m, 1H), 3.18 (dt, J = 17 and 7 Hz, 1H), 3.45 (m, 1H), 3.80-3.95 (m, 2H), 4.00-4.15 (m, 2H), 4.47 (dt, J = 9.5 and 4 Hz, 1H), 4.59 (mt, 1H), 4.78 (dd, J = 10 and 1.5 Hz, 1H), 4.83 (dd, J = 9 and 3Hz, 1H), 5.05-5.35 (mt, 4H), 5.69 (m, 1H), 5.82 (dd, J = 16 and 2Hz, 1H), 5.90 (m , 1H), 6.00 (m, 1H), 6.25 (d, J = 16 Hz, 1H), 6.51 (dd, J = 16 and 4 Hz, 1H), 8.11 (s, 1H). (16S) -14-O-Allyl-16-hydroxypristinamycin II B can be obtained as follows: Up to 10.6 g of (16S) -16-hydroxypristinamycin II B (prepared as described in example 1) in In a solution in 500 cm 3 of 2-butanone, 19 g of potassium carbonate and 31.5 cm 3 of allyl bromide are added and the reaction mixture is heated under reflux for 90 hours. After cooling to 20 ° C and filtration, the reaction mixture is concentrated under reduced pressure (2.7 kPa), and the remainder is mixed with 100 cm 3 of distilled water and 300 cm 3 of chloroform . The organic phase is decanted, then washed with 100 cm 3 of distilled water, dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa), giving 12.5 g of the residue - a network which is purified by flash chromatography [eluent: dichloromethane / methanol (95/5 v / v partial)]. A solid is obtained, which is mixed in diethyl ether, filtered and dried (2.7 kPa) at 20 ° C, obtaining 1.4 g of (16S) -14-O-allyl-16-hydroxypristinamycin II B in the form of a colorless powder. (16R) -16-Desoxy-16-fluoro-14-O- (tert-butyldimethylsilyl) pristinamycin II B can be obtained as follows: Proceeding analogously to the method described in example 1, but proceeding from ac with 22 g of (16S) - -16-hydroxy-14-O- (tert-butyldimethylsilyl) pristinamycin II B in solution in 500 cm 3 of dichloromethane, slowly added at 20 ° C under argon atmosphere 6.7 cm 3 of diethylaminosulfur trifluoride. After 4 hours of stirring and working up in an analogous manner to that in Example 1, 25 g of an orange oil are obtained which is purified by flash chromatography [eluent: dichloromethane / methanol / acetonitrile gradient (100/0/0, 99/0, 5 / 0.5 to 96/2/2 ethical vol.)]. There are obtained 6.6 g of (16R) -16-deoxy-16-fluoro-14-O- (tert-butyldimethylsilyl) pristinamycin II B as a light yellow solid, m.p. 128 ° C (decomp. track). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.97 (d, J = 6.5 Hz, 3H), 1.04 (d, J = 6.5 Hz, 3H), 1.07 (d, J = 6.5Hz, 3H), 1.70-2.05 (m, 5H), 1.75 (s, 3H), 2.12 (m, 1H), 2.34 ( broad d, J = 16Hz, 1H), 2.77 (m, 1H), 2.85 (dd, J = 16 and 10Hz, 1H), 3.09 (dd, J = 16 and 3Hz, 1H), 3 , 32 (m, 1H), 3.75-3.90 (m, 3H), 4.05-4.15 (m, 2H), 4.42 (m, 1H), 4.53 (m, 1H ), 4.65-4.75 (m, 3H), 5.15-5.30 (m, 2H), 5.65-5.80 (m, 1H), 5.70 (broad d, J = 9Hz, 1H), 5.80 (dd, J = 16 and 1.5Hz, 1H), 5.79 (m, 1H), 5.98 (m, 1H), 6.25 (d, J = 16Hz, 1H), 6.45 (dd, J = 16 and 4 Hz, 1H), 8.14 (s, 1H). (16R) -16-Deoxy-16-dicyanopristinamycin II B To 0.85 g of (16R) -16-deoxy-16-thiocyanato-14-O- (tert-butyldiphenylsilyl) pristinamycin II B in solution in 40 cm 3 of dichloromethane is added at a temperature of 20 ° C 5 cm 3 of triethylamine trifluoride. After 20 hours of stirring under reflux, 3 cm 3 of triethylamine trifluoride are added and the mixture is kept under reflux for a further 3 hours. The reaction mixture is then poured into 80 cm 3 of water and neutralized by the slow addition of sodium carbonate hydrogen. The organic phase is decanted, dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) to obtain 0.61 g of a solid which is purified by equilibrium chromatography [eluent : dichloromethane / methanol (96/4 vol. ethical)]. 0.36 g of (16R) -16-deoxy-16-thiocyanatopristinamycin II B is obtained as a colorless solid with a melting point of approximately 140 DEG C. (with decomposition). (16R) -16-Desoxy-16-fluoro-14-O- (tert-butyldimethylsilyl) pristinamycin II B can be obtained as follows: Proceeding analogously to the method described in example 1, but starting from 22 g of (16S) - -16-hydroxy-14-O- (tert-butyldimethylsilyl) pristinamycin II B in solution in 500 cm 3 of dichloromethane are added slowly at 20 ° C under argon 6.7 cm 3 diethylaminosulfur trifluoride. After 4 hours of stirring and working up in an analogous manner to that in Example 1, 25 g of an orange oil are obtained which is purified by flash chromatography [eluent: dichloromethane / methanol / acetonitrile gradient (100/0/0, 99/0, 5 / 0.5 to 96/2/2 ethical vol.)]. There are obtained 6.6 g of (16R) -16-deoxy-16-fluoro-14-O- (tert-butyldimethylsilyl) pristinamycin II B as a light yellow solid, m.p. 128 ° C (decomp. track). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.75-2.05 (m, 5H), 1.85 (s, 3H), 2.10-2.30 (m, 2H), 2.77 (m , 1H), 3.15 (dd, J = 17 and 7Hz, 1H)), 3.40 (dd, J = 17 and 7Hz, 1H), 3.52 (m, 1H), 3.62 (m, 1H), 3.83 (m, 1H), 4.02 (m, 1H), 4.52 (m, 1H), 4.75-4.85 (m, 2H), 4.77 (dd, J = 10 and 2Hz, 1H), 5.36 (d, J = 9Hz, 1H), 5.77 (m, 1H), 5.81 (dd, J = 16 and 2Hz, 1H), 6.05 (m , 1H), 6.21 (d, J = 16 Hz, 1H), 6.52 (dd, J = 16 and 5 Hz, 1H), 8.14 (s, 1H). (16R) -16-Deoxy-16-thiocyanato-14-O- (tert-butyldiphenylsilyl) pristinamycin II B can be obtained as follows: Up to 5.85 g of tetra-n-butylammonium thiocyanate in solution in 70 cm 3 of dichloromethane is added at 20 ° C under argon atmosphere 2.6 g (16S) -16-hydroxy-14-O- (tert-butyldiphenylsilyl) pristinamycin II B (prepared as described in example 1), and then, dropwise, 1.56 cm 3 of diethylaminosulfur trifluoride. After 10 minutes of stirring, the reaction mixture is diluted with 100 cm 3 of dichloromethane. The solution obtained is washed successively twice with 100 cm 3 of water and 100 cm 3 of an aqueous saturated sodium chloride solution, then dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa). yielding 7.6 g of a dark yellow oil which was purified by flash chromatography [eluent: cyclohexane / ethyl acetate (6/4 v / v)]. 0.87 g of (16R) -16-deoxy-16-thiocyanato-14-O- (tert-butyldiphenylsilyl) pristinamycin II B is obtained as a colorless solid. (16R) -16-Desoxy-16-fluoro-14-O- (tert-butyldimethylsilyl) pristinamycin II B can be obtained as follows: Proceeding analogously to the method described in example 1, but proceeding from ac with 22 g of (16S) - -16-hydroxy-14-O- (tert-butyldimethylsilyl) pristinamycin II B in solution in 500 cm 3 of dichloromethane, slowly added at 20 ° C under argon atmosphere 6.7 cm 3 of diethylaminosulfur trifluoride. After 4 hours of stirring and working up in an analogous manner to that in Example 1, 25 g of an orange oil are obtained which is purified by flash chromatography [eluent: dichloromethane / methanol / acetonitrile gradient (100/0/0, 99/0, 5 / 0.5 to 96/2/2 ethical vol.)]. There are obtained 6.6 g of (16R) -16-deoxy-16-fluoro-14-O- (tert-butyldimethylsilyl) pristinamycin II B as a light yellow solid, m.p. 128 ° C (decomp. track). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.05-1 . 10 (m, 3H), 1.06 (s, 9H), 1.28 (s, 3H), 1.70-1.95 (m, 4H), 1.96 (m, 1H), 2, 10-2.25 (m, 1H), 3.04PL 203 554 B1 19 (dd, J = 17 and 6Hz, 1H), 3.27 (dd, J = 17 and 8Hz, 1H), 3.40-3 , 50 (m, 2H), 3.75 (m, 1H), 3.95 (m, 1H), 4.53 (m, 1H), 4.67 (m, 1H), 4.75-4. 85 (m, 2H), 5.35 (d, J = 9 Hz, 1H), 5.56 (m, 1H), 5.81 (dd, J = 16 and 1.5 Hz, 1H), 6.04 ( m, 1H), 6.11 (d, J = 16Hz, 1H), 6.49 (dd, J = 16 and 5Hz, 1H), 7.30-7.50 (m, 6H), 7.63 ( broad d, J = 7 Hz, 2H), 7.69 (m, 2H), 8.12 (s, 1H). Example 5 (16R) -16-Deoxy-16-bromopristinamycin II B By analogous to the method described in example 4, but starting with 1.2 g (16R) - -16-deoxy-16-bromo-14 -O- (tert-butyldiphenylsilyl) pristinamycin II B in solution in 30 ml of dichloromethane, 7.5 ml of triethylamine trifluoride are added at a temperature of 20 ° C. After 25 hours of stirring under reflux and treatment analogous to that of Example 4, an orange solid is obtained which is purified by flash chromatography [eluent: dichloromethane / methanol (97/3 vol eto sabotage)]. 0.78 g of a colorless solid is obtained, which crystallizes in 5 cm 3 of acetonitrile, yielding 0.48 g of (16R) -16-deoxy-16-bromopristipinamycin II B in the form of crushed colorless crystals at a temperature of mp approx. 146 ° C (with decomposition). (16R) -16-Desoxy-16-fluoro-14-O- (tert-butyldimethylsilyl) pristinamycin II B can be obtained as follows: Proceeding analogously to the method described in example 1, but starting from 22 g of (16S) - -16-hydroxy-14-O- (tert-butyldimethylsilyl) pristinamycin II B in solution in 500 cm 3 of dichloromethane are added slowly at 20 ° C under an argon atmosphere of 6.7 cm 3 diethylaminosulfur trifluoride. After 4 hours of stirring and working up analogously to that in Example 1, 25 g of an orange oil are obtained which is purified by flash chromatography [eluent: dichloromethane / methanol / acetonitrile gradient (100/0/0, 99 / 0.5 / 0.5 to 96/2/2 vol. Ethical)]. There is obtained 6.6 g of (16R) -16-deoxy-16-fluoro-14-O- (tert-butyldimethylsilyl) pristinamycin II B as a light yellow solid, m.p. 128 ° C (with decomposition) . 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.75-2.05 (m, 5H), 1.90 (s, 3H), 2.15 (m, 1H), 2.32 (m, 1H), 2.77 (m, 1H), 3.22 (dd, J = 17 and 7 Hz, 1H), 3.44 (dd, J = 17 and 7 Hz, 1H), 3.52 (m, 1H), 3, 83 (m, 1H), 4.09 (m, 1H), 4.37 (m, 1H), 4.52 (m, 1H), 4.75-4.90 (m, 2H), 4.79 (dd, J = 10 and 1.5Hz, 1H), 5.34 (d, J = 9Hz, 1H), 5.75 (m, 1H), 5.82 (dd, J = 17 and 1.5Hz, 1H), 6.03 (m, 1H), 6.22 (d, J = 16 Hz, 1H), 6.52 (dd, J = 17 and 5 Hz, 1H), 8.11 (s, 1H). (16R) -16-Desoxy-16-bromo-14-O- (tert-butyldiphenylsilyl) pristinamycin II B can be obtained as follows: Proceed analogously to the method described in example 1, but proceed ac with 5.25 g of tetra-n-butylammonium bromide in solution in 60 cm 3 of dichloromethane, add 2.5 g of (16S) -16-hydroxy-14-O- (tert. -butyl diphenylsilyl) pristinamycin IIB (prepared as described in Example 1) and then slowly 1.5 cm 3 of diethylaminosulfur trifluoride. After 10 minutes of stirring and working up analogously to that in Example 4, 4.6 g of a yellow solid are obtained which is purified by flash chromatography [eluent: cyclohexane / ethyl acetate (6/4 v / v) ]. 1.38 g of (16R) -16-deoxy-16-bromo-14-O- (tert-butyldimethylsilyl) pristinamycin II B are obtained as a colorless solid. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.07 (s , 9H), 1.10 (d, J = 6.5Hz, 3H), 1.37 (s, 3H), 1.70-2.05 (m, 5H), 2.14 (m, 1H), 2.31 (m, 1H), 2.77 (m, 1H), 3.12 (dd, J = 17 and 5.5Hz, 1H), 3.30 (dd, J = 17 and 8Hz, 1H), 3.45 (m, 1H), 3.77 (m, 1H), 4.03 (m, 1H), 4.23 (m, 1H), 4.55 (m, 1H), 4.75-4 , 85 (m, 3H), 5.33 (d, J = 9 Hz, 1H), 5.54 (m, 1H), 5.82 (broad d, J = 16 Hz, 1H), 6.00 (m, 1H), 6.12 (d, J = 16 Hz, 1H), 6.50 (dd, J = 17 and 5 Hz, 1H), 7.30-7.45 (m, 6H), 7.63 (broad d , J = 7 Hz, 2H), 7.69 (broad d, J = 7 Hz, 2H), 8.08 (s, 1H). Example 6 (16R) -16-Deoxy-16-chloropristinamycin II B Proceeding analogously to the method described in example 4, but starting with 1.4 g (16R) - -16-deoxy-16-chloro-14 -O- (tert-butyldiphenylsilyl) pristinamycin II B in solution in 35 ml of dichloromethane, 11 ml of triethylamine trifluoride are added at a temperature of 20 ° C. After 20 hours of stirring under reflux and treatment analogous to that of Example 4, an orange solid is obtained, which is purified by flash chromatography [eluent: dichloromethane / methanol (97 / 3 vol. Eto sabolic)]. 1 g of a colorless solid is obtained, to which are added 0.5 g of a substance obtained from an identical test. After crystallization in 10 cm 3 of acetonitrile, 1.12 g of (16R) -16-deoxy-16-chloropristinamycin II B are obtained in the form of colorless crystals, m.p. decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.75-2.05 (m, 5H), 1.88 (s, 3H), 2.10-2.25 (m, 2H), 2.75 (m , 1H), 3.10 (dd, J = 17 and 7Hz, 1H), 3.30 (dd, J = 17 and 6.5Hz, 1H), 3.53 (m, 1H), 3.84 (m , 1H), 4.06 (m, 1H), 4.37 (m, 1H), 4.49 (m, 1H), 4.75-4.90 (m, 3H), 5.35 (d, J = 9 Hz, 1H), 5.76 (m, 1H), 5.83 (dd, J = 17 and 2 Hz, 1H), 5.99 (m, 1H), 6.22 (d, J = 15, 5Hz, 1H), 6.51 (dd, J = 17 and 5Hz, 1H), 8.09 (s, 1H) (16R) -16-Desoxy-16-chloro-14-O- (tert-butyldimethylsilyl) pristinamycins e II B can be obtained as follows: By following the procedure described in example 1, but starting with 7.27 g of tetra-n-butylammonium chloride in solution in 50 cm 3 of dichloromethane, it is added at temperature - at 20 ° C under argon 4 g of (16S) -16-hydroxy-14-O- (tert-butyldiphenylsilyl) pristinamycin II B (prepared as described in Example 1), followed by a drop of 2.44 cm 3 of diethylaminosulfur trifluoride. After 10 minutes of stirring and working up analogously to that in Example 4, 4.45 g of a yellow solid are obtained which is purified by flash chromatography [eluent: cyclohexane / ethyl acetate (55/45 v / v)] . 0.51 g of (16R) -16-deoxy-16-chloro-14-O- (tert-butyldiphenylsilyl) pristinamycin II B is obtained as a colorless solid. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.07 (s , 9H), 1.10 (d, J = 6.5Hz, 3H), 1.33 (s, 3H), 1.70-1.90 (m, 4H), 1.96 (m, 1H), 2.05-2.25 (m, 2H), 2.77 (m, 1H), 2.98 (dd, J = 17 and 5.5Hz, 1H), 3.16 (dd, J = 17 and 8Hz , 1H), 3.45 (m, 1H), 3.76 (m, 1H), 4.03 (m, 1H), 4.25 (m, 1H), 4.55 (m, 1H), 4 , 75-4.85 (m, 3H), 5.34 (d, J = 9Hz, 1H), 5.54 (m, 1H), 5.82 (dd, J = 16 and 2Hz, 1H), 5 .99 (m, 1H), 6.11 (d, J = 16 Hz, 1H), 6.50 (dd, J = 16 and 5 Hz, 1H), 7.30-7.45 (m, 6H), 7 , 63 (dd, J = 7 and 1.5 Hz, 2H), 7.68 (dd, J = 7 and 1.5 Hz, 2H), 8.08 (s, 1H). Example 7 (16R) -16-Deoxy-16-iodopristinamycin II B Proceeding analogously to the method described in example 4, but starting with 0.83 g (16R) -16-deoxy-16-iodo-14- O- (tert-butyldiphenylsilyl) pristinamycin II B in solution in 15 ml of dichloromethane, 6.2 ml of triethylamine trifluoride are added at a temperature of 20 ° C. After 23 hours of stirring under a reflux cooler and treatment analogous to that of Example 4, 0.9 g of a crushed colorless solid is obtained, which is purified by equilibrium chromatography [eluent: dichloromethane / methanol / acetonitrile (98/1/1 vol ethical)]. 0.41 g of a yellow solid is obtained, which is purified by high-performance liquid chromatography on a Kromasil® C18 column filled with 5 µm silica (column diameter 2 cm, column length 25 cm) [ eluent: water / acetonitrile gradient (80/20 to 40/40 ethical vol)]. 0.18 g of a colorless solid is obtained, to which 0.12 g of the substance obtained in analogous tests is added, 0.3 g of (16R) -16-deoxy-16-iodopristinamycin II B is obtained in the form of as a solid with a melting point of approximately 140 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.67 (d, J = 3Hz, 1H), 1.73 (m, 1H), 1.80-2.05 (m, 4H), 1.94 (s , 3H), 2.17 (m, 1H), 2.36 (m, 1H), 2.77 (m, 1H), 3.31 (dd, J = 17 and 7Hz, 1H), 3.45- 3.60 (m, 1H), 3.53 (dd, J = 17 and 7Hz, 1H), 3.85 (m, 1H), 4.10 (m, 1H), 4.32 (m, 1H) , 4.53 (m, 1H), 4.75-4.85 (m, 3H), 5.31 (d, J = 9Hz, 1H), 5.76 (m, 1H), 5.82 (dd , J = 17 and 1.5Hz, 1H), 6.21 (dd, J = 17 and 5Hz, 1H), 8.11 (s, 1H) (16R) -16-Desoxy-16-iodo-14-O - (tert-butyldiphenylsilyl) pristinamycin II B can be obtained as follows: Proceeding analogously to the method described in example 4, but starting with 7.2 g of tetra-n-butylammonium iodide in a solution of 60 cm 3 of dichloromethane, 3 g of (16S) -16-hydroxy-14-O- (tert-butyldiphenylsilyl) pristinamycin II B (prepared as described in Example 1) are added at a temperature of 20 ° C under argon, and then after drops at 0 ° 1.8 cm 3 of diethyl trifluoride ylamine sulfur. After 20 minutes of stirring at 0 ° and working in an analogous manner to that in Example 4, 10.5 g of an orange oil are obtained, which is stirred for 15 minutes in 30 cm 3 of a cyclohexane / ethyl acetate mixture (60). 40). After filtration and concentration of the filtrate under reduced pressure (2.7 kPa), 5.5 g of a yellow solid are obtained, which is purified by flash chromatography [eluent: cyclohexane / ethyl acetate (60 / 40 vol. Eto sabolic)]. 1.81 g of (16R) -16-deoxy-16-iodo-14-O- (tert-butyldiphenylsilyl) pristinamycin II B are obtained as a colorless solid with a melting point of about 105 ° C (with decomposition). track). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.05 (s, 9H), 1.09 (d, J = 6.5Hz, 3H), 1.41 (s, 3H), 1.70-1.95 (m, 4H), 1.96 ( m, 1H), 2.33 (m, 1H), 2.77 (m, 1H), 3.20 (dd, J = 17 and 6Hz, 1H), 3.38 (dd, J = 17 and 8Hz, 1H), 3.45 (m, 1H), 3.79 (m, 1H), 4.03 (m, 1H), 4.17 (m, 1H), 4.54 (m, 1H), 4. 71 (dt, J = 9 and 3 Hz, 1H), 4.78 (dd, J = 10 and 2.5 Hz, 1H), 4.75-4.85 (m, 1H), 5.30 (d, J = 9Hz, 1H), 5.55 (m, 1H), 5.81 (dd, J = 17 and 2Hz, 1H), 6.11 (d, J = 16Hz, 1H), 6.49 (dd, J = 17 and 5Hz, 1H), 7.30-7.45 (m, 6H), 7.63 (dd, J = 7 and 1.5Hz, 2H), 7.69 (dd, J = 7 and 1, 5 Hz, 2H), 8.08 (s, 1H). Example 8 (16R) -16-Deoxy-16-fluoropristinamycin To 0.97 g of (16R) -16-deoxy-16-fluoro-14-O- (tert-butyldiphenylsilyl) pristinamycin II A in 8 cm solution 3 of tetrahydrofuran are added at a temperature of 20 ° C under an argon atmosphere of 0.2 ml of acetic acid and 0.6 g of tetra-n-butylammonium fluoride trihydrate. After stirring for 168 hours, the reaction mixture is poured onto 50 cm 3 of a saturated aqueous sodium hydrogen carbonate solution. The organic phase is decanted and the aqueous phase is extracted with 30 cm 3 of dichloromethane. The organic phases are combined, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) to obtain a residue which is purified by equilibrium chromatography [eluent: dichloromethane n-methanol / acetonitrile (95 / 2.5 / 2.5 ethical vol)]. 0.38 g of a yellow solid is obtained to which is added 0.21 g of material obtained from an identical test. After stirring in ether, filtering and drying under reduced pressure (2.7 kPa) at 20 ° C, 0.58 g of (16R) -16-deoxy-16-fluoropristinamycin II A is obtained as a light yellow solid with a melting point of approximately 110 ° C (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.99 (m, 6H), 1.14 (d, J = 6.5 Hz, 3H), 1.77 (s, 3H), 1. 85-2.10 (m, 2H), 2.28 (m, 1H), 2.65-2.90 (m, 3H), 3.08 (m, 1H), 3.25 (m, 1H) , 3.98 (broad d, J = 17 Hz, 1H), 4.10-4.25 (m, 2H), 4.31 (m, 1H), 4.55-4.80 (m, 2H), 4.90-5.00 (m, 2H), 5.69 (m, 1H), 5.96 (d, J = 16, 1H), 5.99 (d, J = 16 Hz, 1H), 6, 17 (broad t, J = 3 Hz, 1H), 6.61 (dd, J = 16 and 7 Hz, 1H), 7.06 (m, 1H), 7.93 (s, 1H). (16R) -16-Desoxy-16-fluoro-14-O- (tert-butyldiphenylsilyl) pristinamycin II A can be obtained as follows: Up to 65 g of (16S) -16-hydroxy-14-O- ( tert-butyldiphenylsilyl) pristinamycin II B in solution in 700 ml of dichloromethane is slowly added at 20 ° C under an argon atmosphere of 20.5 ml of diethylaminosulfide trifluoride. After stirring for 3 hours, the reaction mixture is poured slowly onto 1000 cm 3 of an aqueous saturated sodium hydrogen carbonate solution. The organic phase is decanted and the aqueous phase is extracted twice with 500 cm 3 of dichloromethane. The organic phases are combined, dried over magnesium sulfate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) to give 67.62 g of an orange solid. After this substance was stirred solid in pentane, filtered and dried under reduced pressure (2.7 kPa) at 20 ° C, 65.55 g of (16R) -16-deoxy-16-fluoro-14-O- ( tert-butyldiphenylsilyl) pristinamycin IIA as a yellow-orange solid. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.95-1.05 (m, 6H), 1.05 (s, 9H), 1.13 (d, J = 6.5Hz, 3H ), 1.28 (s, 3H), 1.80-2.10 (m, 2H), 2.10-2.30 (m, 1H), 2.65-2.85 (m, 3H), 2.90-3.15 (m, 2H), 3.95-4.10 (m, 2H), 4.16 (m, 1H), 4.28 (m, 1H), 4.40-4, 60 (m, 2H), 4.99 (dd, J = 10 and 1.5 Hz, 1H), 5.05 (d, J = 9 Hz, 1H), 5.50 (m, 1H), 5.90 ( d, J = 16Hz, 1H), 6.00 (broad d, J = 17Hz, 1H), 6.16 (t, J = 3Hz, 1H), 6.61 (dd, J = 17 and 7Hz, 1H) , 7.02 (t, J = 5.5Hz, 1H), 7.25-7.50 (m, 6H), 7.58 (broad d, J = 7Hz, 2H), 7.67 (broad d, J = 7 Hz, 2H), 7.89 (s, 1H). (16S) -16-Hydroxy-14-O- (tert-butyldiphenylsilyl) pristinamycin II A can be obtained in the following way: By analogy to the method described in example 1, but starting from 10 g (16S) - -16-hydroxypristinamycin II A in solution in 100 cm 3 of dichloromethane is added dropwise at 20 ° C under argon, 19.7 cm 3 of tert-butyldiphenylchlorosilane and 0.46 g of 4-dimethylaminopyridine . After stirring for 20 hours and working up analogously to that in Example 1, 35 g of brown oil are obtained, which is purified by flash chromatography [eluent: dichloromethane / -methanol / acetonitrile (96/2/2 covered by strictly)]. 10.5 g of (16S) -16-hydroxy-14-O- (tert-butyldiphenylsilyl) pristinamycin IIA are obtained in the form of a beige solid. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.90-1.05 (m, 6H), 1.05-1.15 (m, 15H), 1.90-2.05 (m , 3H), 2.54 (m, 1H), 2.76 (m, 1H), 2.82 (dd, J = 16 and 11Hz, 1H), 3.11 (dd, J = 16 and 3Hz, 1H ), 3.28 (m, 1H), 3.83 (m, 1H), 4.00-4.15 (m, 2H), 4.50 (m, 1H), 4.57 (m, 1H ), 4.81 (m, 1H), 4.94 (dd, J = 10 and 2Hz, 1H), 5.38 (m, 1H), 5.63 (d, J = 9Hz, 1H), 5, 88 (dd, J = 16 and 1.5Hz, 1H), 5.94 (d, J = 16Hz, 1H), 6.01PL 203 554 B1 22 (t, J = 3Hz, 1H), 6.34 (m , 1H), 6.47 (dd, J = 16 and 5Hz, 1H), 7.25-7.50 (m, 6H), 7.62 (dd, J = 7 and 1.5Hz, 2H), 7 . 68 (dd, J = 7 and 1.5 Hz, 2H), 8.06 (s, 1H). (16S) -16-Hydroxypristinamycin II A can be obtained according to F. Le Goffic et al. , Eur. J. Med. - Chimica Therapeutica, Jan-Feb, 16 (1), 69-72 (1981). Example 9 (16R) -16-deoxy-16-fluoro-14-O- [4- (morpholinyl-4-methyl) benzoyl] pristinamycin methanesulfonate II B Up to 0.15 g (16R) -16-deoxy- 16-fluoro-14-O- [4- (morpholinyl-4-methylbenzoyl] pristinamycin II B in solution in 5 ml of methanol is added at 20 ° C to 2 ml of 0.1N ethanolic methanesulfonic acid solution. After stirring for 10 minutes, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) to give a colorless residue which is stirred in 10 cm 3 of ether. After filtration, washing the solid with 10 cm 3 of diethyl ether and drying under reduced pressure (2.7 kPa) at 20 ° C, 0.15 g of (16R) -16-deoxy-16 methanesulfonate is obtained. -fluoro-14-O- [4- (morpholinyl-4-methylbenzoyl] pristinamycin IIB as a colorless solid, melting point approximately 150 ° C (decomposition). 1 H NMR spectrum (400 MHz, (CD 3) 2 SO d 6, dp ppm): 0.85 (d, J = 6.5 Hz, 3H), 0.95 (d, J = 6.5 Hz, 3H), 1.05 (d, J = 6.5Hz, 3H), 1.54 (m, 1H), 1.75-2.00 (m, 3H), 1.86 (s, 3H), 2.05- 2.25 (m, 2H), 2.30-2.45 (m, 1H), 2.32 (s, 3H), 2.78 (m, 1H), 3.05-4.45 (m, 6H), 3.55-3.70 (m, 3H), 3.72 (m, 1H), 3.84 (m, 1H), 3.90-4.05 (m, 3H), 4.47 (m, 2H), 4.70-4.80 (m, 2H), 5.18 (reduced doublet, J HF = 48Hz, 1H), 5.55 (d, J = 9.5Hz, 1H), 5 , 66 (m, 1H), 5.81 (broad d, J = 16 Hz, 1H), 6.00 (m, 1H), 6.21 (d, J = 16 Hz, 1H), 6.64 (dd, J = 16 and 5Hz, 1H), 7.68 (broad d, J = 7.5Hz, 2H), 8.08 (broad d, J = 7.5Hz, 2H), 8.16 (m, 1H), 8.55 (s, 1H), 9.95 (m, 1H). (16R) -16-deoxy-16-fluoro-14-O- (4-morpholinyl-4-methylbenzoyl) pristinamycin II B can be obtained as follows: Up to 2 g of (16R) -16-deoxy -16-fluoro-14-O- [4- (chloromethyl) benzoyl] pristinamycin II B in solution in 50 cm 3 of tetrahydrofuran is added at a temperature of 20 ° C 0.44 g of sodium iodide and 0.5 cm 3 of mor- folin. After stirring for 17 hours under a reflux condenser, the reaction mixture is poured into 50 cm 3 of water and then extracted twice with 50 cm 3 of dichloromethane. The organic phases are combined, washed twice with 100 cm 3 of water, dried over magnesium sulphate, filtered, and then concentrated to dryness under reduced pressure (2.7 kPa) to give 2.5 g of a residue, which is purified by flash chromatography [eluent: dichloromethane / methanol gradient (100 / 0.99 / 1 and 98/2 by volume by volume)]. A solid is obtained, which is stirred in pentane, filtered and dried (90 Pa) at 30 ° C, yielding 1.69 g (16R) -16-deoxy-16-fluoro-14-O- ( 4-morpholinyl-4-methylbenzoyl) pristinamycin II B as a crushed solid with a melting point of approximately 120 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.75-2.05 (m, 5H), 1.95 (s, 3H), 2.16 (m, 1H), 2.30-2.50 (m , 1H), 2.44 (m, 4H), 2.76 (m, 1H), 3.05 (dt, J = 17 and 6 Hz, 1H), 3.29 (m, 1H), 3.29 ( m, 1H), 3.49 (m, 1H), 3.55 (s, 2H), 3.71 (m, 4H), 3.89 (m, 1H), 4.09 (m, 1H), 4.52 (m, 1H), 4.79 (broad d, J = 10Hz, 1H), 4.83 (dd, J = 9 and 3Hz, 1H), 5.18 (reduced doublet, J HF = 48Hz, 1H), 5.45 (d, J = 9.5Hz, 1H), 5.70-5.85 (m, 1H), 5.82 (broad d, J = 17Hz, 1H), 5.94 (m , 1H), 6.06 (dt, J = 9.5 and 5Hz, 1H), 6.22 (d, J = 17 and 5Hz, 1H), 7.41 (d, J = 8Hz, 2H), 7 , 98 (d, J = 8Hz, 2H), 8.14 (s, 1H) (16R) -16-Desoxy-16-fluoro-14-O- [4- (chloromethyl) benzoyl] pristinamycin II B can be obtained as follows: To 5.32 g of (16R) -16-deoxo-16-fluoropristinamycin II B (prepared as described in example 1) in solution in 150 cm 3 of dichloromethane and 2.1 cm 3 triethylamine is added at a temperature of 10 ° C, 2.84 g of 4- (chloromethyl) benzene chloride lu and 0.095 4-dimethylaminopyridine. After 20 hours of stirring at 20 ° C, the reaction mixture is washed successively with 50 cm 3 of water, 50 cm 3 of 5% aqueous sodium hydrogen carbonate solution, 30 cm 3 of water and 30 cm 3 of saturated water. sodium chloride solution. The organic phase is dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa), obtaining 7.2 g of a beige residue, which is purified by means of equilibrium chromatography [eluent: dichloromethane / methanol / acetonitrile gradient (99/05/05 and 98/1/1 vol. vol.)]. 4.5 g of (16R) -16-deoxy-16-fluoro-14-O- [4-chloromethyl) benzoyl] pristinamycin IIB are obtained in the form of a light yellow solid. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.75-2.05 (m, 5H), 1.95 (s, 3H), 2.16 (m, 1H), 2.40 (m, 1H), 2.76 (m, 1H), 3.04 (dt, PL 203 554 B1 23 J = 17 and 6 Hz, 1H), 3.29 (m, 1H), 3.49 (m, 1H), 3.88 (m, 1H), 4.09 (m, 1H), 4.53 (m, 1H), 4.62 (s, 2H), 4.78 (dd, J = 10 and 2Hz, 1H), 4. 83 (dd, J = 9 and 3Hz, 1H), 5.18 (reduced doublet, J HF = 48Hz, 1H), 5.44 (d, J = 9.5Hz, 1H), 5.75-5.85 (m, 1H), 5.82 (dd, J = 17 and 2Hz, 1H), 5.94 (m, 1H), 6.06 (dt, J = 9.5 and 5Hz, 1H), 6.22 (d, J = 16Hz, 1H), 6.52 (dd, J = 17 and 5Hz, 2H), 7.47 (d, J = 8Hz, 2H), 8.02 (d, J = 8Hz, 2H) . 8.14 (s. 1H). Example 10 (16R) -16-Deoxy-16-fluoro-14-O- [4- (imidazolyl-1-methyl) -benzoyl] pristinamycin II B with 0.499 g of (16R) -16-deoxy-16-fluoro-14-O- [4- (imidazolyl-1-methyl) benzoyl] pristinamycin II B (prepared as described in example 9) in a solution in 30 cm 3 tetrahydrofuran, 0.11 g of sodium iodide and 0.099 g of imidazole are added at a temperature of 20 ° C. After 17 hours of stirring under reflux and treatment analogous to that in Example 9, 0.5 g of a yellow solid is obtained, which is purified by flash chromatography [eluent: dichloromethane / methanol (97/3 volumetrically)]. A solid is obtained, which is stirred in ether, filtered and dried (90 Pa) at 20 ° C, yielding 0.289 g of (16R) -16-deoxy-16-fluoro-14-O- [4 - (imidazolyl-1-methyl) -benzoyl] pristinamycin II B in the form of a yellow solid, melting point approximately 136 ° C (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.75-2.05 (m, 5H), 1.95 (s, 3H), 2.16 (m, 1H), 2.39 (m, 1H), 2.76 (m, 1H), 3.04 (td, J = 17 and 6 Hz, 1H), 3.28 (m, 1H), 3.49 (m, 1H), 3.87 (m, 1H) , 4.08 (m, 1H), 4.53 (m, 1H), 4.78 (broad d, J = 10Hz, 1H), 4.83 (dd, J = 9 and 3Hz, 1H), 5. 17 (reduced doublet, J HF = 48 Hz, 1H), 5.19 (s, 2H), 5.43 (d, J = 9 Hz, 1H), 5.78 (m, 1H), 5.82 (dd, J = 17 and 1.5 Hz, 1H), 5.94 (m, 1H), 6.05 (m, 1H), 6.22 (d, J = 16 Hz, 1H), 6.52 (dd, J = 17 and 5Hz, 1H), 6.90 (s, 1H), 7.13 (s, 1H), 7.20 (d, J = 8Hz, 2H), 7.58 (s, 1H), 8.01 (d, J = 8 Hz, 2H), 8.14 (s, 1H). Example 11 (16R) -16-Desoxy-16-fluoro-14-O- [4- (methylpiperazinyl-1-methyl) benzoyl] pristinamycin II B The procedure is analogous to that described in example 9, but starting from 2 g of (16R) - -16-deoxy-16-fluoro-14-O- [4- (chloromethyl) benzoyl] pristinamycin II B (prepared as described in example 9) in solution in 90 cm 3 of tetrahydrofuran, 0.44 g of sodium iodide and 0.65 ml of methylpiperazine in solution in 10 ml of tetrahydrofuran are added at a temperature of 20 ° C. After 20 hours of stirring under a reflux condenser and treatment analogous to that in Example 9, a residue of 2.4 g is obtained, which is purified by flash chromatography [eluent: dichloromethane / methanol (99/1 vol. Etical)]. A solid is obtained, which is stirred in 15 cm 3 of ether, filtered and dried (90 Pa) at 20 ° C, obtaining 1 g of (16R) -16-deoxy-16-fluoro-14- O- [4- (4-methylpiperazinyl-1-methyl) benzoyl] pristinamycin II B as a light yellow solid, melting point approximately 160 ° C (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.75-2.25 (m, 6H), 1.95 (s, 3H), 2.30-2.50 (m, 1H), 2.40 (s , 3H), 2.62 (m, 8H), 2.76 (m, 1H), 3.04 (dt, J = 17 and 6 Hz, 1H), 3.29 (m, 1H), 3.49 ( m, 1H), 3.59 (s, 2H), 3.88 (m, 1H), 4.08 (m, 1H), 4.52 (m, 1H), 4.79 (broad d, J = 10Hz, 1H), 4.83 (dd, J = 9 and 3Hz, 1H), 5.18 (reduced doublet, J HF = 48Hz, 1H), 5.44 (d, J = 9.5Hz, 1H), 5.70-5.85 (m, 1H), 5.82 (dd, J = 17 and 1.5Hz, 1H), 5.95 (m, 1H), 6.05 (dt, J = 8.5Hz , 2H), 6.22 (d, J = 16Hz, 1H), 6.52 (dd, J = 17 and 5Hz, 1H), 7.40 (d, J = 8.5Hz, 2H), 7.97 (d, J = 8.5 Hz, 2H), 8.14 (s, 1H). Example 12 (16R) -16-Desoxy-16-fluoro-14-O- [4- (diethylaminomethyl) benzoyl] pristinamycin II B Proceed analogously to the method described in example 9, but starting with 0.55 g (16R) -16-deoxy-16-fluoro-14-O- [4- (chloromethyl) benzoyl] pristinamycin II B (prepared as described in example 9) in solution in 30 cm 3 of tetrahydrofuran is added at a temperature of 20 ° C 0.12 g of sodium iodide and 0.17 g of diethylamine. After 15.5 hours of stirring under reflux and a treatment analogous to that in Example 9, a residue is obtained, which is purified by flash chromatography [eluent: dichloromethane / methanol (95/5 vol. V / v)] . A solid is obtained, which is stirred in 20 cm 3 of pentane, filtered and dried (90 Pa) at 20 ° C, yielding 0.14 g of (16R) -16-deoxy-16-fluoro-14- O- [4- (diethylaminomethyl) benzoyl] pristinamycin II B as a light yellow solid, melting point approximately 150 ° C (with decomposition). 1H NMR spectrum (400 MHz, CDCl3, dp ppm): 0.96 (d, J = 6.5Hz, 3H), 1.03 (m, 9H), 1.09 (d, J = 6.5Hz , 3H), 1.75-2.05 (m, 5H), 1.95 (s, 3H), 2.16 (m, 1H), 2.40 (m, 1H), 2.52 (g, J = 7 Hz, 4H), 2.77 (m, 1H), 3.05 (td, J = 17 and 6 Hz, 1H), 3.28 (m, 1H), 3.48 (m, 1H), 3 . 61 (s, 2H), 3.89 (m, 1H), 4.09 (m, 1H), 4.53 (m, 1H), 4.79 (broad d, J = 10Hz , 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.17 (reduced doublet, J HF = 48Hz, 1H), 5.44 (d, J = 9Hz, 1H), 5.77 (m, 1H), 5.82 (dd, J = 17 and 1.5Hz, 1H), 5.92 (m, 1H), 6.05 (m, 1H), 6.21 (d, J = 6Hz , 1H), 6.50 (dd, J = 16 and 5Hz, 1H), 7.42 (d, J = 8Hz, 2H), 7.96 (d, J = 8Hz, 2H), 8.14 (s , 1H). Example 13 (16R) -16-Deoxy-16-fluoro-14-O- {4 - [((2S) -2-hydroxymethyl) pyrrolidinyl-1-methyl] benzoyl} pristinamycin II B Follow the procedure analogously to of the method described in example 9, but starting from 1 g of (16R) -16-deoxy-16-fluoro-14-O- [4- (chloromethyl) benzoyl] pristinamycin II B (prepared as described in example on 9) in solution in 45 cm 3 of tetrahydrofuran, 0.22 g of sodium iodide and 0.29 g of L-prolinol in solution in 5 cm 3 of tetrahydrofuran are added at a temperature of 20 ° C. After 12 hours of stirring under reflux and treatment analogous to that of Example 9, 1.25 g of a residue is obtained, which is purified by flash chromatography [eluent: dichloromethane / methanol (98 / 2 vol. Eto sabolic)]. A solid is obtained, which is stirred in 10 cm 3 of ether, filtered and dried (90 Pa) at 20 ° C, yielding 0.4 g of (16R) -16-deoxy-16-fluoro-14-O - {4- - [((2S) -2-hydroxymethyl) pyrrolidinyl-1-methyl] benzoyl} pristinamycin IIB as a colorless solid, melting point approximately 158 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.55-2.05 (m, 8H), 1.96 (s, 3H), 2.17 (m, 1H), 2.29 (m, 1H), 2.41 (m, 1H), 2.77 (m, 2H), 2.96 (m, 1H), 3.05 (td, J = 17 and 6Hz, 1H), 3.29 (m, 1H) , 3.40-3.55 (m, 3H), 3.66 (dd, J = 11 and 4Hz, 1H), 3.88 (m, 1H), 4.02 (d, J = 13Hz, 1H) , 4.09 (m, 1H), 4.53 (m, 1H), 4.79 (dd, J = 10 and 2Hz, 1H), 4.83 (dd, J = 9 and 3Hz, 1H), 5 , 18 (reduced doublet, J HF = 48Hz, 1H), 5.45 (d, J = 9.5Hz, 1H), 5.78 (m, 1H), 5.82 (dd, J = 16 and 2Hz, 1H), 5.95 (m, 1H), 6.05 (m, 1H), 6.22 (d, J = 16Hz, 1H), 6.52 (dd, J = 16 and 5Hz, 1H), 7 , 38 (d, J = 8 Hz, 2H), 7.98 (d, J = 8 Hz, 2H), 8.14 (s, 1H). Example 14 (16R) -16-Desoxy-16-fluoro-14-O- [4- (2-picolylaminomethyl) benzoyl] pristinamycin II B Proceed analogously to the method described in example 9, but starting from 2 g (16R) - -16-deoxy-16-fluoro-14-O- [4- (chloromethyl) benzoyl] pristinamycin II B (prepared as described in example 9) in solution in 20 cm 3 of tetrahydrofuran is added at a temperature of 20 ° C 0.44 g of sodium iodide and 1.2 cm 3 of 2- (aminomethyl) pyridine. After 17 hours of stirring under a refrigerator, reflux and treatment analogous to that in Example 9, 2.1 g of a dark yellow solid are obtained, which is purified by two successive equilibrium chromatographies [eluent: respectively dichloromethane (methanol / acetonitrile (92/4/4 and 95 / 2.5 / 2.5 ethical vol)]. A solid is obtained, which is stirred in ether, filtered and dried (90 Pa) at 20 ° C, yielding 1.59 g (16R) - -16-deoxy-16-fluoro-14-O- [ 4- (2-picolylaminomethyl) benzoyl] pristinamycin II B as a colorless solid with a melting point of approximately 106 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.75-2.05 (m, 5H), 1.95 (s, 3H), 2.16 (m, 1H), 2.40 (m, 1H), 2.77 (m, 1H), 3.05 (dt, J = 17 and 6 Hz, 1H), 3.29 (m, 1H), 3.49 (m, 1H), 3.90 (m, 1H) , 3.92 (s, 2H), 3.93 (s, 2H), 4.10 (m, 1H), 4.53 (m, 1H), 4.79 (dd, J = 10 and 2Hz, 1H ), 4.83 (dd, J = 9 and 3.5Hz, 1H), 5.18 (reduced doublet, J HF = 48Hz, 1H), 5.45 (d, J = 9Hz, 1H), 5.79 (m, 1H), 5.82 (dd, J = 16 and 2Hz, 1H), 5.92 (m, 1H), 6.06 (m, 1H), 6.22 (d, J = 16Hz, 1H ), 6.51 (dd, J = 16 and 5Hz, 1H), 7.18 (dd, J = 8 and 5Hz, 1H), 7.30 (d, J = 8Hz, 1H), 7.45 (d , J = 9Hz, 2H), 7.65 (dt, J = 8 and 2Hz, 1H), 7.99 (d, J = 8Hz, 2H), 8.14 (s, 1H), 3.58 (broad d, J = 5 Hz, 1H). Example 15 (16R) -16-Desoxy-16-fluoro-14-O- [4- (pyrrolidinyl-1) benzoyl] pristinamycin II B By analogous to the method described in example 9, but starting with 1 g (16R) - -16-deoxy-16-fluoro-14-O- [4- (chloromethyl) benzoyl] pristinamycin II B (prepared as described in example 9) in solution in 50 cm 3 of tetrahydrofuran is added at a temperature 20 ° C 0.22 g of sodium iodide and 0.24 g of pyrrolidine. After 17 hours of stirring under reflux and treatment analogous to that of Example 9, a residue is obtained which is purified by flash chromatography [eluent: dichloromethane / methanol (99/1 by vol. strictly)]. Thus, after stirring in 10 cm 3 of pentane, filtering and drying (90 Pa) at 20 ° C, 0.4 g of (16R) - -16-deoxy-16-fluoro-14-O is obtained. - [4- (pyrrolidinyl-1) benzoyl] pristinamycin II B as a yellow solid, melting point approximately 170 ° C (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.70-2.05 (m, 5H), 1.81 (m, 4H), 1.95 (s, 3H), 2.16 (m, 1H), 2.40 (m, 1H), 2.53 (m, PL 203 554 B1 4H), 2.76 (m, 1H), 3.04 (td, J = 17 and 6 Hz, 1H), 3.28 (m, 1H), 3.48 (m, 1H), 3.68 (s, 2H), 3.88 (m, 1H), 4.09 (m, 1H), 4.53 (m, 1H) , 4.79 (dd, J = 10 and 1Hz, 1H), 4.83 (dd, J = 9 and 3Hz, 1H), 5.17 (reduced doublet, J HF = 48Hz, 1H), 5.45 ( d, J = 9.5 Hz, 1H), 5.77 (m, 1H), 5.81 (dd, J = 17 and 1.5 Hz, 1H), 5.95 (m, 1H), 6.05 ( m, 1H), 6.22 (d, J = 16Hz, 1H), 6.51 (dd, J = 17 and 5Hz, 1H), 7.42 (d, J = 8Hz, 2H), 7.97 ( d, J = 8 Hz, 2H), 8.14 (s, 1H). Example 16 (16R) -16-Deoxy-16-fluoro-14-O- [4- (piperidinyl-1) benzoyl] pristinamycin II B By analogous to the method described in example 9, but starting from 0, 75 g of (16R) -16-deoxy-16-fluoro-14-O- [4- (chloromethyl) benzoyl] pristinamycin II B (prepared as described in example 9) in solution in 20 cm 3 of tetrahydrofuran is added at 20 ° C, 0.16 g of sodium iodide and 0.22 cm 3 of piperidine. After 15 hours of stirring at 66 ° C and a treatment analogous to that in Example 9, 0.33 g of (16R) -16-deoxy-16-fluoro-14-O- [4- (piperidinyl- 1) benzoyl] pristinamycin II B in the form of a colorless solid with a melting point of approximately 110 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.35-1.70 (m, 6H), 1.75-2.05 (m, 5H), 1.95 (s, 3H), 2.16 (m , 1H), 2.30-2.50 (m, 5H), 2.76 (m, 1H), 3.05 (td, J = 17 and 6 Hz, 1H), 3.29 (m, 1H), 3.49 (m, 1H), 3.52 (s, 2H), 3.89 (m, 1H), 4.09 (m, 1H), 4.53 (m, 1H), 4.79 (dd , J = 10 and 1.5 Hz, 1H), 4.83 (dd, J = 9 and 3 Hz, 1H), 5.18 (reduced doublet, J HF = 48 Hz, 1H), 5.45 (d, J = 9.5Hz, 1H), 5.77 (m, 1H), 5.82 (dd, J = 16 and 2Hz, 1H), 5.93 (m, 1H), 6.05 (m, 1H), 6 , 22 (d, J = 16Hz, 1H), 6.51 (dd, J = 16 and 5Hz, 1H), 7.40 (d, J = 8Hz, 2H), 7.97 (d, J = 8Hz, 2H), 8.14 (s, 1H). Example 17 (16R) -16-Desoxy-16-fluoro-14-O- {4 - [(2-hydroxyethyl) aminomethyl] benzoyl} pristinamycin II B The procedure is analogous to that described in example 9, but starting from with 0.8 g of (16R) - -16-deoxy-16-fluoro-14-O- [4- (chloromethyl) benzoyl] pristinamycin II B (prepared as described in example 9) in a solution in 20 cm 3 tetrahydrofuran, 0.17 g of sodium iodide and 0.14 cm 3 of ethanolamine, after 16 hours of stirring under reflux and treatment analogous to the treatment in Example 9, 0.8 g of a beige solid is obtained, which a is purified by flash chromatography [eluent: dichloromethane / methanol gradient (95/5 and 90/10 by volume by volume)]. After stirring in ether, filtration and drying (90 Pa), 0.36 g of a colorless solid is obtained, which is purified by high-performance liquid chromatography on a 5 µm Hypersil® column (column diameter 2 cm). , 25 cm sc column length) [eluent: dichloromethane / methanol gradient (97/3 ethical vol)]. 0.129 g of (16R) -16-deoxy-16-fluoro-14-O- {4 - [(2-hydroxyethyl) aminomethyl] benzoyl (pristinamycin II B as a colorless solid with a melting point of approx. 194 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5 Hz, 3H), 1.70-2.05 (m, 5H), 1.95 (s, 3H), 2.16 (m, 1H), 2.39 (m, 1H), 2.76 (m, 1H), 2.81 (t, J = 5.5Hz, 2H), 3.04 (td, J = 17 and 6Hz, 1H), 3.28 (m, 1H), 3, 48 (m, 1H), 3.67 (t, J = 5.5 Hz, 2H), 3.85-3.95 (m, 1H), 3.88 (s, 2H), 4.09 (m, 1H), 4.52 (m, 1H), 4.78 (broad d, J = 10Hz, 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.17 (reduced doublet, J HF = 48Hz, 1H), 5.44 (d, J = 9.5Hz, 1H), 5.78 (m, 1H), 5.81 (broad d, J = 16.1H), 5.93 (m, 1H), 6.05 (m, 1H), 6.22 (d, J = 16Hz, 1H), 6.51 (dd, J = 16 and 5Hz, 1H), 7.40 (d, J = 8Hz, 2H), 7.99 (d, J = 8 Hz, 2H), 8.13 (s, 1H). Example 18 (16R) -16-Desoxy-16-fluoro-14-O- {4 - [(2-diethylamino) ethylthiomethyl] benzoyl} pristinamycin II B To 0.46 cm 3 of diethylaminoethanethiol in solution in 10 cm of tetrahydrofuran is added at 0 ° C 0.82 cm 3 of a butyllithium solution (2.5 M in hexane). After stirring for 15 minutes, 1.4 g of (16R) -16-deoxy-16-fluoro-14-O- [4- (chloromethyl) benzoyl] pristinamycin II B ( obtained as described in Example 9) in solution in 15 cm 3 of tetrahydrofuran. After 6.5 hours of stirring at 0 ° C and 15 hours at 20 ° C, the solution prepared as above is added dropwise, but starting with 0.153 cm 3 of 2-diethylaminoethanethiol, 0.205 cm 3 of butyllithium solution (2 , 5M in hexane) in 0.5 cm 3 of tetrahydrofuran. After 3.5 hours of stirring at 20 ° C, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) to obtain a residue which is extracted with a cm 3 of dichloromethane. This solution is washed with 50 cm 3 of water and then decanted. The aqueous phase is extracted with 20 cm 3 of dichloromethane. The organic phases are combined, washed twice with 70 cm 3 of water, dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa), giving 1.6 g of yellow a solid which is purified by flash chromatography [eluent: dichloromethane / methanol / acetonitrile (92/4/4 v / v, partial)]. Thus, after stirring in pentane, filtration and drying (2.7 kPa) at 20 ° C, 0.926 g of (16R) -16-deoxy-16-fluoro-14-O- [4 - [(2 - dimethylamino) ethylthiomethyl] benzoyl} pristinamycin II B in the form of a beige solid, m.p. 84 ° C (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.90-1.05 (m, 12H), 1.10 (d, J = 6.5Hz, 3H), 1.75-2.05 (m, 5H), 1.96 (s, 3H), 2.16 (m, 1H), 2.40 (m, 1H), 2.50 (m, 6H), 2.62 (m, 2H) , 2.76 (m, 1H), 3.05 (dt, J = 17 and 6 Hz, 1H), 3.29 (m, 1H), 3.49 (m, 1H), 3.77 (s, 2H ), 3.89 (m, 1H), 4.09 (m, 1H), 4.53 (m, 1H), 4.78 (dd, J = 10 and 1.5Hz, 1H), 4.83 ( dd, J = 9 and 3 Hz, 1H), 5.17 (reduced doublet, J HF = 48 Hz, 1H), 5.45 (d, J = 9 Hz, 1H), 5.78 (m, 1H), 5, 82 (dd, J = 17 and 1.5 Hz, 1H), 5.92 (m, 1H), 6.05 (m, 1H), 6.22 (d, J = 16 Hz, 1H), 6.52 ( dd, J = 17 and 5 Hz, 1H), 7.40 (d, J = 8.5 Hz, 2H), 7.97 (d, J = 8.5 Hz, 2H), 8.14 (s, 1H). Example 19 (16R) -16-Deoxy-16-fluoro-14-O- [4- (carboxymethylthiomethyl) benzoyl] pristinamycin II B To 0.4 cm 3 of mercaptoacetic acid in 10 cm 3 solution of tetrahydrofuran is added at a temperature of 0 ° C 4.64 cm 3 of a butyllithium solution (2.5M in hexane). After stirring for 15 minutes, the temperature of the reaction mixture is lowered to -50 ° C and 2 g of (16R) -16-deoxy-16-fluoro-14-O- [4- (chloromethyl) benzoyl] pristinamycin II are slowly added dropwise. B (prepared as described in Example 9) in solution in 10 cm 3 of tetrahydrofuran. After 3 hours of stirring at -50 ° C and 15 hours at 20 ° C, the temperature of the reaction mixture is lowered again to -50 ° C and the previously prepared solution is added dropwise at -50 ° C, but starting from 0.2 cm 2 of mercaptoacetic acid and 2.32 cm 3 of a butyllithium solution (2.5 M in hexane) in 5 cm 2 of tetrahydrofuran. After stirring for 5 hours at -50 ° C, the reaction mixture is poured into 100 cm 3 of water and the pH value is adjusted to 3-4 by adding 0.1N aqueous hydrochloric acid solution. After the addition of 20 cm 3 of dichloromethane and 20 cm 3 of a saturated aqueous sodium chloride solution, the organic phase is decanted and the aqueous phase is extracted with 20 cm 3 of dichloromethane. The organic phases are combined, dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa), yielding 2.1 g of a yellow solid which is purified by equilibrium chromatography [eluent: dichloromethane / methanol / acetonitrile (90/5/5 vol. ethosic)]. Thus, after stirring in ether, filtration and drying (90 Pa) at 20 ° C, 0.21 g of (16R) -16-deoxy-16-fluoro-14-O- [4- (carboxymethylthiomethyl) benzoyl] is obtained. pristinamycin II B as a yellow solid with a melting point of approximately 142 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5 Hz, 3H), 1.75-2.05 (m, 5H), 1.95 (s, 3H), 2.17 (m, 1H), 2.39 (m, 1H), 2.76 (m, 1H), 3.05 (dt, J = 17 and 6 Hz, 1H), 3.08 (s, 2H), 3.28 (m, 1H), 3.50 (m, 1H) , 3.88 (m, 1H), 3.88 (s, 2H), 4.10 (m, 1H), 4.52 (m, 1H), 4.78 (dd, J = 10 and 2Hz, 1H ), 4.83 (dd, J = 9 and 3.5Hz, 1H), 5.19 (reduced doublet, J HF = 48Hz, 1H), 5.44 (d, J = 9Hz, 1H), 5.78 (m, 1H), 5.83 (dd, J = 16 and 2Hz, 1H), 6.00 (m, 1H), 6.05 (m, 1H), 6.22 (d, J = 16Hz, 1H ), 6.52 (dd, J = 16 and 5Hz, 1H), 7.41 (d, J = 8Hz, 2H), 7.97 (d, J = 8Hz, 2H), 8.16 (s, 1H ). Example 20 (16R) -16-Deoxy-16-fluoro-14-O- {4 - [(2-diethylamino) ethoxymethyl] benzoyl} pristinamycin II B Up to 1 g (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in Example 1) in a solution of 15 cm 3 of dichloromethane, 0.6 g of 4 - ((2-diethylamino) ethoxymethyl) benzoic acid, 3.05 g of 4 is added at a temperature of 20 ° C. - dimethylaminopyridine, 0.43 g of N, N'-dicyclohexylcarbodiimide and 2 g of magnesium sulfate. After stirring for 20 hours at 20 ° C, 0.24 g of 4 - [(2-diethylamino) ethoxymethyl] benzoic acid, 0.025 g of 4-dimethylaminopyridine and 0.2 g of N, N'-dicyclohexylcarbodiimide are added. After 3 hours of additional stirring at 20 ° C, the reaction mixture is filtered and the undissolved components are washed with 20 cm 3 of dichloromethane. The filtrate is washed 3 times with 100 cm 3 of water, dried over magnesium sulphate, filtered, and lastly concentrated to dryness under reduced pressure (2.7 cPa) to give 1.5 g of a beige solid which is purified by equilibrium chromatography [eluent: dichloromethane / methanol / acetonitrile gradient (90/5/5 and 84/8/8 / v / v, ethical)]. Thus, after stirring in 20 cm 3 of ether, filtration and drying, 0.86 g of a colorless solid is obtained which is dissolved in 20 cm 3 of dichloromethane. The solution obtained is washed twice with 50 cm 3 of an aqueous saturated solution of sodium hydrogen carbonate, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C. C to obtain 0.67 g of (16R) -16-deoxy-16-fluoro-14-O- {4 - [(2-diethylamino) ethoxymethyl] benzoyl} pristinamycin II B as a colorless substance solid with a melting point of approximately 76 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.05 (t , J = Hz, 6H), 1.10 (d, J = 6.5Hz, 3H), 1.75-2.05 (m, 5H), 1.95 (s, 3H), 2.16 (m , 1H), 2.40 (m, 1H), 2.60 (q, J = 7Hz, 4H), 2.72 (t, J = 6.5Hz, 2H), 2.77 (m, 1H), 3.04 (dt, J = 17.5 and 6Hz, 1H), 3.29 (m, 1H), 3.49 (m, 1H), 3.59 (t, J = 6.5Hz, 2H), 3.89 (m, 1H), 4.09 (m, 1H), 4.53 (m, 1H), 4.59 (s, 2H), 4.79 (dd, J = 10 and 2Hz, 1H) , 4.83 (dd, J = 9 and 3.5Hz, 1H), 5.18 (reduced doublet, J HF = 48Hz, 1H), 5.45 (d, J = 9Hz, 1H), 5.78 ( m, 1H), 5.82 (dd, J = 17 and 2Hz, 1H), 5.92 (m, 1H), 6.05 (m, 1H), 5.22 (d, J = 16Hz, 1H) , 6.51 (dd, J = 17 and 5Hz, 1H), 7.41 (d, J = 8Hz, 2H), 7.99 (d, J = 8Hz, 2H), 8.14 (s, 1H) . 4 - [(2-diethylamino) ethoxymethyl] benzoic acid can be obtained as follows: To 3.67 g of methyl 4 - [(2-diethylamino) ethoxymethyl] benzoate in solution in 50 cm 3 of methanol is added at 20 ° C 28 cm 3 of 1N aqueous sodium hydroxide solution. After stirring for 2.5 hours at 20 ° C., the pH value of the reaction mixture is adjusted to 5 by adding 29 cm 3 of a 1N aqueous hydrochloric acid solution. The reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) to give a residue which is stirred in 50 cm 3 of methanol. After filtering out the insoluble parts, the filtrate is concentrated to dryness under reduced pressure (2.7 kPa), obtaining a residue which is mixed in 50 cm 3 of dichloromethane. After filtering off the insoluble parts, the filtrate is concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C, obtaining 3.5 g of 4 - [(2-diethylamino) ethoxymethyl] benzoic acid in the form of yellow oil. 1 H NMR spectrum (300 MHz, (CD 3) 2 SO d 6, dp ppm): 1.07 (t, J = 7.5 Hz, 6H), 2.79 (q, J = 7.5 Hz, 4H), 2.93 (t, J = 6.5Hz, 2H), 3.66 (t, J = 6.5Hz, 2H), 4.57 (s, 2H), 7.42 (d, J = 8Hz, 2H ), 7.92 (d, J = 8 Hz, 2H). Methyl 4 - [(2-diethylamino) ethoxymethyl] benzoate can be obtained as follows: To 5.8 cm 3 of N, N-diethylethanolamine in solution in 15 cm 3 of dimethylformamide are added at 0 ° C 2.64 g sodium hydride (60% by weight in white oil). After one hour of stirring at 0 ° C., 10 g of methyl 4- (bromomethyl) benzoate in solution in 10 cm 3 of dimethylformamide are added dropwise over 20 minutes and then 50 cm 3 of dimethylformamide. After stirring for 17 hours at 20 ° C, 100 cm 3 of methanol are added, and then the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) to obtain a yellow oil which is diluted e 200 cm 3 of ethyl acetate. The resulting solution is washed with 300 cm 3 of water. The aqueous phase is decanted and then extracted with 100 cm 3 of ethyl acetate. The organic phases are combined, washed twice with 500 cm 3 of water, dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) to give 10 g of a yellow oil which is purified By means of flash chromatography [eluent: dichloromethane / methanol gradient (96/4 and 90/10 by volume by volume)]. Thus, 3.67 g of methyl 4 - [(2-diethylamino) ethoxymethyl] benzoate are obtained in the form of a yellow oil. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 1.02 (t, J = 7.5 Hz, 6H), 2.58 (q, J = 7.5 Hz, 4H), 2.70 (t , J = 6Hz, 2H), 3.57 (t, J = 6Hz, 2H), 3.88 (s, 3H), 4.56 (s, 2H), 7.38 (d, J = 8Hz, 2H . 7.99 (d, J = 8 Hz, 2H). Example 21 (16R) -16-Desoxy-16-fluoro-14-O- [3- (morpholinyl-4-methyl) benzoyl] pristinamycin IIB The procedure is analogous to that described in example 9, but starting from 1 g of (16R) - -16-deoxy-16-fluoro-14-O- [3- (chloromethyl) benzoyl] pristinamycin II B in solution in 25 cm 3 of tetrahydrofuran, 0.212 g of iodide is added at 20 ° C sodium and 0.253 cc of morpholine. After 16 hours of stirring under reflux and treatment analogous to that in Example 9, 1 g of a yellow solid is obtained, which is purified by flash chromatography [eluent: dichloromethane / methanol / acetonitrile gradient (100/0/0 and then 98/1/1 vol. Vol.)]. Thus 0.8 g of a yellow solid is obtained which, after stirring in 10 cm 3 of ether, filtering and drying (90 Pa) at 20 ° C, yields 0.68 g (16R) -16-deoxy-. 16-fluoro-14-O- [3- (morpholinyl-4-methyl) benzoyl] pristinamycin IIB as a colorless solid, melting point approximately 198 ° C (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.75-2.05 (m, 5H), 1.96 (s, 3H), 2.17 (m, 1H), 2.35-2.50 (m , 1H), 2.46 (m, 4H), 2.76 (m, 1H), 3.05 (td, J = 17 and 6 Hz, 1H), 3.29 (m, 1H), 3.45- 3.60 (m, 1H), 3.54 (s, 2H), 3.72 (m, 4H), 3.88 (m, 1H), 4.10 (m, 1H), 4.53 (m , 1H), 4.79 (dd, J = 10 and 1.5 Hz, 1H), 4.83 (dd, J = 9 and 3 Hz, 1H), 5.18 (reduced doublet, J HF = 48 Hz, 1H), 5.45 (d, J = 9 Hz, 1H), 5.79 (m, 1H), 5.82 (dd, J = 17 and 2 Hz, 1H), 5.93 (m, PL 203 554 B1 28 1H), 6.06 (m, 1H), 6.22 (d, J = 16Hz, 1H), 6.52 (dd, J = 17 and 5Hz, 1H), 7.40 (t, J = 8Hz , 1H), 7.56 (broad d, J = 8Hz, 1H), 7.92 (broad d, J = 8Hz, 1H), 7.96 (broad d, 1H) m 8.14 (s, 1H) . (16R) -16-Deoxy-16-fluoro-14-O- [3-chloromethyl) benzoyl] pristinamycin II B can be obtained as follows: Up to 5 g of (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in Example 1) in a solution in 250 cm 3 of chloroform are added at a temperature of 20 ° C 2 cm 3 of triethylamine, 2 cm 3 of 3- (chloromethyl) benzoyl chloride and 0.23 g of 4- dimethylaminopyridine. After 24 hours of stirring at 20 ° C, the reaction mixture is washed 3 times with 120 cm of water, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa ) obtaining a yellow and a solid which is mixed in 50 cm 3 of ether. After filtration, sweeping the solid twice with 10 cm 3 of diethyl ether and drying under reduced pressure (2.7 kPa) at 20 ° C, 5.56 g (16R) -16- is obtained deoxy-16-fluoro-14-O- [3-chloromethyl) benzoyl] pristimycin II B in the form of a colorless solid with a melting point of approximately 190 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.80-2.05 (m, 5H), 1.96 (s, 3H), 2.17 (m, 1H), 2.40 (m, 1H), 2.76 (m, 1H), 3.05 (dt, J = 17 and 6 Hz, 1H), 3.29 (m, 1H), 3.50 (m, 1H), 3.88 (m, 1H) , 4.10 (m, 1H), 4.53 (m, 1H), 4.63 (s, 2H), 4.79 (dd, J = 10 and 2Hz, 1H), 4.84 (dd, J = 9 and 3Hz, 1H), 5.18 (reduced doublet, J HF = 48Hz, 1H), 5.45 (d, J = 9.5Hz, 1H), 5.75-5.85 (m, 1H) , 5.82 (dd, J = 16 and 1.5 Hz, 1H), 5.92 (m, 1H), 6.07 (dt, J = 9.5 and 5 Hz, 1H), 6.23 (d, J = 16Hz, 1H), 6.52 (dd, J = 16 and 5Hz, 1H), 7.46 (t, J = 8Hz, 1H), 7.61 (broad d, J = 8Hz, 1H), 7 .99 (broad d, J = 8 Hz, 1H), 8.04 (broad s, 1H), 8.14 (s, 1H). Example 22 (16R) -16-deoxy-16-fluoro-14-O- [3- (imidazolyl-1-methyl) benzoyl] pristinamycin II B methanesulfonate II B Up to 0.450 g (16R) -16-deoxy-16- fluoro-14-O- [3- (imidazolyl-1-methyl) benzoyl] pristinamycin IIB in solution in 10 cm 3 of ethanol is added at 20 ° C. to 6.28 cm 3 of 0.1N ethanolic methanesulfonic acid solution. After 10 minutes of stirring, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) to give a residue which is stirred in 7 cm 3 of ether. After filtration, washing the solid twice with 2 cm 3 of diethyl ether and drying under reduced pressure (2.7 kPa), 0.479 g of (16R) -16-deoxy-16-fluoro-14-O methanesulfonate are obtained. - [3- (Imidazolyl-1-methyl) benzoyl] pristinamycin IIB as a colorless solid, melting point approximately 160 ° C (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.11 (d , J = 6.5Hz, 3H), 1.75-2.05 (m, 5H), 1.96 (s, 3H), 2.17 (m, 1H), 2.37 (m, 1H), 2.77 (m, 1H), 2.86 (s, 3H), 3.05 (m, 1H), 3.29 (m, 1H), 3.53 (m, 1H), 3.85 (m , 1H), 4.11 (m, 1H), 4.53 (m, 1H), 4.80 (broad d, J = 10Hz, 1H), 4.84 (dd, J = 9 and 3Hz, 1H) , 5.18 (reduced doublet, J HF = 48Hz, 1H), 5.35-5.50 (m, 3H), 5.82 (m, 1H), 5.86 (broad d, J = 17Hz, 1H ), 6.07 (m, 1H), 6.11 (m, 1H), 6.22 (d, J = 16Hz, 1H), 6.55 (dd, J = 17 and 5Hz, 1H), 7, 10 (broad s, 1H), 7.43 (broad s, 1H), 7.54 (m, 2H), 7.95 (broad s, 1H), 8.09 (m, 1H), 8.12 ( s, 1H), 9.11, 1H). (16R) -16-Deoxy-16-fluoro-14-O- [3- (imidazolyl-1-methyl) benzoyl] pristinamycin II B can be obtained as follows: on 9, but starting from 1.2 g of (16R) - -16-deoxy-16-fluoro-14-O- [3- (chloromethyl) benzoyl] pristinamycin II B (prepared as described in example 21 ) in solution in 30 ml of tetrahydrofuran, 0.263 g of sodium iodide and 0.238 g of imidazole are added at a temperature of 20 ° C. After 16 hours of stirring under reflux and working up analogous to that in Example 9, 0.9 g of a yellow solid is obtained which is purified by flash chromatography [eluent: dichloromethane / methanol / acetonitrile gradient (98 / 1/1, 96/2/2, and then 90/5/5 volumetric)]. Thus, 0.53 g of (16R) -16-deoxy-16-fluoro-14-O- [3- (imidazolyl-1-methyl) benzoyl] pristinamycin II B is obtained in the form of a yellow solid with melting point approximately 125 ° C (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.75-2.05 (m, 5H), 2.16 (m, 1H), 2.38 (m, 1H), 2.76 (m, 1H), 3.04 (dt, J = 17 and 6 Hz, 1H), 3.28 (m, 1H), 3.50 (m, 1H), 3.86 (m, 1H), 4.10 (m, 1H) , 4.53 (m, 1H), 4.79 (dd, J = 10 and 2Hz, 1H), 4.83 (dd, J = 9 and 4Hz, 1H), 5.17 (reduced doublet, J HF = 48Hz, 1H), 5.43 (d, J = 9Hz, 1H), 5.79 (m, 1H), 5.82 (dd, J = 16 and 2Hz, 1H), 5.97 (m, 1H) , 6.06 (m, 1H), 6.22 (d, J = 16 Hz, 1H), 6.52 (dd, J = 16 and 5 Hz, 1H), PL 203 554 B1 29 6.91 (m, 1H ), 7.11 (broad s, 1H), 7.32 (broad d, J = 8Hz, 1H), 7.44 (t, J = 8Hz, 1H), 7.57 (broad s, 1H), 7 . 88 (broad s, 1H), 7.99 (broad d, J = 8 Hz, 1H), 8.14 (s, 1H). Example 23 (16R) -16-Desoxy-16-fluoro-14-O- [3- (diethylaminomethyl) benzoyl] pristinamycin II B Proceed analogously to the method described in example 9, but starting from 1 g (16R ) - -16-deoxy-16-fluoro-14-O- [3- (chloromethyl) benzoyl] pristinamycin II B (prepared as described in example 21) in solution in 25 cm 3 of tetrahydrofuran, is added at temperature 20 ° C 0.217 g of sodium iodide and 0.3 cm 3 of diethylamine. After 16 hours of stirring under reflux and treatment analogous to that in Example 9, 1 g of a yellow solid is obtained, which is purified by flash chromatography [eluent: dichloromethane / methanol / acetonitrile gradient (100 (0/0 and then 98/1/1 vol. Vol.)]. A solid is obtained, which is mixed in pentane, filtered and dried (2.7 kPa) at 20 ° C, yielding 0.313 g (16R) -16-deoxy-16-fluoro-14-O - [3- (diethylaminomethyl) benzoyl] pristinamycin II B as a yellow solid, melting point approximately 115 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.05-1 , 15 (m, 9H), 1.75-2.05 (m, 5H), 1.97 (s, 3H), 2.16 (m, 1H), 2.41 (m, 1H), 2. 56 (m, 4H), 2.77 (m, 1H), 3.05 (td, J = 17 and 6 Hz, 1H), 3.29 (m, 1H), 3.49 (m, 1H), 3 , 64 (broad s, 2H), 3.89 (m, 1H), 4.10 (m, 1H), 4.53 (m, 1H), 4.79 (dd, J = 10 and 1.5Hz, 1H), 4.83 (dd, J = 9 and 3Hz, 1H), 5.19 (reduced doublet, J HF = 48Hz, 1H), 5.46 (d, J = 9.5Hz, 1H), 5. 78 (m, 1H), 5.82 (dd, J = 16 and 2Hz, 1H), 5.94 (m, 1H), 6.06 (1H, 1H), 6.23 (d, J = 16Hz, 1H), 6.52 (dd, J = 16 and 5Hz, 1H), 7.40 (t, J = 8Hz, 1H), 7.62 (m, 1H), 7.91 (d, J = 8Hz, 1H), 7.97 (broad s, 1H), 8.14 (s, 1H). Example 24 (16R) -16-Deoxy-14-O- [4- (morpholinyl-4-methyl) phenylacetyl] pristinamycin II B To 0.87 g (16R) -16-deoxy-16-fluoro-14-O - [4- (halomethyl) phenylacetyl] pristinamycin II B (mixture of chlorine and bromine derivatives) in solution in 5 cm 3 of dimethylformamide, 0.25 cm 3 of morpholine and some sodium iodide crystals are added at 20 ° C. After 15 minutes of stirring at 85 ° C., the reaction mixture is poured onto 90 cm 3 of water. The aqueous phase is decanted and then extracted twice with 50 cm 3 of ethyl acetate. The organic phases are combined, washed successively with 30 cm 3 of water and 30 cm 3 of an aqueous saturated sodium chloride solution, then dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa). . Thus, 0.91 g of a brown-orange solid is obtained, which is purified by flash chromatography [eluent: dichloromethane / methanol / acetonitrile (92/4/4 vol. , 46 g of a yellow solid which is extracted with 5 cm 3 of dichloromethane. After filtration through Celite®, Celite® is rinsed with dichloromethane and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa) to give 0.42 g of a yellow solid which is it is stirred for 15 minutes in 5 cm 3 of water. After filtration and drying under reduced pressure (2.7 kPa) at 20 ° C, 0.38 g of (16R) -16-deoxy-16-fluoro-14-O- [4- - (morpholinyl- 1-methyl) phenylacetyl] pristinamycin II B as a yellow solid, melting point approximately 100 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.60-2.05 (m, 5H), 1.85 (s, 3H), 2.10-2.30 (m, 2H), 2.76 (m , 1H), 2.97 (dt, J = 17 and 6 Hz, 1H), 3.22 (m, 1H), 3.40-3.55 (m, 1H), 3.48 (s, 1H), 3.59 (s, 1H), 3.71 (m, 4H), 3.85 (m, 1H), 4.04 (m, 1H), 4.52 (m, 1H), 4.78 (broad d, J = 10Hz, 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.06 (reduced double, J HF = 48Hz, 1H), 5.31 (d, J = 9Hz , 1H), 5.75-5.85 (m, 1H), 5.75 (m, 1H), 5.81 (broad d, J = 17Hz, 1H), 5.93 (m, 1H), 6 , 18 (dd, J = 17 and 4 Hz, 1H), 7.22 (d, J = 8 Hz, 2H), 7.29 (d, J = 8 Hz, 2H), 8.12 (s, 1H). (16R) -16-Desoxy-14-O- [4- (halomethyl) phenylacetyl] pristinamycin II B (mixture of chlorine and bromine derivatives) can be obtained as follows: Up to 2 g (16R) - 16-deoxy-16-fluoropristinamycin II B (prepared as described in Example 1) in solution in 60 cm 3 of dichloromethane is added for 5 minutes at 20 ° C under argon to 1.3 cm 3 of diisopropylethylamine and 1.75 g of 4- (bromomethyl) phenyl acetyl chloride. After stirring for 16 hours at 20 ° C, the reaction mixture is washed twice successively with 25 cm 3 of water and 25 cm 3 of a saturated aqueous sodium chloride solution, then dried over magnesium sulfate, filtered and concentrated. dry under reduced pressure (2.7 kPa). Thus, 2.79 g of an orange solid are obtained, which is purified by flash chromatography [eluent: dichloromethane / methanol (97/3 v / v)] to give 1.3 g of a yellow solid. a funnel which is extracted with 50 cm 3 of ethyl acetate. The resulting PL 203 554 B1 solution is washed twice with 25 cm 3 of an aqueous saturated sodium hydrogen carbonate solution, then dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C to obtain 1.04 g of (16R) -16-deoxy-16-fluoro-14-O- - [4- (halomethyl) phenylacetyl] pristinamycin II B (mixture of chlorine and bromine derivatives) as a yellow solid. 4- (bromomethyl) phenylacetyl chloride can be prepared in accordance with EP 274 999. Example 25 (16R) -16-deoxy-16-fluoro-14-O - [(2-imidazolyl-1-ethoxy) acetyl] prispinamycin methanesulfonate II B To 0.19 g (16R) -16-deoxy- 16-fluoro-14-O - [(2-imidazolyl-1-ethoxy) acetyl] pristinamycin IIB in solution in 8 ml of ethanol is added at 20 ° C. to 0.26 ml of 1.09N ethanolic methanesultonic acid solution. After stirring for 10 minutes, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) to give an oily residue which is stirred in 5 cm 3 of diethyl ether. Then the solvent is removed under reduced pressure (2.7 kPa), the thus obtained substance is stirred in 5 cm 3 of diethyl ether, then filtered, rinsed with diethyl ether and dried under reduced pressure ( 2.7 kPa) to obtain 0.189 (16R) -16-deoxy-16-fluoro-14-O - [(2-imidazolyl-1-ethoxy) acetyl] pristinamycin II B methanesulfonate in the form of a beige powder with a melting point of 115 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.95 (m, 6H), 1.12 (d, J = 6.5 Hz, 3H), 1.50-2.25 (m, 7H ), 1.86 (s, 3H), 2.79 (m, 1H), 2.83 (s, 3H), 3.02 (m, 1H), 3.26 (m, 1H), 3.58 (m, 1H), 3.72 (m, 1H), 3.80-3.90 (m, 2H), 4.00-4.15 (m, 3H), 4.34 (m, 1H), 4.50-4.60 (m, 2H), 4.80-4.90 (m, 2H), 4.90-5.00 (m, 1H), 4.94 (broad d, J = 10Hz, 1H), 5.75-5.95 (m, 2H), 6.06 (broad d, J = 16 Hz, 1H), 6.12 (d, J = 16 Hz, 1H), 6.65 (dd, J = 16 and 5Hz, 1H), 6.95 (m, 1H), 7.30 (broad s, 1H), 7.36 (broad s, 1H), 8.12 (s, 1H), 9.18 ( broad m, 1H). (16R) -16-Desoxy-16-fluoro-14-O - [(2-imidazolyl-1-ethoxy) acetyl] pristinamycin II B can be obtained as follows: Up to 1.3 g (16R) - 16-deoxy-16-fluoro-14-O - [(2-imidazolyl-1-ethoxy) acetyl] pristinamycin II B in a solution in 8 cm 3 of ethanol is added at a temperature of 20 ° C 0.26 cm 3 1.09 N ethanol methanesulfonic acid solution. After stirring for 10 minutes, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) to give an oily residue which is stirred in 5 cm 3 of diethyl ether. Then the solvent is removed under reduced pressure (2.7 kPa), and the solid thus obtained is stirred in 5 cm 3 of diethyl ether, then filtered, rinsed with diethyl ether and dried under reduced pressure. (2.7 kPa) to obtain 0.189 (16R) -16-deoxy-16-fluoro-14-O - [(2-imidazolyl-1-ethoxy) acetyl] pristinamycin II B methanesulfonate II B as a beige powder, m.p. approximately 115 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.95 (m, 6H), 1.12 (d, J = 6.5 Hz, 3H), 1.50-2.25 (m, 7H ), 1.86 (s, 3H), 2.79 (m, 1H), 2.83 (s, 3H), 3.02 (m, 1H), 3.26 (m, 1H), 3.58 (m, 1H), 3.72 (m, 1H), 3.80-3.90 (m, 2H), 4.00-4.15 (m, 3H), 4.34 (m, 1H), 4.50-4.60 (m, 2H), 4.80-4.90 (m, 2H), 4.90-5.00 (m, 1H), 4.94 (broad d, J = 10Hz, 1H), 5.75-5.95 (m, 2H), 6.06 (broad d, J = 16 Hz, 1H), 6.12 (d, J = 16 Hz, 1H), 6.65 (dd, J = 16 and 5Hz, 1H), 6.95 (m, 1H), 7.30 (broad s, 1H), 7.36 (broad s, 1H), 8.12 (s, 1H), 9.18 ( broad m, 1H). (16R) -16-Desoxy-16-fluoro-14-O - [(2-imidazolyl-1-ethoxy) acetyl] pristinamycin II B can be obtained as follows: Up to 1.3 g (16R ) -16-deoxy-16-fluoro-14-O - [(2-chloro-ethoxyacetyl] pristinamycin II B in solution in 6.5 cm 3 of dimethyl sulfoxide is added at a temperature of 20 ° C 0.41 g of imidazole and a few crystals of sodium iodide. After 4 hours of stirring at 60 ° C., 0.3 g of sodium iodide is added. After further 4 hours of stirring at 60 ° C, 72 hours of stirring at 85 ° C, and then 60 hours of stirring at 20 ° C, the reaction mixture is poured onto a mixture of 35 cm 3 of water and ice, and then 0.17 g of sodium bicarbonate is added. After filtration and washing of the solid with water and then drying in air, an oily residue is obtained, which is diluted with 30 cm 3 of dichloromethane. After concentration under reduced pressure (2.7 kPa), 1.23 g of a yellow solid are obtained, which is purified by flash chromatography on Amicon®__20-40 A silica [eluent: dichloromethane / methanol / acetonitrile (86/6/6 ethical v / v)]. Thus, 0.64 g of (16R) -16-deoxy-16-fluoro-14-O - [(2-imidazolyl-1-ethoxy) acetyl] pristinamycin IIB is obtained in the form of a light yellow powder. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d, J = 6.5Hz, 3H), 1.65-2.05 (m, 5H), 1.89 (s, 3H), 2.10-2.30 (m, 2H), 2.76 (m, 1H), 2.99 (dt, J = 17 and 6.5Hz, 1H), 3.24 (m, 1H), 3.51 (m, 1H), 3.75-3, 90 (m, 3H), 4.03 (cutoff AB, 2H), 4.07 (m, 1H), 4.17 (t, J = 5Hz, 2H)), 4.55 (m, 1H), 4 , 75-4.85 (m, 2H), 5.10 (reduced doublet, J HF = 48Hz, 1H), 5.24 (d, J = 9Hz, 1H), 5.78 (m, 1H), 5 , 80-5.95 (m, 1H), 5.87 (dd, J = 16 and 2Hz, 1H), 6.18 (d, J = 16Hz, 1H), 6.31 (m, 1H), 6 , 56 (dd, J = 16 and 5 Hz, 1H), 7.01 (s, 1H), 7.08 (s, 1H), 7.59 (s, 1H), 8.12 (s, 1H). (16R) -16-Deoxy-16-fluoro-14-O- [2-chloroacetoxy-acetyl] pristinamycin II B can be obtained as follows: Up to 5.32 g of (16R) -16-deoxy-16 -fluoropristinamycin II B (prepared as described in Example 1) in solution in 130 ml of dichloromethane are added at 20 ° C 3.1 g of N, N-dicyclohexylcarbodiimide, 0.61 g of 4-methylaminopyridine and 2.08 g of 2-chloroethoxyacetic acid in 20 cm 3 of dichloromethane. After 1 hour of stirring at 20 ° C, the reaction mixture is filtered and the residue rinsed with dichloromethane. The filtrate is concentrated to dryness under reduced pressure (2.7 kPa) to obtain 7.68 g of an orange solid which is purified by equilibrium chromatography on Amicon®__20-40 A silica. [eluent: dichloromethane / ethyl acetate (50/50 vol. vol)]. Thus, 4.68 g of (16R) -16-deoxy-16-fluoro-14-O- [2-chloroethoxyacetyl] pristinamycin II B are obtained in the form of a white powder. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.70-2.05 (m, 5H), 1.90 (s, 3H), 2.15 (m, 1H), 2.26 (m, 1H), 2.76 (m, 1H), 2.99 (dt, J = 17 and 6.5Hz, 1H), 3.24 (m, 1H), 3.50 (m, 1H), 3.67 (t, J = 6Hz, 2H), 3.80-3.90 (m, 1H), 3.83 (t, J = 6Hz, 2H), 4.05 (m, 1H), 4.14 (AB limit, J = 13Hz, 2H), 4.52 (m, 1H), 4.78 (dd, J = 10 and 1.5Hz, 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.12 (reduced doublet, J HF = 48 Hz, 1H), 5.31 (broad d, J = 9 Hz, 1H), 5.78 (m, 1H), 5.82 (dd, J = 16 and 2 Hz, 1H) 5.85-5.95 (m, 2H), 6.19 (d, J = 16 Hz, 1H), 6.52 (dd, J = 16 and 5 Hz, 1H), 8.12 (s, 1H). 2-chloroethoxyacetic acid can be obtained according to E. J. Corey and Christopher J. Helal, Tetrahedron Letters, Vol. 37, No. 28, pp. 4837-4840, 1996. Example 26 (16R) -14-O- {3,3-Dimethyl-3- [4,6-dimethyl-2- (4-morpholinyl-4-butyryloxy) phenyl] propionyl} -16-deoxy-16 -fluoropristinamycin II B Up to 1.6 g (16R) -14-O- {3- [2- (4-bromobutyroxy) -4,6-dimethylphenyl] -3,3-dimethylpropionyl} - -16-deoxy-16- Fluoropristinamycin II B in solution in 8 cm 3 of dimethyl sulfoxide is added at 20 ° C. under an argon atmosphere of 0.48 cm 3 of morpholine. After 30 minutes of stirring at 60 ° C, the reaction mixture is poured onto 300 cm 3 of a water-ice mixture. The precipitate is separated by filtration, flushed twice with 20 cm 3 of distilled water, and then dissolved in 150 cm 3 of dichloromethane. The solution obtained is washed three times with 20 cm 3 of distilled water, dried over magnesium sulphate, filtered, and then concentrated to dryness under reduced pressure (2.7 kPa), yielding 1.7 g of the residue, which is purified by flash chromatography [eluent: dichloromethane / methanol (94/6 v / v, partial)]. A solid is obtained which, after stirring in diisopropyl ether, filtering and drying (2.7 kPa) at 20 ° C, gives 0.52 g (16R) -14-O- {3.3- dimethyl-3- [4,6-dimethyl-2- (4-morpholinyl-4-butyryloxy) phenyl] propionyl} -16-deoxy-16-fluoropristinamycin II B as a colorless solid, melting point approx. 88 ° C (with distribution). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.40-1.60 (m, 1H), 1.56 (s, 3H), 1.58 (s, 3H), 1.75-2.05 (m , 7H), 1.80 (s, 3H), 2.14 (m, 1H), 2.25 (s, 3H), 2.40-2.50 (m, 6H), 2.54 (s, 3H), 2.63 (t, J = 7.5 Hz, 2H), 2.70-2.80 (m, 1H), 2.75 (d, J = 15 Hz, 1H), 2.85 (g, J = 15Hz, 1H), 2.91 (m, 1H), 3.15 (m, 1H), 3.45 (m, 1H), 3.73 (t, J = 5Hz, 4H), 3.86 (m, 1H), 4.01 (m, 1H), 4.53 (m, 1H), 4.70-4.95 (m, 1H), 4.77 (dd, J = 10 and 1.5Hz , 1H), 4.80 (dd, J = 9 and 3 Hz, 1H), 5.11 (d, J = 9 Hz, 1H), 5.66 (m, 1H), 5.71 (m, 1H), 5.81 (dd, J = 17 and 2Hz, 1H), 5.93 (m, 1H), 6.12 (d, J = 16Hz, 1H), 6.50 (dd, J = 17 and 5Hz, 1H ), 6.61 (d, J = 1.5 Hz, 1H), 6.81 (broad s, 1H), 8.12 (s, 1H). (16R) -14-O- {3- [2- (4-bromobutyryloxy) -4,6-dimethylphenyl] -3,3-dimethylpropionyl} -16-deoxy-16-fluoropristinamycin II B can be obtained from as follows: To 2.7 g of 3- [2- (4-bromobutyryloxy) -4,6-dimethylphenyl] -3,3-dimethylpropionic acid in solution in 150 cm 3 of dichloromethane is added at a temperature of 20 ° C in an atmosphere of argon, 1.2 g of N, N'-dicyclohexylcarbodiimide, 2.06 g of (16R) -16-deoxy-16-fluoropristinamycin IIB (prepared as described in Example 1) and 0.07 g of 4-dimethylaminopyridine. After 18 hours of stirring, the reaction mixture is filtered to remove insoluble matter. The filtrate is washed four times with 25 cm 3 of distilled water, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa), giving 4.6 g of the remainder. The content of the residue which is purified by two successive flash chromatographies (eluent: dichloromethane / - methanol, 96/4, then 97/3 v / v batchwise). There are obtained 1.6 g of (16R) -14-O- {3- [2- (4-bromobutyryloxy) -4,61-dimethylphenyl] -3,3-dimethylpropionyl} -16-deoxy-16-fluoropristinamycin II B as a creamy solid. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.45-2.05 (m, 12H), 1.79 (s, 3H), 2.13 (m, 1H), 2.24 (s, 3H), 2.29 (m, 2H), 2.54 (s, 3H), 2.70-2.90 (m, 5H), 2.91 (m, 1H), 3.15 (m, 1H), 3 , 56 (t, J = 6.5 Hz, 2H), 3.86 (m, 1H), 4.01 (m, 1H), 4.53 (m, 1H), 4.75-4.95 (m , 1H), 4.77 (dd, J = 10 and 2Hz, 1H), 4.80 (dd, J = 9 and 3Hz, 1H), 5.12 (d, J = 9Hz, 1H), 5.60 -5.75 (m, 2H), 5.81 (dd, J = 16 and 2Hz, 1H), 5.92 (m, 1H), 6.13 (d, J = 16Hz, 1H), 6.50 (dd, J = 16 and 5Hz, 1H), 6.59 (d, J = 1.5Hz, 1H), 6.82 (d, J = 1.5Hz, 1H), 8.12 (s, 1H) . 3- [2- (4-Bromobutyryloxy) -4,6-dimethylphenyl] -3,3-dimethylpropionic acid can be obtained as follows: Up to 2.3 g of 3- [2- (4-bromobutyryloxy) -4 , 6-dimethylphenyl] -3,3-dimethylpropanal in solution in 200 ml of acetone is added dropwise at 20 ° C a solution of 1 g of potassium permanganate in a mixture of 46 ml of distilled water and 30 ml of acetone. After stirring for 24 hours, the reaction mixture is added to 100 cm 3 of distilled water, acidified to pH 1-2 by adding an aqueous solution of 1N hydrochloric acid, and then extracted five times with 100 cm 3 of dichloromethane. The organic phases are combined, dried over magnesium sulfate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa). 2.7 g of 3- [2- (4-bromobutyryloxy) -4,6-dimethylphenyl] -3,3-dimethylpropionic acid are obtained in the form of a colorless oil. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm), (2 conformers in the ratio 80-20): 1.58 and 1.59 (2s, total 6H), 2.23 and 2.24 (2s, total 3H), 2.29 (m, 2H), 2.54 and 2.55 (2s, total 3H), 2.78 (t, J = 7Hz, 2H), 2.84 and 2.87 ( 2s, total 2H), 3.55 (t, J = 6.5Hz, 2H), 6.57 and 6.59 (2 broad s, total 1H), 6.81 and 6.83 (2 broad s , total 1H). 3- [2- (4-Bromobutyryloxy) -4,6-dimethylphenyl] -3,3-dimethylpropanal can be prepared as follows: at 24 ° C 2.5 g of 3- [2- (4-bromobutyryloxy) -4,6-dimethylphenylpropanol-1 in solution in 160 ml of dichloromethane. After 2 hours of stirring at 24 ° C, the reaction mixture is filtered through 630 g of silica (grain size 0.063 to 0.2 mm), elution successively with pure dichloromethane and then with a mixture of dichloromethane and ethyl acetate (80/20 vol. gravity). Thus, 2.4 g of 3- [2- (4-bromobutyryloxy) -4,6-dimethylphenyl] -3,3-dimethylpropanal are obtained in the form of a colorless, g est oil. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm), (2 conformers in the ratio 80-20): 1.57 (s, 6H), 2.25 (s, 3H), 2.29 (m, 2H ), 2.55 (s, 3H), 2.78 (t, J = 7Hz, 2H), 2.80-2.90 (m, 2H), 3.56 (t, J = 6Hz, 2H), 6.59 and 6.61 (2 broad s, total 1H), 6.85 and 6.87 (2 broad s, total 1H), 9.55 (broad s, 1H). 3- [2- (4-Bromobutyryloxy) -4,6-dimethylphenyl] -3,3-dimethylpropanol-1 can be prepared in the following way: Up to 5.4 g 4-bromomosilane 2- {3- ( tert-butyldimethylsilyloxy]) - 1,1-dimethylpropyl} -3,5-dimethylphenol in 60 ml of dichloromethane is added dropwise at 0 ° C. under an argon atmosphere of 2.24 ml of triethylamine trifluoride. After 42 hours of stirring at 20 ° C, the reaction mixture is filtered through 750 g of silica (granulation 0.063-0.2 mm), eluting successively with dichloromethane and then with the dichloromethane / acetate mixture. ethyl (90/10 vol ethical). Thus, 2.6 g of 3- [2- (4-bromobutyryloxy) -4,6-dimethylphenyl] -3,3-dimethylpropanol-1 are obtained in the form of a colorless g ester oil. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm), (2 conformers in the ratio 80-20): 1.50 and 1.52 (2s, total 6H), 2.00-2.10 (m, 2H), 2.23 and 2.24 (s, total 3H), 2.30 (m, 2H), 2.54 (s, 3H), 2.78 (t, J = 7Hz, 2H), 3 , 50-3.60 (m, 4H), 6.55 and 6.56 (2 broad s, total 1H), 6.82 and 6.84 (2 broad s, total 1H). 4-Bromomosa slan 2- {3- (tert-butyldimethylsilyloxy) -1,1-dimethylpropyl} -3,5-dimethylphenol can be prepared as follows: Up to 3.22 g of 2- {3- (tert. -butyldimethylsilyloxy]) - 1,1-dimethylpropyl} -3,5-dimethylphenol in a solution in 60 cm 3 of tetrahydrofuran is added at a temperature of 20 ° C under argon in small portions of 0.32 g of sodium hydride (concentration 75% in mineral oil) and then 15 minutes later 1.16 cm 6 of 4-bromobutyryl chloride. After stirring for 40 minutes, 100 cm 3 of ether, 10 cm 3 of distilled water and 10 cm 3 of a saturated aqueous sodium chloride solution are added. After stirring, the organic phase is decanted, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) to obtain a residue which is filtered through 75 g of silica (approx. granulation 0.063-0.2 mm) eluting successively with cyclohexane and then with a mixture of cyclohexane / ethyl acetate (90/10 vol. vol. partial). Thus, 2 g of 2- {3- (tert-butyldimethylsilyloxy) -1,1-dimethylpropyl} -3,5-dimethylphenol 4-bromomate are obtained in the form of a colorless oil. 1 H NMR spectrum (300 MHz, CDCl 3, dp ppm), (2 conformers in the ratio 80-20): 0.00 and 0.03 (2s, total 6H), 0.87 and 0.89 (2s, total 9H), 1.45 and 1.55 (m, 6H), 2.05 (t, J = 7.5Hz, 2H), 2.24 and 2.25 (2s, total 3H), 2, 31 (m, 2H), 2.54 (s, 3H), 2.77 (t, J = 7 Hz, 2H), 3.40-3.65 (m, 4H), 6.56 and 6.58 ( 2 broad s, total 1H), 6.81 and 6.83 (2 broad s, total 1H). 2- {3- (tert-Butyl dimethylsilyloxy) -1,1-dimethylpropyl} -3,5-dimethylphenol can be obtained according to Amsberry K. NS. , Gerstenberger A. E. , Borchardt R. T. , Pharm. Res. 1991, 8 (4), 455-61. Example 27 (16R) -16-deoxy-16-fluoro-14-O- [4- (morpholinyl) butyryl) pristinamycin methanesulfonate II B To 0.453 g (16R) -16-deoxy-16-fluoro-14- O- [4- (morpholinyl-4-) butyryl] pristinamycin II B in solution in 10 cm 3 of ethanol is added at 20 ° C to 6.58 cm 3 of 1.09N ethanolic methanesulfonic acid solution. After 10 minutes of stirring, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) to give a residue which is stirred in 10 cm 3 of diethyl ether. After filtration, expanding the solid with 4 cm 3 of diethyl ether and drying under reduced pressure (2.7 kPa) at 20 ° C, 0.506 of the methanesulphonate (16R) -16-deoxy-16 is obtained -fluoro-14-O- [4- (morpholinyl-4) butyryl] pristinamycin II B as a white powder, melting point approximately 122 ° C (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 0.99 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.60-2.00 (m, 5H), 1.89 (s, 3H), 2.10-2.30 (m, 4H), 2.48 (t , J = 7 Hz, 2H), 2.77 (m, 1H), 2.82 (s, 3H), 2.88 (m, 2H), 2.99 (dt, J = 17 and 6 Hz, 1H), 3.13 (m, 2H), 3.23 (dt, J = 17 and 6 Hz, 1H), 3.45-3.60 (m, 3H), 3.82 (m, 1H), 3.95- 4.20 (m, 5H), 4.53 (m, 1H), 4.79 (dd, J = 10 and 2Hz, 1H), 4.83 (dd, J = 9 and 3.5Hz, 1H), 5.11 (reduced multiplet, J HF = 48Hz, 1H), 5.28 (d, J = 10Hz, 1H), 5.75-5.85 (m, 2H), 5.84 (J = 17 and 2Hz , 1H), 6.09 (m, 1H), 6.19 (d, J = 16 Hz, 1H), 6.53 (dd, J = 17 and 5 Hz, 1H), 8.11 (s, 1H). (16R) -16-Desoxy-16-fluoro-14-O- [4- (morpholinyl-4) -butyryl] pristinamycin II B can be obtained as follows: Up to 1.3 g (16R) -16 - deoxy-16-fluoropristinamycin II B (prepared as described in example 1) in solution in 35 cm 3 of dichloromethane is added at a temperature of 20 ° C 0.512 cm 3 of 4- (morpholinyl-4) -mas acid hydrochloride and 0.343 ml of triethylamine in solution in 35 ml of dichloromethane, 0.503 g of N, N'-dicyclohexylcarbodiimide and 0.03 g of 4-dimethylaminopyridine. After stirring for 16 hours at 20 ° C., the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa). The residue is dissolved in 10 cm 3 of dichloromethane and then filtered. The filtrate is diluted with 40 cm3 of dichloromethane, washed with 50 cm 3 of water, and then dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa), yielding 1 g of yellow a solid which is purified by flash chromatography [eluent: gradient dichloromethane / methanol / acetonitrile (98/1/1 then 96/2/2 by volume). Thus, 0.584 g of a colorless solid is obtained which is dissolved in 20 cm 3 of dichloromethane. The solution obtained is washed with 20 cm 3 of water, dried over magnesium sulphate, filtered, and then concentrated to dryness under reduced pressure (2.7 kPa) to obtain, after stirring in pentane, filtration and drying (2 , 7 kPa) at 20 ° C, 0.524 g of (16R) -16-deoxy-16-fluoro-14-O- [4- (morpholinyl-4) butyryl] pristinamycin II B as a colorless solid with a melting point about 100 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.60-2.05 (m, 7H), 1.89 (s, 3H), 2.16 (m, 1H), 2.23 (m, 1H), 2.35 (m, 4H), 2.43 (m, 4H), 2.76 (m, 1H), 2.99 (dt, J = 17 and 6 Hz, 1H), 3.24 (m, 1H) , 3.49 (m, 1H), 3.71 (m, 4H), 3.85 (m, 1H), 4.07 (m, 1H), 4.54 (m, 1H), 4.78 ( dd, J = 10 and 1.5 Hz, 1H), 4.82 (dd, J = 9 and 3 Hz, 1H), 5.11 (reduced doublet, J HF = 48 Hz, 1H), 5.30 (d , J = 9Hz, 1H), 5.75-5.85 (m, 1H), 5.76 (m, 1H), 5.81 (dd, J = 17 and 1.5Hz, 1H), 5.95 (m, 1H), 6.19 (d, J = 16 Hz, 1H), 6.51 (dd, J = 17 and 5 Hz, 1H), 8.12 (s, 1H). The hydrochloride of 4- (morpholinyl-4) butyric acid can be obtained according to Raj K. Razdan, Barbara Zitko Terris, Harry G. Pars, J. Med. Chem. 1976, 19 (4), 454-461. PL 203 554 B1 34 Example 28 (16R) -16-Desoxy-16-fluoro-14-O- (4-imidazolyl-1-butyryl) pristinamycin II B Up to 600 mg (16R) -14-O- (4- 150 mg of imidazole are added to bromobutyryl) -16-deoxy-16-fluoropristinamycin II B in solution in 2.5 ml of dimethylformamide. After 4 hours of stirring at 60 ° C, 0.5 g of additional imidazole is added and stirring is continued for 2 hours at 65 ° C. The mixture is concentrated under reduced pressure (2.7 kPa) to obtain a residue which is dissolved in 20 cm 3 of distilled water and 25 cm 3 of dichloromethane. The organic phase is decanted and then washed twice with 20 cm 3 of distilled water. The organic phase is dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa), yielding 1.13 g of a solid, which is purified by means of equilibrium chromatography [ eluent: dichloromethane-methanol (98-2 vol ethical followed by 95-5 vol ethical)]. Thus, 325 mg of product is obtained, which is stirred in diethyl ether, filtered and then dried at 20 ° C (90 Pa), yielding 248 mg (16R) -16-deoxy-16-fluoro-14-. O- (4-imidazolyl-1-butyril) pristinamycin IIB as a beige solid, m.p. 125 ° C. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5 Hz, 3H), 1.60-2.05 (m, 5H), 1.90 (s, 3H), 2.00-2.35 (m, 2H), 2.08 (m , 2H), 2.26 (m, 2H), 2.76 (m, 1H), 2.99 (dt, J = 17 and 6.5 Hz, 1H), 3.24 (m, 1H), 3. 50 (m, 1H), 3.94 (m, 1H), 4.01 (t, J = 7 Hz, 2H), 4.06 (m, 1H), 4.54 (m, 1H), 4.79 (dd, J = 10 and 2 Hz, 1H), 4.82 (dd, J = 9 and 3 Hz, 1H), 5.11 (reduced doublet, J HF = 48 Hz, 1H), 5.28 (d, J = 9Hz, 1H), 5.75-5.90 (m, 1H), 5.78 (m, 1H), 5.84 (dd, J = 16 and 1.5Hz, 1H), 6.09 ( m, 1H), 6.20 (d, J = 16 Hz, 1H), 6.53 (dd, J = 16 and 5 Hz, 1H), 6.91 (s, 1H), 7.07 (s, 1H) , 7.44 (s, 1H), 8.12 (s, 1H). (16R) -14-O- (4-Bromobutyryl) -16-deoxy-16-fluoropristinamycin II B can be obtained in the following way: Up to 5 g of (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in Example 1) in a solution in 150 ml of dichloromethane, 2.64 g of triethylamine are added, followed by 2.3 ml of 4-bromobutyric acid chloride. After 18 hours of stirring at 25 ° C., additionally 1.32 cm 3 of triethylamine and 1.15 cm 3 of 4-bromobutyric acid chloride are added. The reaction mixture is stirred for 2 hours at 25 ° C and then washed twice with 100 cm 3 of distilled water. The organic phase is mixed over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) to obtain 8.19 g of brown oil which is purified by equilibrium chromatography [eluent : dichloromethane-methanol (97-3 ethical vol)]. Thus, 3.4 g of product are obtained which are stirred in diisopropyl ether, filtered, dried and then purified again by flash chromatography [eluent: dichloromethane-methanol (98-2 vol. Vol. Thus, after stirring in diisopropyl ether, filtration and drying at 20 ° C (90 Pa), 1.32 g of (16R) -14-O- (4-bromobutyryl) -16-de- are obtained. zoxy-16-fluoropristinamycin II B as a white crushed solid which is used as such a. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.65-2.05 (m, 5H), 1.89 (s, 3H), 2.10-2.35 (m, 2H), 2.17 (m , 2H), 2.49 (m, 2H), 2.77 (m, 1H), 2.99 (m, 1H), 3.45-3.55 (m, 1H), 3.47 (t, J = 6.5Hz, 2H), 3.86 (m, 1H), 4.06 (m, 1H), 4.54 (m, 1H), 4.78 (dd, J = 10 and 1.5Hz, 1H), 4.82 (dd, J = 9 and 3 Hz, 1H), 5.13 (reduced doublet, J HF = 48 Hz, 1H), 5.31 (d, J = 9 Hz, 1H), 5.75- 5.90 (m, 1H), 5.77 (m, 1H), 5.82 (dd, J = 16 and 2Hz, 1H), 5.93 (m, 1H), 6.20 (d, J = 15 Hz, 1H), 6.52 (dd, J = 16 and 5 Hz, 1H), 8.12 (s, 1H). Example 29 (16R) -16-Desoxy-16-fluoro-14-O- {4- [4- (pyrrolidinyl-1-carbonylmethyl) piperazinyl) butyryl} pristinamycin II B Up to 680 mg (16R) -14- O- (4-bromobutyryl) -16-deoxy-16-fluoropristinamycin II B (prepared as described in Example 28) in solution in 3 ml of dimethylformamide is added 590 mg of 1- (pyrrolidinecarbonylmethyl) piperazine. After 4 hours of stirring at 60 ° C, the mixture is concentrated under reduced pressure (2.7 kPa) to obtain the remaining residue which is dissolved in 40 cm 3 of distilled water and 20 cm 3 of dichloromethane. After adding sodium chloride, the aqueous phase is decanted and then extracted twice with 20 cm 3 of dichloromethane. The organic phases are combined, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) to obtain 1 brown solid which is purified by chromatography. - balance [eluent: dichloromethane-methanol (95-5 ethical vol)]. Thus, 650 mg of product are obtained, which is stirred in diethyl ether for 1 hour, filtered and then dried at 20 ° C (90 Pa), yielding 413 mg of (16R) -16-deoxy-16. -fluoro-14-O- {4- [4- (pyrrolidinyl-1-carbonylmethyl) piperazinyl-1) butyryl} pristinamycin IIB as a crushed, colorless solid, m.p. 128 ° C. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.60-2.05 (m, 11H), 1.88 (s, 3H), 2.10-2.35 (m, 2H), 2.32 (t , J = 7.5Hz, 2H), 2.40 (m, 2H), 2.50-2.70 (m, 8H), 2.99 (dt, J = 17 and 6Hz, 1H), 3.12 (s, 2H), 3.24 (m, 1H), 3.40-3.55 (m, 5H), 3.86 (m, 1H), 4.06 (m, 1H), 4.53 ( m, 1H), 4.78 (dd, J = 10 and 1.5Hz, 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.09 (reduced doublet, J HF = 48Hz, 1H ), 5.29 (d, J = 9Hz, 1H), 5.75-5.85 (m, 1H), 5.75 (m, 1H), 5.83 (dd, J = 17 and 1.5Hz , 1H), 6.05 (m, 1H), 6.18 (d, J = 16 Hz, 1H), 6.52 (dd, J = 17 and 5 Hz, 1H), 8.12 (s, 1H). Example 30 (16R) -16-deoxy-16-fluoro-14-O- [5- (morpholinyl-4) pentanoyl] pristinamycin methanesulfonate II B To 0.79 g (16R) -16-deoxy-16-fluoro 14-O- [5- (morpholinyl-4) pentanoyl] pristinamycin II B in solution in 15 ml of ethanol is added at 20 ° C. to 11 ml of 0.1N ethanolic methanesulfonic acid solution. After stirring for 20 minutes, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) to give a residue which is stirred in 10 cm 3 of ether. After filtration, dissolving the solid with 5 cm 3 of diethyl ether and drying under reduced pressure (2.7 kPa) at 20 ° C, 0.89 methanesulfonate (16R) -16-deoxy- is obtained. 16-fluoro-14-O- [5- (morpholinyl-4) pentanoyl] pristinamycin II B as a crushed colorless solid, melting point approximately 120 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.85 (d, J = 6.5 Hz, 3H), 0.94 (d, J = 6.5 Hz, 3H), 1.03 (d , J = 6.5Hz, 3H), 1.45-1.70 (m, 5H), 1.70-2.25 (m, 6H), 1.77 (s, 3H), 2.39 (t , J = 7Hz, 2H), 2.95-3.50 (m, 8H), 3.50-3.70 (m, 4H), 3.80 (m, 1H), 3.90-4.05 (m, 3H), 4.70-4.80 (m, 2H), 5.09 (reduced multiplet, J HF = 48Hz, 1H), 5.42 (d, J = 9.5Hz, 1H) , 5.62 (m, 1H), 5.75 (m, 1H), 5.80 (broad d, J = 16Hz, 1H), 6.18 (d, J = 16Hz, 1H), 6.62 ( dd, J = 16 and 4 Hz, 1H), 8.15 (m, 1H), 8.52 (s, 1H), 9.46 (broad mf, 1H). (16R) -16-Deoxy-16-fluoro-14-O- [5- (morpholinyl-4) -pentanoyl] pristinamycin II B can be obtained as follows: Up to 2 g of (16R) -16-deoxy -16-fluoro-14-O- (5-chloropentanoyl) pristinamycin II B in solution in 30 ml of tetrahydrofuran is added at a temperature of 20 ° C. 0.46 g of sodium iodide and 0.54 ml of morpholine. After 27 hours of stirring under a reflux cooler, 0.54 cm 3 of additional morpholine is added. After 16 hours of additional stirring under a reflux condenser, 1 cm 3 of dimethylformamide and 0.54 cm 3 of morpholine are added. After a further 24 hours of stirring under a reflux condenser, the reaction mixture is diluted with 20 cm 3 of dichloromethane and washed with 50 cm 3 of water. The organic phase is decanted and the aqueous phase is extracted with 50 cm 3 of dichloromethane. The organic phases are combined, washed three times with 150 cm 3 of water, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) to give 2 g of the residue. which is purified by flash chromatography [eluent: dichloromethane / methanol / acetonitrile (92/4/4 v / v)]. Thus, after stirring in pentane, filtration and drying (2.7 kPa) at 20 ° C, 0.81 g of (16R) -16-deoxy-16-fluoro-14-O- [5- (morpholinyl-4) pentanoyl] pristinamycin II B in the form of a beige substance. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.52 (m , 2H), 1.5-2.05 (m, 7H), 1.89 (s, 3H), 2.10-2.35 (m, 2H), 2.32 (m, 4H), 2, 42 (m, 4H), 2.76 (m, 1H), 2.99 (dt, J = 17 and 6 Hz, 1H), 3.24 (m, 1H), 3.48 (m, 1H), 3 , 72 (t, J = 5Hz, 4H), 3.86 (m, 1H), 4.07 (m, 1H), 4.53 (m, 1H), 4.78 (dd, J = 10 and 2Hz , 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.11 (reduced doublet, J HF = 48Hz, 1H), 5.30 (d, J = 9Hz, 1H), 5.70 -5.85 (m, 2H), 5.82 (dd, J = 16.5 and 2Hz, 1H), 5.96 (m, 1H), 6.19 (d, J = 16Hz, 1H), 6 . 51 (dd, J = 16.5 and 5 Hz, 1H), 8.12 (s, 1H). (16R) -16-Desoxy-16-fluoro-14-O- (5-chloropentanoyl) pristinamycin II B can be obtained as follows: Up to 4 g of (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in Example 1) in solution in 100 cm 3 of dichloromethane, 2.1 cm 3 of triethylamine, 2 cm 3 of 5-chloropentanoyl chloride and 0.18 g of 4 are added at a temperature of 28 ° C. -dimethylaminopyridine. After 2 hours of stirring at 28 ° C., the reaction mixture is poured onto 100 cm 3 of water. The organic phase is decanted and the aqueous phase is extracted with 100 cm 3 of dichloromethane. The organic phases are combined, washed twice with 200 cm 3 of water, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) to obtain 6 g of a chestnut solid, which is purified by flash chromatography [eluent: dichloromethane / methanol (98/2 v / v, partial)]. Thus, after stirring in pentane, filtering and drying (2.7 kPa) at 20 ° C, 3.77 g of (16R) -16-deoxy-16-fluoro-14- are obtained. O- (5-chloropentanoyl) pristinamycin II B as a colorless solid. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.65-2.05 (m, 9H), 1.89 (s, 3H), 2.15 (m, 1H), 2.24 (m, 1H), 2.33 (t, J = 7 Hz, 2H), 2.76 (m, 1H), 2.99 (m, 1H), 3.24 (m, 1H), 3.49 (m, 1H), 3 , 55 (t, J = 7Hz, 2H), 3.86 (m, 1H), 4.06 (m, 1H), 4.52 (m, 1H), 4.78 (dd, J = 10 and 2Hz , 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.11 (reduced doublet, J HF = 48Hz, 1H), 5.30 (d, J = 9Hz, 1H), 5.75 -5.85 (m, 1H), 5.76 (m, 1H), 5.82 (dd, J = 17 and 2Hz, 1H), 5.96 (m, 1H), 6.19 (d, J = 16 Hz, 1H), 6.51 (dd, J = 17 and 5 Hz, 1H), 8.13 (s, 1H). Example 31 (16R) -16-deoxy-16-fluoro-14-O- [5- (imidazolyl-1) pentanoyl] pristinamycin methanesulfonate II B To 0.66 g (16R) -16-deoxy-16-fluoro 14-O- [5- (imidazolyl-1) pentanoyl] pristinamycin II B in solution in 10 cm 3 of ethanol is added at 20 ° C to 10.2 cm 3 of 0.095N ethanolic methanesulfonic acid solution. After 10 minutes of stirring, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) to give a residue which is stirred in 20 cm 3 of ether. After filtration, washing the solid with 5 cm 3 of diethyl ether and drying under reduced pressure (2.7 kPa), 0.712 g of (16R) -16-deoxy-16-fluoro-14-O- methanesulfonate is obtained. [5- (imidazolyl-1) pentanoyl] pristinamycin II B as a yellow solid, melting point approximately 126 ° C (decomposition). 1 H NMR spectrum (400 MHz, (CD 3) 2 SO d6, dp ppm): 0.85 (d, J = 6.5Hz, 3H), 0.94 (d, J = 6.5Hz, 3H), 1.03 (d, J = 6.5Hz, 3H), 1.40-1.60 (m, 3H), 1.70-2.30 (m, 8H), 1.76 (t, J = 7Hz , 2H), 2.77 (m, 1H), 3.10-3.40 (m, 2H), 3.58 (m, 1H), 3.67 (m, 1H), 3.80 (m, 1H), 3.97 (m, 1H), 4.21 (t, J = 7Hz, 2H), 4.65-4.80 (m, 2H), 5.08 (reduced doublet, J HF = 48Hz, 1H), 5.40 (d, J = 9.5Hz, 1H), 5.61 (m, 1H), 5.73 (m, 1H), 5.80 (broad d, J = 16Hz, 1H), 6.18 (d, J = 16 Hz, 1H), 6.63 (dd, J = 16 and 4 Hz, 1H), 7.72 (broad s, 1H), 7.80 (broad s, 1H), 8, 15 (t, J = 6 Hz, 1H), 8.52 (s, 1H), 9.14 (broad s, 1H). (16R) -16-Desoxy-16-fluoro-14-O- [5- (imidazolyl-1) pentanoyl] pristinamycin II B can be obtained as follows: Up to 1.4 g (16R) -16- deoxy-16-fluoro-14-O- (5-chloropentanoyl) pristinamycin II B (prepared as described in example 30) in solution in 20 cm 3 of tetrahydrofuran is added at a temperature of 20 ° C 0.29 g of imidazole and 0.32 g of sodium iodide. After stirring for 20 hours under a reflux condenser, 1 cm 3 of dimethylformamide and 0.29 g of imidazole are added. After 8.5 hours of additional stirring under a reflux condenser, 0.29 g of imidazole is added. After a further 15.5 hours of stirring under a reflux condenser, the reaction mixture is diluted with 50 cm 3 of dichloromethane and then washed with 100 cm 3 of water. The organic phase is decanted and the aqueous phase is extracted with 50 cm of dichloromethane. The organic phases are combined, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) to obtain 1.6 g of an orange solid which is purified by two successive flash chromatographies [eluent: dichloromethane / methanol (97/3 v / v)]. Thus, after stirring in diethyl ether, filtration and drying (2.7 kPa) at 20 ° C, 0.66 g of (16R) -16-deoxy-16-fluoro-14-O- [5- (imidazolyl-1) pentanoyl] pristinamycin II B as a yellow solid. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.11 (d , J = 6.5Hz, 3H), 1.60-2.05 (m, 9H), 1.90 (s, 3H), 2.10-2.25 (m, 2H), 2.31 (t , J = 7 Hz, 2H), 2.76 (m, 1H), 3.00 (m, 1H), 3.25 (dt, J = 17 and 5.5 Hz, 1H), 3.51 (m, 1H ), 3.84 (m, 1H), 3.94 (t, J = 7 Hz, 2H), 4.06 (m, 1H), 4.56 (m, 1H), 4.75-4.90 ( m, 2H), 5.06 (reduced doublet, J HF = 48 Hz, 1H), 5.24 (d, J = 9 Hz, 1H), 5.75-5.90 (m, 2H), 5.90 ( dd, J = 16 and 1.5Hz, 1H), 5.96 (m, 1H), 6.19 (d, J = 16Hz, 1H), 6.51 (dd, J = 16, 5 and 5Hz, 1H ). 8.12 (s, 1H). (16R) -16-Desoxy-16-fluoro-14-O- (5-chloropentanoyl) pristinamycin II B can be obtained as follows: Up to 4 g of (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in Example 1) in solution in 100 cm 3 of dichloromethane, 2.1 cm 3 of triethylamine, 2 cm 3 of 5-chloropentanoyl chloride and 0.18 g of 4 are added at a temperature of 28 ° C. -dimethylaminopyridine. After 2 hours of stirring at 28 ° C., the reaction mixture is poured onto 100 cm 3 of water. The organic phase is decanted and the aqueous phase is extracted with 100 cm 3 of dichloromethane. The organic phases are combined, washed twice with 200 cm 3 of water, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) to obtain 6 g of a chestnut solid, which is purified by flash chromatography [eluent: dichloromethane / methanol (98/2 v / v, partial)]. Thus, after stirring in pentane, filtering and drying (2.7 kPa) at 20 ° C, 3.77 g of (16R) -16-deoxy-16-fluoro-14- are obtained. O- (5-chloropentanoyl) pristinamycin II B as a colorless solid. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.65-2.05 (m, 9H), 1.89 (s, 3H), 2.15 (m, 1H), 2.24 (m, 1H), 2.33 (t, J = 7 Hz, 2H), 2.76 (m, 1H), 2.99 (m, 1H), 3.24 (m, 1H), 3.49 (m, 1H), 3 , 55 (t, J = 7Hz, 2H), 3.86 (m, 1H), 4.06 (m, 1H), 4.52 (m, 1H), 4.78 (dd, J = 10 and 2Hz , 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.11 (reduced doublet, J HF = 48Hz, 1H), 5.24 (d, J = 9Hz, 1H), 5.75 -5.90 (m, 2H), 5.90 (dd, J = 16 and 1.5 Hz, 1H), 6.17 (d, J = 15 Hz, 1H), 6.52 (m, 1H), 6 , 57 (dd, J = 16 and 5 Hz), 6.89 (s, 1H), 7.06 (s, 1H), 8.10 (s, 1H). Example 32 (16R) -16-Desoxy-16-fluoro-14-O- {5- [4- (pyrrolidinyl-1-carbonylmethyl) piperazinyl-1) pentanoyl} pristinamycin II B Up to 1.8 g (16R ) -16-deoxy-16-fluoro-14-O- (5-chloropentanoyl) pristinamycin II B (prepared as described in example 30) in solution in 20 cm 3 of dimethylformamide is added at a temperature of 20 ° C 1, 1 g of (pyrrolidinyl-1-carbonylmethyl) piperazine and 0.42 g of sodium iodide. After 27.5 hours of stirring at 50 ° C., 0.55 g of (pyrrolidinyl-1-carbonylmethyl) piperazine are added. After 27.5 hours of additional stirring at 54 ° C, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) to obtain a residue which is diluted in 100 cm 3 of dichloromethane. The resulting solution is washed 4 times with 300 cm 3 of water. The organic phase is dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa), obtaining 1.61 g of a yellow solid, which is purified by flash chromatography [eluent: dichloromethane-methanol (95-5 v / v)]. Thus, after stirring in pentane, filtering and drying (2.7 kPa), 0.726 g of (16R) -16-deoxy-16-fluoro-14-O- {5- [4- (pyrrolidinyl-1 -carbonylmethyl) piperazinyl-1) -pentanoyl} prispinamycin IIB as a beige solid, m.p. 100 ° C (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.51 (m, 2H), 1.55-1.80 (m, 3H), 1.75-2.05 (m, 8H), 1.88 (s , 3H), 2.23 (m, 1H), 2.25-2.40 (m, 4H), 2.50 (m, 4H), 2.58 (m, 4H), 2.76 (m, 1H), 2.99 (dt, J = 17 and 6 Hz, 1H), 3.11 (s, 2H), 3.24 (m, 1H), 3.45-3.55 (m, 5H), 3 , 86 (m, 1H), 4.06 (m, 1H), 4.53 (m, 1H), 4.78 (dd, J = 10 and 2Hz, 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.09 (reduced doublet, J HF = 48Hz, 1H), 5.30 (d, J = 9Hz, 1H), 5.75-5.90 (m, 1H), 5.75 (m, 1H), 5.83 (dd, J = 17 and 1.5 Hz, 1H), 6.04 (m, 1H), 6.19 (d, J = 16 Hz, 1H), 6.53 (dd , J = 17 and 5 Hz, 1H), 8.12 (s, 1H). Example 33 (16R) -16-Deoxy-16-fluoro-14-O - [(RR, SS) -trans-2- (morpholinomethyl) -1-cyclopropanecarbonyl] pristinamycin II B, mixture of two diastereoisomers in the ratio 50 / 50 To 2.1 g of (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in example 1) in solution in 80 cm 3 of dichloromethane are added at 20 ° C under argon atmosphere 1 , 1 g of (RR, SS) -trans-2- (morpholinomethyl) -1-cyclopropanecarboxylic acid, 1.24 g of N, N'-dicyclohexylcarbodiimide, and 0.73 g of 4-dimethylaminopyridine. After 16 hours of stirring, the reaction mixture is filtered to remove insoluble parts, and then concentrated to dryness under reduced pressure (2.7 kPa) to obtain 4.2 g of the residue, which is then purified. by flash chromatography [eluent: dichloromethane / methanol gradient (98/2 to 95/5 v / v)]. A solid is obtained, which is stirred in diisopropyl ether, filtered and dried (2.7 kPa) at 20 ° C, yielding 1.5 g of (16R) -16-deoxy-16-fluoro-14- O - [(RR, SS) -trans-2- (morpholinomethyl) -1-cyclopropanecarbonyl] pristinamycin II B, 50/50 mixture of the two diastereoisomers, as a white powder. 1 H NMR spectrum (400 MHz, CDCl 3, d in ppm). . The presence of sc of two diastereoisomers in the ratio 50-50: 0.77 (m, 1H), 0.96 (d, J = 6.5Hz, 3H), 1.00 (d, J = 6.5Hz) is observed. , 3H), 1.09 (d, J = 6.5Hz, 3H), 1.24 (m, 1H), 1.41 (m, 1H), 1.52 (m, 1H), 1.60- 2.05 (m, 5H), 1.87 (s, 3H), 2.05-2.45 (m, 4H), 2.50 (m, 4H), 2.76 (m, 1H), 2 .99 (m, 1H), 3.24 (m, 1H), 3.49 (m, 1H), 3.73 (t, J = 5Hz, 4H), 3.84 (m, 1H), 4. 06 (m, 1H), 4.53 (m, 1H), 4.75-4.85 (m, 2H), 5.09 (reduced doublet, J HF = 48Hz, 1H), 5.30 (m, 1H), 5.70-5.85 (m, 3H), 5.96 and 6.03 (2m, total 1H), 6.19 (d, J = 16Hz, 1H), 6.651 (m, 1H), 8.12 (s, 1H). (RR, SS) -trans-2- (morpholinomethyl) -1-cyclopropanecarboxylic acid can be obtained as follows: Up to 1.0 g (RR, SS) -trans-2- (morpholinomethyl) -1- Ethyl cyclopropanecarboxylate in solution in 50 ml of ethanol is added at 20 ° C. to 10 ml of 1N aqueous sodium hydroxide solution. After stirring for 2 hours at 80 ° C, the ethanol is concentrated under reduced pressure (2.7 kPa), and the remaining aqueous phase is washed with 50 cm 3 of acetate ethyl. The aqueous phase is adjusted to pH 6 by adding a 1N aqueous hydrochloric acid solution and then concentrated to dryness under reduced pressure (2.7 kPa). The residue is recovered twice with 50 cm3 of toluene and concentrated to dryness under reduced pressure (2.7 kPa). The residue is dissolved at 50 ° C in 50 cm 3 of ethanol, the insoluble parts are removed by filtration, and the filtrate is concentrated under reduced pressure (2.7 kPa). Thus, 0.9 g of (RR, SS) -trans-2- (morpholinomethyl) -1-cyclopropanecarboxylic acid is obtained in the form of a yellow oil. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.68 (m, 1H), 1.20 (m, 1H), 1.46 (m, 1H), 1.56 (m, 1H) , 2.28 (dd, J = 13 and 8Hz, 1H), 2.60 (dd, J = 13 and 5Hz, 1H), 2.66 (unres.: 2H), 2.77 (unresolved, 2H), 3 . 78 (t, J = 5 Hz, 4H). Ethyl (RR, SS) -trans-2- (morpholinomethyl) -1-cyclopropanecarboxylate can be obtained as follows: Up to 2.82 g of ethyl (RR, SS) -trans-2-formyl-1-cyclopropanecarboxylate In a solution in 100 cm 3 of dichloromethane, 1.74 cm 3 of morpholine and 6.36 g of sodium hydroborate tris (acetate-O) are added at a temperature of 20 ° C. under an argon atmosphere. After stirring for 4 hours, 100 cm 3 of distilled water are added. After mixing, the organic phase is decanted and then washed with 100 cm 3 of distilled water. The organic phase is dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa). Thus, 1.1 g of ethyl (RR, SS) -trans-2- (morpholinomethyl) -1-cyclopropanecarboxylate are obtained in the form of a yellow oil. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.76 (m, 1H), 1.20-1.35 (m, 4H), 1.44 (m, 1H), 1.54 ( m, 1H), 2.31 (dd, J = 13 and 7Hz, 1H), 2.36 (dd, J = 13 and 7Hz, 1H), 2.50 (broad t, J = 5Hz, 4H), 3 . 73 (t, J = 5 Hz, 4H), 4.13 (m, 2H). Example 34 (16R) -16-Deoxy-16-fluoro-14-O- [6-imidazolyl-1) -hexanoyl] pristinamycin II B To 1.42 g (16R) -16-deoxy-16-fluoro-14 -O- (6-bromohexanoyl) pristinamycin IIB in solution in 7 ml of dimethyl sulphoxide are added at a temperature of 20 ° C. 0.34 g of imidazole and a few crystals of sodium iodide. After 2 hours of stirring at 53 ° C, and then 16 hours of stirring at 20 ° C, the reaction mixture is poured onto 35 cm 3 of water and filtered through sintered glass. The insolubles are washed with water and dissolved in 70 ml of ethyl acetate. The solution obtained was extracted with 25 ml of 0.1N aqueous hydrochloric acid solution. The aqueous phase is decanted, extracted with 10 cm 3 of ethyl acetate and then neutralized with 0.5 cm 3 of 5N aqueous sodium hydroxide solution. The aqueous phase is then extracted twice with 25 cm 3 of ethyl acetate. The organic phases are combined, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) to obtain 1 g of a light yellow solid which is then purified by flash chromatography [eluent: dichloromethane / methanol / acetonitrile (88/6/6 v / v)]. 0.59 g of a colorless solid is obtained which is dissolved in 5 cm 3 of dichloromethane. The organic phase is filtered through Celite®. Celite® is flushed with dichloromethane. The filtrate is concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C, obtaining 0.58 g of (16R) -16-deoxy-16-fluoro-14-O- (6-imidazolyl) -1) hexanoyl] pristinamycin II B as a colorless solid with a melting point of approximately 90 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.95 (d, J = 6.5 Hz, 3H), 0.99 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.27 (m, 2H), 1.60-2.10 (m, 5H), 1.63 (m, 2H), 1.78 (m, 2H), 1.88 (s, 3H), 2.10-2.25 (m, 2H), 2.27 (t, J = 7Hz, 2H), 2.75 (m, 1H), 3.00 (m, 1H), 3.25 (dt, J = 17 and 5Hz, 1H), 3.51 (m, 1H), 3.82 (m, 1H), 3.94 (t, J = 7Hz, 2H), 4 . 08 (m, 1H), 4.58 (m, 1H), 4.75-4.85 (m, 2H), 5.07 (reduced doublet, J HF = 48Hz, 1H), 5.20 (d, J = 9 Hz, 1H), 5.75-5.85 (m, 2H), 5.90 (dd, J = 16 and 1.5 Hz, 1H), 6.18 (d, J = 16 Hz, 1H), 6.56 (dd, J = 16 and 5 Hz, 1H), 6.77 (m, 1H), 6.90 (s, 1H), 7.10 (s, 1H), 7.45 (s , 1H). 8.12 (s, 1H). (16R) -16-Deoxy-16-fluoro-14-O- (6-Bromohexanoyl) pristinamycin II B can be obtained in the following way: Up to 5.32 g (16R) -16-deoxy-16 -fluoropristinamycin II B (prepared as described in example 1) in solution in 150 ml of dichloromethane is added at 28 ° C. 1.7 ml of triethylamine and 1.8 ml of 6-bromohexanoyl chloride. After stirring for 21.5 hours at 23 ° C., 0.43 cm 3 of triethylamine and 0.45 cm 3 of 6-bromohexanoyl chloride are added. After stirring for an additional 21 hours at 28 ° C, the reaction mixture is poured onto 50 cm 3 of water. The organic phase is decanted, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) to obtain 8.05 g of a brown solid which is purified by means of flash chromatography [eluent: dichloromethane-methanol / acetonitrile (96/2/2 v / v)]. Thus, 5.6 g of (16R) -16-deoxy-16-fluoro-14-O- (6-bromohexanoyl) prispinamycin IIB are obtained in the form of a light yellow solid. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.48 (m, 2H), 1.60-2.05 (m, 9H), 1.88 (s, 3H), 2.15 (m, 1H), 2.24 (m, 1H), 2.31 (t, J = 7.5 Hz, 2H), 2.76 (m, 1H), 2.99 (m, 1H), 3.24 (m, 1H) , 3.41 (t, J = 7 Hz, 2H), 3.49 (m, 1H), 3.86 (m, 1H), 4.06 (m, 1H), 4.53 (m, 1H), 4.78 (dd, J = 10 and 2Hz, 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.11 (reduced doublet, J HF = 48Hz, 1H), 5.31 (d, J = 9 Hz, 1H), 5.75 (m, 1H), 5.75 (m, 1H), 5.82 (dd, J = 17 and 2 Hz, 1H), 5.95 (m, 1H), 6.19 (d, J = 16 Hz, 1H), 6.51 (dd, J = 16 and 4 Hz, 1H), 8.13 (s, 1H). Example 35 (16R) -16-Deoxy-16-fluoro-14-O- [6 (4-methylpiperazinyl-1) hexanoyl] pristinamycin II B To 1.42 g (16R) -16-deoxy-16-fluoro- 14-O- (6-bromohexanoyl) pristinamycin IIB (prepared as described in Example 34) in solution in 7 ml of dimethyl sulphoxide are added at 20 ° C. to 0.67 ml of N-methyl-piperazine. After stirring for 0.5 hours at 60 ° C., the reaction mixture is poured into 35 cm 3 of ice-water and extracted with 50 cm 3 of dichloromethane. The organic phase is washed with 25 cm 3 of a saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered and then concentrated under reduced pressure (2.7 kPa) to obtain 1.2 g of orange a neural solid which is dissolved in 30 cm 3 of ethyl acetate. The solution obtained is extracted successively with 20 cm 3 of 0.1N aqueous hydrochloric acid solution and 10 cm 3 of water. The aqueous phases are combined and neutralized with 0.4 cm 3 of 5N aqueous sodium hydroxide solution. The aqueous phase is extracted twice with 25 cm 3 of dichloromethane. The organic phases are combined, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) to obtain 0.94 g of a yellow solid which is purified by chromatography equilibrium [eluent: dichloromethane / methanol (90/10 ethical vol)]. Thus, 0.27 g of a colorless solid is obtained which is dissolved in 5 cm 3 of dichloromethane. The organic phase is filtered through Celite®. Celite® is flushed with dichloromethane. The filtrate is concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C to obtain 0.26 g of (16R) -16-deoxy-16-fluoro-14-O- [6- (4 -methylpiperazinyl-1) hexanoyl] pristinamycin II B in the form of a colorless solid, melting point approximately 95 ° C (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.33 (m, 2H), 1.51 (m, 2H), 1.55-2.05 (m, 7H), 1.88 (s, 3H), 2.10-2.65 (m, 14H), 2.29 (s, 3H), 2.76 (m, 1H), 2.99 (m, 1H), 3.24 (m, 1H), 3 , 48 (m, 1H), 3.86 (m, 1H, 4.06 (m, 1H), 4.53 (m, 1H), 4.78 (dd, J = 10 and 2Hz, 1H), 4 , 82 (dd, J = 9 and 3Hz, 1H), 5.10 (reduced doublet, J HF = 48Hz, 1H), 5.30 (d, J = 9Hz, 1H), 5.75-5.85 ( m, 1H), 5.75 (m, 1H), 5.82 (dd, J = 17 and 2Hz, 1H), 5.98 (m, 1H), 6.19 (d, J = 16Hz, 1H) , 6.52 (dd, J = 17 and 5 Hz, 1H), 8.13 (s, 1H). Example 36 (16R) -16-Deoxy-16-fluoro-14-O- {6- [4- (pyrrolidinyl-1-carbonylmethyl) piperazinyl-1] hexanoyl} pristinamycin II B Up to 1.35 g (16R ) -16-deoxy-16-fluoro-14-O- (6-bromohexanoyl) pristinamycin II B (prepared as described in example 34) in solution in 7 cm 3 of dimethyl sulfoxide is added at a temperature of 20 ° C 1 , 18 g (pyrrolidinyl-1-carbonylmethyl) piperazine. After stirring for 3 hours at 60 ° C., the reaction mixture is poured into 35 cm 3 of ice water and extracted twice with 50 cm 3 of ethyl acetate. The organic phases are combined, dried over magnesium sulfate, filtered, and then concentrated to dryness under reduced pressure (2.7 kPa), obtaining 1.53 g of a gummy residue, which is purified by means of equilibrium chromatography [ eluent: dichloromethane / methanol (90/10 ethical vol)]. 0.96 g of sticky rubber is obtained which is dissolved in 10 cm 3 of dichloromethane. This solution is filtered through Celite®. Celite® is flushed with dichloromethane and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C to give a gum which is successively stirred in ether diethyl and pentane. After filtration and then drying under reduced pressure (2.7 kPa), 0.78 g of (16R) -16-deoxy-16-fluoro-14-O- {6- [4- (pyrrolidinyl- 1-carbonylmethyl) piperazinyl-1] hexanoyl} pristinamycin IIB as a yellow solid, melting point approximately 80 ° C (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.32 (m, 2H), 1.50 (m, 2H), 1.60-2.05 (m, 11H), 1.88 (s, 3H), 2.10-2.40 (m, 6H), 2.50 (unres. Comp, 4H), 2.59 (unres. Comp., 4H), 2.76 (m, 1H), 2.99 (m, 1H), 3 , 12 (m, 2H), 3.24 (m, 1H), 3.40-3.55 (m, 5H), 3.86 (m, 1H), 4.05 (m, 1H), 4. 52 (m, 1H), 4.78 (dd, J = 10 and 2 Hz, 1H), 4.82 (dd, J = 9 and 3 Hz, 1H), 5.10 (doublet PL 203 554 B1 40 reduced, J HF = 48Hz, 1H), 5.30 (d, J = 9Hz, 1H), 5.75-5.90 (m, 1H), 5.75 (m, 1H), 5.82 (dd, J = 17 and 2Hz, 1H), 6.02 (m, 1H), 6.19 (d, J = 16Hz, 1H), 6.52 (dd, J = 17 and 5Hz, 1H), 8.13 (s, 1H ). Example 37 (16R) -16-deoxy-16-fluoro-14-O- [7- (imidazolylol) heptanoyl] pristinamycin II B methanesulfonate II B To 1.96 g (16R) -16-deoxy-16-fluoro-14- O- [7- (imidazolyl-1) heptanoyl] pristinamycin II B in a solution in 10 cm 3 of ethanol is added at 20 ° C. 2.7 cm 3 of a 1N ethanolic methanesulfonic acid solution. After 10 minutes of stirring, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) to give a residue which is stirred in 20 cm 3 of ether. After filtration, washing the solid with 5 cm 3 of diethyl ether and drying under reduced pressure (2.7 kPa), 2.13 g of (16R) -16-deoxy-16-fluoro-14- methanesulfonate are obtained. O- [7- - (imidazolyl-1) heptanoyl] pristinamycin II B as a cream solid with a melting point of approximately 110 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.95 (d, J = 6.5 Hz, 3H), 0.98 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.25-1.45 (m, 4H), 1.55-2.05 (m, 9H), 1.88 (s, 3H), 2.10-2 , 30 (m, 2H), 2.28 (t, J = 7.5 Hz, 2H), 2.76 (m, 1H), 2.85 (s, 3H), 3.00 (dt, J = 17 and 6Hz, 1H), 3.24 (m, 1H), 3.51 (m, 1H), 3.84 (m, 1H), 4.05 (m, 1H), 4.18 (t, J = 7.5Hz, 2H), 4.49 (m, 1H), 4.78 (dd, J = 10 and 2Hz, 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.09 ( reduced doublet, J HF = 48Hz, 1H), 5.28 (d, J = 9.5Hz, 1H), 5.70-5.85 (m, 2H), 5.84 (dd, J = 16 and 2Hz , 1H), 6.13 (m, 1H), 6.18 (d, J = 16Hz, 1H), 6.53 (dd, J = 16 and 5Hz, 1H), 7.13 (s, 1H), 7.41 (s, 1H), 8.12 (s, 1H), 8.92 (s, 1H). (16R) -16-Deoxy-16-fluoro-14-O- [7- (imidazolyl-1) -heptanoyl] pristinamycin II B can be obtained as follows: Up to 3.2 g (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in Example 1) in solution in 100 cm 3 of tetrahydrofuran is added at 23 ° C 1.49 g of N, N'-di-cyclohexylcarbodiimide, 0.075 g of 4-dimethylaminopyridine, 1.68 g of 6- (imidazolyl-1) hexane carboxylic acid hydrochloride and 1 cm 3 of triethylamine. After 84 hours of stirring at 23 ° C., the reaction mixture is filtered and the insoluble matter is rinsed with dichloromethane. The filtrate is concentrated to dryness under reduced pressure (2.7 kPa), yielding an oily residue which is diluted in 100 cm 3 of ethyl acetate. The solution obtained is washed successively twice with 40 cm 3 of water and 40 cm 3 of a saturated aqueous sodium chloride solution and then extracted with 60 cm 3 of 0.1N aqueous hydrochloric acid solution. Acid, the aqueous phase is then extracted with 20 cm 3 of ethyl acetate, the pH is adjusted to 8 by adding 6 cm 3 of 1N aqueous sodium hydroxide solution and then extracted twice with 40 cm 3 ethyl acetate. The organic phases are combined, washed with a saturated aqueous sodium chloride solution, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) to give 3.05 g of light yellow is a solid which is purified by flash chromatography [eluent: dichloromethane / methanol / acetonitrile (86/7/7 v / v)]. In this way, 2.58 g of a solid are obtained, which is dissolved in 10 cm 3 of dichloromethane. This solution is filtered through Celite®, Celite® is rinsed with chloromethane and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C to give 2, 58 g of (16R) -16-deoxy-16-fluoro-14-O- [7- (imidazolyl-1) heptanoyl] pristinamycin II B as a colorless solid with a melting point of approx. 80 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.95 (d, J = 6.5 Hz, 3H), 0.99 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.25-1.40 (m, 4H), 1.55-2.05 (m, 9H), 1.88 (s, 3H), 2.10-2 , 30 (m, 2H), 2.27 (t, J = 7.5Hz, 2H), 2.76 (m, 1H), 2.99 (dt, J = 17 and 6Hz, 1H), 3.24 (mt, 1H), 3.48 (m, 1H), 3.85 (m, 1H), 3.93 (t, J = 7.5 Hz, 2H), 4.06 (m, 1H), 4. 53 (m, 1H), 4.78 (dd, J = 10 and 2Hz), 4.82 (dd, J = 9 and 3Hz), 5.09 (reduced doublet, J HF = 48Hz, 1H), 5, 29 (d, J = 9 Hz, 1H), 5.70-5.85 (m, 2H), 5.83 (dd, J = 16.5 and 2 Hz, 1H), 6.17 (m, 1H), 6.19 (d, J = 15 Hz, 1H), 6.52 (dd, J = 16.5 and 5 Hz, 1H), 6.90 (s, 1H), 7.06 (s, 1H), 7, 45 (s, 1H), 8.12 (s, 1H). The hydrochloride of 6- (imidazolyl-1) hexane carboxylic acid can be prepared according to Kinji Iizuka et al. , J. Med. Chem. Vol. 24, No. 10, pages 1139 to 1148 (1981). Example 38 (16R) -16-Deoxy-16-fluoro-14-O- (4-methylpiperazinyl-1) carbonylacetylpristinamycin II B Up to 2.5 g (16R) -16-deoxy-16-fluoropristinamycin II B (obtained from 1.74 g of 4-methylpiperazinyl-1-carbonylacetic acid, 1.44 g of N, N'-dicyclohexylcarbon are added in a solution in 100 cm 3 of dichloromethane under argon atmosphere. bodvimide and 0.09 4-dimethylaminopyridine. After stirring for 18 hours, 50 ml of dichloromethane are added to the reaction mixture, filtered to remove insoluble matter, and then washed four times with 50 ml of distilled water. The organic phase is decanted, dried over magnesium sulphate and then concentrated to dryness under reduced pressure (2.7 kPa). The residue (3.4 g) was purified by flash chromatography [eluent: dichloromethane / methanol gradient (97/3 and 92/8 v / v)]. A colorless solid is obtained which, after stirring in diethyl ether, filtering and drying (2.7 kPa), gives 1.3 g of (16R) -16-deoxy-16-fluoro-14-O- [4-methylpiperazinyl-1) carbonylacetyl pristinamycin as a colorless solid. 1 H NMR spectrum (500 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.70-2.00 (m, 5H), 1.89 (s, 3H), 2.15 (m, 1H), 2.25-2.35 (m , 1H), 2.31 (s, 3H), 2.40 (m, 4H), 2.76 (m, 1H), 3.01 (dt, J = 16 and 6Hz, 1H), 3.23 ( m, 1H), 3.40-3.55 (m, 5H), 3.66 (m, 2H), 3.87 (m, 1H), 4.05 (m, 1H), 4.53 (m , 1H), 4.78 (broad d, J = 10Hz, 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.14 (reduced duet, J HF = 48Hz, 1H), 5.34 (d, J = 9.5Hz, 1H), 5.77 (m, 1H), 5.82 (dd, J = 16 and 2Hz, 1H), 5.88 (dt, J = 9.5 and 5Hz, 1H), 6.95 (m, 1H), 6.20 (d, J = 16Hz, 1H), 6.51 (dd, J = 16 and 4Hz, 1H), 8.12 (s, 1H ). 4-methylpiperazinyl-1-carbonylacetic acid can be obtained as follows: To 4.5 g of ethyl 4-methylpiperazinyl-1-carbonylacetate in a solution in 100 cm 3 of ethanol is added at a temperature of 20 ° C 23 cm 3 0.1N aqueous sodium hydroxide solution. After 24 hours of stirring, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa), the remainder is dissolved in 50 cm 3 of distilled water, and the solution is washed four times with 50 cm 3. dichloromethane. The aqueous phase is adjusted to pH 5-6 with a 1N aqueous hydrochloric acid solution, extracted twice with 50 cm 3 of dichloromethane and then concentrated to dryness under reduced pressure (2.7 kPa). The residue is recovered three times with 100 cm 3 of toluene and concentrated to dryness under the same conditions. There are obtained 4.6 g of a residue in the form of a yellow paste which is stirred in 50 cm 3 of ethanol at a temperature of about 60 ° C. The insoluble matter is removed by filtration and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa). Thus, 3.5 g of 4-methylpiperazinyl-1-carbonyl acetic acid are obtained in the form of a sticky, hygroscopic mass, which is used as such. 1 H NMR spectrum (300 MHz, (CD 3) 2 SO d 6, dp ppm): 2.21 (s, 3H), 2.29 (t, J = 5 Hz, 2H), 2.34 (t, J = 5 Hz, 2H), 3.30-3.50 (m, 4H), 3.39 (s, 2H). Ethyl 4-methylpiperazinyl-1-carbonylacetate can be obtained according to Morren H. , Trolin S. , Grivsky E. , Bull. Soc. Chim. B elg. 1950, 59, 228-232. Example 39 (16R) -14-O- [4-Carboxybutyryl) -16-deoxy-16-fluoropristinamycin II B Up to 400 mg (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in the example 1) 258 mg of glutaric anhydride and 84.5 mg of 4-dimethylaminopyridine in a solution in 2 cm 3 of pyridine are added at 20 ° C. After stirring for 20 hours, the pyridines are evaporated off under reduced pressure (2.7 kPa) and the oil obtained is dissolved in 20 cm 3 of ethyl acetate. The solution obtained is washed twice with 10 cm 3 of distilled water and then with 0.1N aqueous hydrochloric acid solution. The aqueous phase is extracted with ethyl acetate and then decanted. The organic phase is washed with distilled water and then twice with 2 cm 3 of saturated sodium chloride solution. The organic phase is decanted, dried over sodium sulphate, filtered, then concentrated to dryness under reduced pressure (2.7 kPa), obtaining a light yellow and a solid, which is mixed in 20 cm 3 of diethyl ether, filtered and then dried under reduced pressure (2.7 kPa). Thus, 363 mg of a solid is obtained, which is purified by flash chromatography [eluent: dichloromethane / methanol (97-3 v / v)] to give 100 mg of (16R) -14-O- (4-carboxybutyryl) -16-deoxy-16-fluoropristinamycin as a colorless solid, mp 98 ° C. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.55 2.05 (m, 7H), 1.89 (s, 3H), 2.17 (m, 1H), 2.25 (m, 1H), 2 , 37 (t, J = 7Hz, 2H), 2.42 (t, J = 7Hz, 2H), 2.77 (m, 1H), 3.00 (td, J = 17 and 6Hz, 1H), 3 , 25 (m, 1H), 3.50 (m, 1H), 3.86 (m, 1H), 4.08 (m, 1H), 4.53 (m, 1H), 4.79 (dd, J = 10 by 1.5 Hz, 1H), 4.82 (dd, J = 9 and 3 Hz, 1H), 5.13 (reduced doublet, J HF = 48 Hz, 1H), 5.31 (d, J = 9.5Hz, 1H), 5.75-5.90 (m, 1H), 5.77 (m, 1H), 5.83 (dd, J = 17 and 2Hz, 1H), 5.97 (m , 1H), 6.19 (d, J = 16 Hz, 1H), 6.53 (dd, J = 17 and 5 Hz, 1H), 8.14 (s, 1H). Example 40 (16R) -16-deoxy-16-fluoro-14-O- [3- (4-methylpiperazinyl-1-carbonyl) propionyl] pristinamycin hydrochloride II BPL 203 554 B1 42 To 615 mg (16R) - 16-deoxy-16-fluoro-14-O- [3- (4-methylpiperazinyl-1-carbonyl) propionyl] pristinamycin II B dissolved in 6 cm 3 of methyl isobutyl ketone, 3N ethereal hydrogen chloride solution is added until a plentiful precipitate is obtained, which is filtered, rinsed 2 times with 2 cm 3 of methyl isobutyl ketone and then 3 times with diethyl ether. After drying at 50 ° C (90 Pa), 600 mg of (16R) -16-deoxy-16-fluoro-14-O- [3- (4-methylpiperazinyl-1-carbonyl) propionyl hydrochloride ] pristinamycin II B in the form of a white powder, m.p. 160 ° C. (16R) -16-Desoxy-16-fluoro-14-O- [3- (4-methylpiperazinyl-1-carbonyl) propionyl] pristinamycin II B can be obtained as follows: under an atmosphere of nitrogen are placed 450 mg of 4- (4-methylpiperazinyl-1-) - 4-oxobutyric acid, 1 g of (16R) -16-deoxy-16-fluoropristinamycin II B (obtained as described in Example 1), 470 mg of N, N'-dicyclohexylcarbodiimide, 140 mg of 4-dimethylaminopyridine and then 20 ml of dichloromethane. The reaction mixture is stirred at 20 ° C for 48 hours, then diluted with 10 cm 3 of dichloromethane and poured onto 50 cm 3 of distilled water. The resulting mixture is filtered over cotton. The organic phase is decanted and the aqueous phase is extracted twice with 5 cm 3 of dichloromethane. The organic phases are combined, dried over magnesium sulphate, filtered, and then concentrated to dryness under reduced pressure (2.7 kPa), yielding 1.66 g of a mixture, which is purified by chromatography equilibrium [eluent: dichloromethane-methanol (95-5 ethical vol)]. Thus, 975 mg of the product is obtained, which is stirred in 10 cm 3 of diethyl ether, filtered and dried and then purified again by flash chromatography [eluent: ethyl acetate-methanol (93-7 vol. Ethanol) ]. The fractions are concentrated to give a solid which is dissolved in 10 cm 3 of diethyl ether and stirred for 30 minutes. The obtained colorless solid is filtered, washed with diethyl ether and then dried at 50 ° C (90 Pa), giving 500 mg (16R) -16-deoxy-16-fluoro 14- O- [3- (4-methylpiperazinyl-1-carbonyl) propionyl] pristinamycin IIB as a white powder, m.p. 130 ° C. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.65-2.05 (m, 5H), 1.88 (s, 3H), 2.15 (m, 1H), 2.20-2.45 (m , 5H), 2.31 (s, 3H), 2.50-2.75 (m, 4H), 2.76 (m, 1H), 3.00 (m, 1H), 3.23 (m, 1H), 3.40-3.55 (m, 1H), 3.50 (m, 2H), 3.63 (m, 2H), 3.87 (m, 1H), 4.06 (m, 1H ), 4.53 (m, 1H), 4.78 (broad d, J = 10Hz, 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.14 (reduced doublet, J HF = 48Hz, 1H), 5.33 (d, J = 9.5Hz, 1H), 5.75-5.90 (m, 1H), 5.75 (m, 1H), 5.81 (broad d, J = 16Hz, 1H), 5.96 (m, 1H), 6.20 (d, J = 16Hz, 1H), 6.51 (dd, J = 16 and 5Hz, 1H), 8.12 (s, 1H ). 4- (4-methylpiperazinyl-1) -4-oxobutyric acid can be obtained as follows: 1.17 g of succinic anhydride is added to 20 cm 3 of dioxane, and then 1.19 cm 3 of N-methylpiperazine . After 18 hours of stirring at ambient temperature, the precipitate obtained is filtered and then washed successively with the minimum amount of dioxane, twice with 10 cm 3 of acetone and with 10 cm 3 of diethyl ether. After drying under reduced pressure (2.7 kPa) at 20 ° C, 1.09 g of 4- (4-methylpiperazinyl-1) -4-oxobutyric acid is obtained as a colorless solid, m.p. 114 ° C. Example 41 (16R) -16-Desoxy-16-fluoro-14-O- (3- [4- (pyridinyl-2) -piperazinyl-1-carbonyl] propionyl} pristinamycin II B The procedure is as described in example 40, but starting from 240 mg of 4-oxo-4- - [4- (pyridinyl2) piperazinyl-1)] butyric acid, 400 mg of (16R) -16-deoxy-16-fluoropristinamycin II B (obtained as described in Example 1), 190 mg of N, N'-dicyclohexylcarbodiimide, 46 mg of 4-dimethylaminopyridine and then 6 ml of dichloromethane. After 66 hours of stirring and working up analogous to that of Example 40, 655 mg of a solid are obtained which is purified by flash chromatography [eluent: dichloromethane-methanol (95-5 v / v)]. A solid is separated and stirred for 20 minutes in 4 cm 3 of diethyl ether. The obtained solid was filtered, washed with diethyl ether and then dried at 50 ° C (90 Pa), yielding 308 mg (16R) -16-deoxy-16-fluoro-14-O. - {3- [4- (pyridinyl-2) piperazinyl-1-carbonyl] propionyl} pristinamycin IIB as a white powder, melting point approximately 140 ° C (decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.65-2.05 (m, 5H), 1.88 (s, 3H), 2.15 (m, 1H), 2.30 (m, 1H), 2.55-2. 80 (m, 4H), 2.76 (m, 1H), 3.00 (m, 1H), 3.23 (m, 1H), 3.46 (m, 1H), 3 , 51 (m, 2H), 3.63 (m, 4H), 3.75 (m, 2H), 3.87 (m, 1H), 4.06 (m, 1H), 4.53 (m, 1H), 4.78 (dd, J = 10 and 1.5Hz, 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.14 (doublet PL 203 554 B1 43 reduced, J HF = 48Hz , 1H), 5.34 (d, J = 9.5Hz, 1H), 5.75-5.90 (m, 1H), 5.75 (m, 1H), 5.81 (dd, J = 16 and 1.5Hz, 1H), 5.96 (m, 1H), 6.20 (d, J = 16Hz, 1H), 6.51 (dd, J = 16 and 5Hz, 1H), 6, 60-6 , 70 (m, 2H), 7.52 (m, 1H), 8.12 (s, 1H), 8.21 (dd, J = 5 and 1.5 Hz, 1H). 4-oxo-4- [4- (pyridinyl-2) piperazinyl-1)] butyric acid can be obtained as follows: 0.97 g of succinic anhydride is added to 15 cm 3 of dioxane, and then 1 , 5 cm3 1- (2-pyridyl) piperazine. After stirring for 4.5 hours at 20 ° C, the solvent is evaporated under reduced pressure (2.7 kPa) at 20 ° C to obtain a solid which crystallizes hot from 33 cm. 3 acetone. After filtration, the solid is rinsed successively with a minimal amount of acetone and with diethyl ether, and then dried under reduced pressure (2.7 kPa) at 20 ° C, yielding 986 mg of acid 4- oxo-4- [4- (pyridinyl-2) piperazinyl-1)] butyric as a colorless solid, m.p. 134 ° C. Example 42 (16R) -16-Deoxy-16-fluoro-14-O- (3- [4- (pyrrolidinyl-1-carbonylmethyl) piperazinyl-1-carbonyl] propionyl} pristinamycin II B in example 40, but starting with 750 mg of 4-oxo-4- [4- - (2-oxo-2-pyrrolidinyl-1-ethyl) piperazinyl-1)] butyric acid, 1 g (16R) -16- deoxy-16-fluoropristinamycin II B (prepared as described in Example 1), 190 mg of N, N'-dicyclohexylcarbodiimide, 60 mg of 4-dimethylaminopyridine, and then 20 ml of dichloromethane. After 25 hours of stirring and working up in an analogous manner to that of Example 40, additional 95 mg of N, N'-dicyclohexylcarbodiimide and 95 mg of 4-dimethylaminopyridine are added and stirring is continued for 19 hours. After work-up, 1.54 g of a solid is obtained, which is purified by equilibrium chromatography [eluent: dichloromethane-methanol (95-5 vol.% By volume)]. The fractions are concentrated to give 530 mg of a solid which is dissolved in 5 cm 3 of diethyl ether. The obtained colorless solid was filtered, washed with diethyl ether and then dried at 50 ° C (90 Pa), yielding 480 mg of (16R) -16-deoxy-16-fluoro. 14-O- {3- [4- (pyridinyl-1-carbonylmethyl) piperazinyl-1-carbonyl] propionyl} pristinamycin IIB as a white powder, m.p. approximately 132 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.95 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.65-2.05 (m, 9H), 1.88 (s, 3H), 2.14 (m, 1H), 2.28 (m, 1H), 2.45-2.75 (m, 8H), 2.76 (m, 1H), 3.00 (td, J = 17 and 6Hz, 1H), 3.14 (s, 2H), 3.25 ( m, 1H), 3.40-3.55 (m, 7H), 3.66 (m, 2H), 3.87 (m, 1H), 4.05 (m, 1H), 4.52 (m , 1H), 4.78 (dd, J = 10 and 1.5Hz, 1H), 4.81 (dd, J = 9 and 3Hz, 1H), 5.12 (reduced doublet, J HF = 48Hz, 1H) , 5.33 (d, J = 9.5 Hz, 1H), 5.74 (m, 1H), 5.75-5.85 (m, 1H), 5.81 (dd, J = 17 and 1, 5Hz, 1H), 6.00 (m, 1H), 6.19 (d, J = 16Hz, 1H), 6.51 (dd, J = 17 and 5Hz, 1H), 8, 12 (s, 1H) . 4-oxo-4- [4- (2-oxo-2-pyrrolidinyl-1-ethyl) piperazinyl-1] butyric acid can be obtained as follows: Place 20 cm 3 in a flask maintained under nitrogen atmosphere. of dioxane, 0.72 g of succinic anhydride, followed by 1.5 cm 3 of 95% 1- (pyrrolidinocarbonylmethyl) piperazine. After 4.75 hours of stirring at ambient temperature, the solvent is evaporated off under reduced pressure (2.7 kPa) at 20 ° C to give 2.4 g of the acid 4-oxo-4- [4- (2-oxo-2 -pyrrolidinyl-1-ethyl) -piperazinyl-1] buttery in the form of a light yellow paste which is used as such. Example 43 (16R) -16-Deoxy-16-fluoro-14-O- [3- (2-dimethylaminoethylcarbamoyl) propionyl] -16-fluoropristinamycin II B Follow the procedure described in example 40, but proceed ac from 170 mg of N- (2-dimethylaminoethyl) succinic acid, 400 mg of (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in Example 1), 190 mg of N, N'-dicyclohexyiocarbodimide 46 mg of 4-dimethylaminopyridine and then 6 cm 3 of dichloromethane are obtained after 18 hours of mixing and treatment analogous to the treatment of e.g. 40 580 mg of solid, which is added with 15 cm 3 of dichloromethane and 100 cm 3 of distilled water. Then 0.1 M hydrochloric acid is added in such a way that the pH value is adjusted to 4. The aqueous phase is extracted twice with 5 cm 3 of dichloromethane and then the pH is adjusted to 7 by adding sodium hydrogen carbonate solution. After decantation, the aqueous phase is extracted 3 times with 10 cm 3 of dichloromethane. The organic phases are combined, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C to obtain a solid which is mixed in 5 cm 3 of diethyl ether, filtered and then dried at 50 ° C (90 Pa). Obtained PL 203 554 B1 44 Aug 112 mg of (16R) -16-deoxy-14-O- [3- (2-dimethylaminoethylcarbamoyl)] propionyl] -16-fluoropristinamycin II B in the form of a white powder with a melting point of 114 ° C (with distribution). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.97 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.65-2.05 (m, 5H), 1.88 (s, 3H), 2.10-2.35 (m, 2H), 2.24 (s , 6H), 2.35-2.75 (m, 4H), 2.41 (t, J = 6Hz, 2H), 2.77 (m, 1H), 3.00 (td, J = 17 and 6Hz , 1H), 3.33 (q, J = 6Hz, 2H), 3.47 (m, 1H), 3.87 (m, 1H), 4.07 (m, 1H), 4.54 (m, 1H), 4.78 (broad d, J = 10Hz, 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.13 (reduced double, J HF = 48Hz, 1H), 5 , 32 (d, J = 9.5Hz, 1H), 5.75-5.90 (m, 1H), 5.75 (m, 1H), 5.82 (wide d, J = 17Hz, 1H ), 5.98 (m, 1H), 6.10-6.25 (m, 1H), 6.20 (d, J = 16Hz, 1H), 6.51 (dd, J = 17 and 5Hz, 1H ). 8.13 (s. 1H). N- (2-dimethylaminoethyl) succinic acid can be obtained as follows: 1.4 g of succinic anhydride are added to 15 cm 3 of dioxane, followed by 1.5 cm 3 of 2-dimethylaminoethylamine. After 18 hours of stirring at ambient temperature, the solvent is evaporated off under reduced pressure (2.7 kPa) at 20 ° C to give a residue which is dissolved hot in 40 cm 3 of methyl ethyl ketone. After cooling, the dissolved fraction is removed and the gummy fraction is crystallized hot from 15 cm 3 of acetone. After filtration, the solid is washed with a minimum amount of acetone, and then with diethyl ether, dried under reduced pressure (2.7 kPa) at a temperature of 20 ° C, yielding 2.03 g of N- (2 dimethylamino-ethyl) succinic amide as a colorless solid, m.p. 155 ° C. Example 44 (16R) -14-O- (3-carboxypropionyl) -16-deoxy-16-fluoropristinamycin II B Following as described in example 39 but starting with 5 g (16R) -16-deoxy -16-fluoro-pristinamycin II B (prepared as described in Example 1), 2.82 g of succinic anhydride, 1.15 g of 4-dimethylaminopyridine and 25 ml of pyridine, after 4 hours and 50 minutes of stirring, is obtained is a pale orange oil which is blended for 18 hours in diethyl ether to give a crushed white powder. This solid is filtered then stirred in diethyl ether, filtered and dried at 30 ° C (90 Pa) to give 4.96 g of a solid. One gram of this solid is stirred for 1 hour in 10 cm 3 of dichloromethane, filtered and then rinsed in diethyl ether. The obtained solid is washed 3 times with distilled water and then with diethyl ether, yielding 820 mg of (16R) -14-O- (3-carboxypropionyl) -16-deoxy-16-fluoropristinamycin II B as a colorless solid with a melting point of approximately 192 ° C. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.97 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.55-2.05 (m, 5H), 1.88 (s, 3H), 2.16 (m, 1H), 2.27 (m, 1H), 2.55-2, 70 (m, 4H), 2.77 (m, 1H), 3.00 (td, J = 17 and 6 Hz, 1H), 3.25 (m, 1H), 3.50 ( m, 1H), 3.87 (m, 1H), 4.07 1H), 4.52 (m, 1H), 4.79 (dd, J = 10 and 1.5Hz, 1H), 4.83 ( dd, J = 9 and 3Hz, 1H), 5.12 (reduced doublet, J HF = 48Hz, 1H), 5.33 (d, J = 9.5Hz, 1H), 5.75-5.90 (m , 1H), 5.77 (m, 1H), 5.83 (broad d, J = 17 Hz, 1H), 6.20 (d, J = 16 Hz, 1H), 6.53 (dd, J = 17 and 5 Hz, 1H), 8.13 (s, 1H). Example 45 (16R) -16-deoxy-16-fluoro-14-O- [4- (2-morpholinoethylcarbamoyl) butyryl] pristimycin hydrochloride II B Up to 280 mg (16R) -16-deoxy-16-fluoro 14-O- [4- (2-morpholinoethylcarbamoyl) butyryl] pristinamycin II B in solution in 3 ml of methyl isobutyl ketone is added at 4 ° C to 0.2 ml of 3M ethereal hydrochloric acid. The precipitate formed is filtered through sintered glass No. 4, washed several times with methyl ethyl ketone and then with diethyl ether. The obtained white powder is dried at 20 ° C (90 Pa) to obtain 268 mg of (16R) -16-deoxy-16-fluoro-14-O- [4- (2-morpholinoethylcarbamoyl) butyryl] pristinamycin hydrochloride II B as a colorless solid with a melting point of 134 ° C. (16R) -16-Desoxy-16-fluoro-14-O- [4- (2-morpholinoethylcarbamoyl) butyryl] pristinamycin II B can be obtained as follows: Up to 1 g of 5- (2-morpholinoethylamino) acid -5-oxobutanecarboxylic acid in solution in 40 cm 3 of dichloromethane, 459 mg of (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in Example 1), 388 mg of N, N'-dicyclohexylcarbodiimide are added, and then 23 mg of 4-dimethylaminopyridine. The reaction mixture is stirred at 20 ° C for 48 hours, and the dicyclohexylurea formed is filtered through sintered glass No. 4 and washed with ethyl acetate. The filtrate is concentrated to dryness under reduced pressure (2.7 kPa) to obtain 1.35 g of a solid which is purified by flash chromatography [eluent: dichloromethane-PL 203 554 B1 45 methanol (95 -5 vol. Eto sabolic)]. Thus, 490 mg of product is obtained which is purified again by flash chromatography on alumina [eluent: ethyl acetate-methanol (98-2 vol. Vol.%)]. The fractions are concentrated under reduced pressure (2.7 kPa) to obtain a solid which is mixed with diethyl ether and stirred for 18 hours. The obtained colorless solid was filtered, rinsed twice with diethyl ether, and then dried at 20 ° C, yielding 294 mg (16R) -14-O- [4- (2-morpholinoethylcarbamoyl) butyryl ] -16-deoxy-16-fluoropristimycin II B in the form of a white powder. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.65-2.05 (m, 5H), 1.90 (s, 3H), 1.95 (m, 2H), 2.10-2.30 (m , 2H), 2.25 (t, J = 7 Hz, 2H), 2.37 (m, 2H), 2.47 (m, 6H), 2.76 (m, 1H), 2.99 (dt, J = 17 and 6 Hz, 1H), 3.24 (m, 1H), 3.36 (dt, J = 7 and 6 Hz, 1H), 3.48 (m, 1H), 3.71 (t, J = 5Hz, 4H), 3.85 (m, 1H), 4.07 (m, 1H), 4.54 (m, 1H), 4.79 (broad d, J = 10Hz, 1H), 4.82 ( dd, J = 9 and 3Hz, 1H), 5.12 (reduced doublet, J HF = 48Hz, 1H), 5.30 (d, J = 9Hz, 1H), 5.70-5.85 (m, 2H ), 5.82 (broad d, J = 17Hz, 1H), 6.00 (m, 2H), 6.19 (d, J = 16Hz, 1H), 6.52 (dd, J = 17 and 5Hz, 1H), 8.12 (s, 1H). 4- (2-morpholinoethylamino) -4-oxobutanecarboxylic acid can be obtained as follows: 1.517 g of glutaric anhydride is added to 10 cm 3 of dioxane, and then, dropwise, 1.75 cm 5 N- (2 -aminoethyl) morpholine. Stirring is continued at 20 ° C for 0.75 hours, and the colorless solid formed is filtered, washed successively with dioxane and diethyl ether and then dried at 20 ° C (90 Pa ) to give 1.94 g of 4- (2-morpholinoethylamino) -4-oxo-butane carboxylic acid as a colorless solid, m.p. 96 ° C. Example 46 (16R) -16-deoxy-16-fluoro-14-O - {(3RS) -3-methyl-4- [4- (pyrrolidinyl-1-carbonylmethyl) piperazinyl-1-carbonyl] butyryl hydrochloride } pristinamycin II B 1 g of (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in Example 1) and 40 cm 3 of dichloromethane are introduced into the flask under nitrogen. The mixture is heated to dissolve, and then 620 mg of 2-methyl-4-oxo-5- [4- (2-oxo-2-pyrrolidinyl-1-ethyl) piperazinyl] acid are added at 20 ° C. 1] butanecarboxylic acid, 389 mg of N, N'-dicyclohexylcarbodiimide, and then 45 mg of 4-dimethylaminopyridine. After 24 hours of stirring at 20 ° C, 124 mg of 2-methyl-4-oxo-4- [4- (2-oxo-2-pyrrolidinyl-1-ethyl) piperazinyl-1] acid are additionally added. butanecarboxylic acid, 78 mg of N, N-dicyclohexylcarbodiimide, and 9 mg of 4-dimethylaminopyridine. The reaction mixture is stirred at 20 ° C. for 24 hours and then filtered, rinsed with ethyl acetate and reduced pressure (2.7 kPa). The remaining residue is stirred for 1 hour in a mixture of 30 cm 3 of ethyl acetate and 6 cm 3 of dichloromethane and then filtered. The insoluble material was separated by filtration and washed with ethyl acetate. The filtrate is filtered and then washed successively twice with 5 cm 3 of a 5% aqueous solution of sodium carbonate and 10 cm 3 of water saturated with sodium chloride. The organic phase obtained is dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa). The obtained yellow and solid are stirred for 18 hours in 40 cm 3 of diethyl ether, filtered and then purified by flash chromatography [eluent: dichloromethane-methanol (95-5 vol. V / v)]. Thus, a product is obtained, which is stirred in diethyl ether, filtered and then dried at 30 ° C (90 Pa), yielding 610 mg of (16R) -16-deoxy-16-fluoro14-O- { (3RS) -3-methyl-4 - [[4- (pyrrolidinyl-1-carbonylmethyl) piperazinyl-1-carbonyl] butyryl} pristinamycin IIB as a white powder. To this solid, dissolved in 3 cm 3 of absolute ethanol, 0.25 cm 3 of a 3M ethereal hydrochloric acid solution is added, followed by 10 cm 3 of diethyl ether. The solvents are evaporated off under reduced pressure and the obtained solid is mixed with 20 cm 3 of diethyl ether. After filtration and drying at 25 ° C (90 Pa), 610 mg of (16R) -16-deoxy-16-fluoro-14-O - {(3RS) -3-methyl-4- [4- (pyrrolidinyl) hydrochloride are obtained. -1-carbonylmethyl) piperazine-1-carbonyl] butyryl} pristinamycin IIB as a colorless solid, mp 180 ° C. 1 H NMR spectrum (400 MHz, (CD 3) 2 SO d 6, dp ppm): 0.88 (d, J = 6.5 Hz, 3H), 0.90-1.00 (m, 3H), 1. 06 (d, J = 6.5Hz, 3H), 1.58 (m, 1H), 1.70-2.50 (m, 15H), 1.80 (s, 3H), 2.78 (m, 1H), 3.00-3.50 (m, 10H), 3.40 (m, 4H), 3.65 (m, 1H), 3.72 (m, 1H), 3.81 (m, 1H ), 3.95 (m, 1H), 4.15 (m, 2H), 4.70-4.80 (m, 2H), 5.10 (reduced doublet, J HF = 48Hz, 1H), 5, 43 (d, J = 9 Hz, 1H), 5.66 (m, 1H), 5.76 (m, 1H), 5.83PL 203 554 B1 46 (dd, J = 16 and 1.5Hz, 1H), 6.20 (d, J = 16 Hz, 1H), 6.63 (dd, J = 16 and 4 Hz, 1H), 8.04 (t, J = 6 Hz, 1H), 8.48 (s, 1H), 9.85-10.50 (very stretchy, 1H). (3RS) -2-methyl-4-oxo-4- [4- (2-oxo-2-pyrrolidinyl-1-ethyl) piperazinyl-1] butane carboxylic acid can be obtained as follows: Up to 10 cm 3 of dioxane is added to 1.6 g of 3-methylglutaric anhydride and then to 2.62 g of pyrrolidinecarbonylmethylpiperazine. After stirring for 8 hours, an additional 320 mg of 3-methylglutaric anhydride is added, and then stirring is continued for 18 hours at 20 ° C. The solvent was then evaporated under reduced pressure and the obtained oil was dried at 45 ° C (90 Pa) to obtain 4.5 g of the acid (3RS) -2-methyl-4-oxo-4- [4- ( 2-oxo-2-pyrrolidinyl-1-ethyl) piperazinyl-1] butane carboxylic acid in the form of an orange oil which is used as is. Example 47 (16R) -16-deoxy-16-fluoro-14-O- [4- (4-methylpiperazinyl-1-carbonyl) butyryl] pristinamycin hydrochloride II B Proceed as described in example 45, but starting ac with 580 mg of 4- (4-methyl-piperazinyl-1] -4-oxobutanecarboxylic acid, 1.21 g of (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in Example 1) , 700 mg of N, N'-dicyclohexylcarbodiimide, 170 mg of 4-dimethylaminopyridine in 25 cm 3 of dichloromethane, a solid is obtained, which is purified by flash chromatography [eluent: dichloromethane / -methanol (95 / 5 subject to permanent)]. Thus, after concentration of the fraction to dryness under reduced pressure (2.7 kPa) at 20 ° C, 1.45 g of (16R) -16-deoxy-16-fluoro-14-O- [4- ( 4-methylpiperazinyl-1-carbonyl) butyryl] pristinamycin II B. To this solid in 8 cm 3 of methyl isobutyl ketone is added a 3N ethereal solution of hydrochloric acid until complete precipitation is obtained. The precipitate obtained is filtered, rinsed successively 3 times with 2 cm 3 of methyl isobutyl ketone and 3 times with 10 cm 3 of diethyl ether, and then dried (90 Pa) at 50 ° C to obtain 1.24 g of hydrochloride ( 16R) -16-deoxy-16-fluoro-14-O- [4- (4-methylpiperazinyl-1-carbonyl) butyrylristinamycin as a colorless solid, m.p. approximately 165 ° C (decomposition). 1 H NMR spectrum (400 MHz, (CD 3) 2 SO d 6, dp ppm): 0.86 (m, 3H), 0.94 (d, J = 6.5Hz, 3H), 1.04 (d, J = 6.5Hz, 3H), 1.52 (m, 1H), 1.65-2.15 (m, 7H), 1.77 (s, 3H), 2.20 (m, 1H), 2 , 25-2.45 (m, 4H), 2.70-2.80 (m, 1H), 2.76 (s, 3H), 2.80-3.10 (m, 3H), 3.10 -3.50 (m, 5H), 3.60 (broad d, J = 14Hz, 1H), 3.68 (m, 1H), 3.81 (m, 1H), 3.90-4.10 ( m, 2H), 4.43 (m, 1H), 4.70-4.80 (m, 2H), 5.10 (reduced doublet, J HF = 48Hz, 1H), 5.43 (d, J = 9Hz, 1H), 5.61 (m, 1H), 5.74 (m, 1H), 5.80 (broad d, J = 16Hz, 1H), 6.19 (d, J = 16Hz, 1H ), 6.62 (dd, J = 16 and 4 Hz, 1H), 8.17 (m, 1H), 8.52 (s, 1H), 10.91 (m, 1H). 4- (4-methylpiperazinyl-1) -4-oxobutanecarboxylic acid can be obtained as follows: 1.6 g of 3-methylglutaric anhydride are added to 20 cm 3 of dioxane, and then 2.62 g of - perazine-1-carboxylmethylpyrrolidine. After stirring for 8 hours, an additional 320 mg of 3-methylglutaric anhydride are added and then stirring is continued for 18 hours at 20 ° C. The solvent was then evaporated under reduced pressure and the obtained oil was dried at 45 ° C (90 Pa) to obtain 4.5 g of 4- (4-methylpiperazinyl-1) -4-oxo-butane carboxylic acid in orange oil, which is used as such. Example 48 (16R) -16-deoxy-16-fluoro-14-O- [4- (4-ethylpiperazinyl-1-carbonyl) butyryl] pristinamycin hydrochloride II B Up to 390 mg (16R) -16-deoxy- 16-fluoro-14-O- [4- (4-ethylpiperazinyl-1-carbonyl) butyryl] pristinamycin II B in solution in 5 cm 3 of methyl isobutyl ketone is added at 20 ° C 0.35 cm 3 of 3M ethereal acid solution hydrochloric acid. The formed precipitate is filtered, washed successively with a minimum amount of methyl isobutyl ketone and with diethyl ether, and then dried at 20 ° C (90 Pa) to give 340 mg of (16R) -16-deoxy-16 hydrochloride. -fluoro-14-O- [4- - (4-ethyl-piperazinyl-1-carbonyl) butyryl] pristinamycin IIB as a colorless solid, melting point approximately 150 ° C (decomposition). 1 H NMR spectrum (400 MHz, (CD 3) 2 SO d 6, dp ppm): 0.87 (m, 3H), 0.95 (d, J = 6.5 Hz, 3H), 1.05 (d, J = 6.5Hz, 3H), 1.25 (broad t, J = 7Hz, 3H), 1.53 (m, 1H), 1.65-2.15 (m, 7H), 1.79 (s , 3H), 2.20 (m, 1H), 2.30-2.45 (m, 4H), 2.77 (m, 1H), 2.80-3.55 (m, 10H), 3. 61 (broad d, J = 15Hz, 1H), 3.69 (m, 1H), 3.82 (m, 1H), 3.96 (m, 1H), 4.04 (broad d, J = 13, 5Hz, 1H), 4.48 (broad d, J = 13.5Hz, 1H), 4.70-4.80 (m, 2H), 5.10 (reduced doublet, J HF = 48Hz, 1H), 5 , 43 (d, J = 9 Hz, 1H), 5.62 (m, 1H), 5.75 (m, 1H), 5.81 (dd, J = 16 and 1.5 Hz, 1H ), 6.19 (d, J = 16 Hz, 1H), 6.63 (dd, J = 16 and 4 Hz, 1H), 8.15 (m, 1H), 8.51 (s, 1H), 10, 16 (m broad, 1H). (16R) -16-Desoxy-16-fluoro-14-O- [4- (4-ethylpiperazinyl-1-carbonyl) butyryl] pristinamycin II B can be obtained as follows: Example 45, but starting with 430 mg of 4- (4-ethylpyrazine-1) -4-oxo-butanecarboxylic acid, 1 g of (16R) -16-deoxy-16-fluoropristinamycin II B (prepared by described in Example 1), 390 mg of N, N'-dicyclohexylcarbodiimide, 23 mg of 4-dimethylaminopyridine in 40 cm 3 of dichloromethane, after adding 50 mg of magnesium sulphate, additionally 43 mg of 4- (4- ethylpiperazinyl-1) -4-oxobutanecarboxylic acid, 39 mg of N, N'-dicyclohexylcarbodiimide, and 2.3 mg of dimethylaminopyridine. After four additional hours of reaction and work-up, 1.16 g of a solid are obtained which is purified by flash chromatography [eluent: dichloromethane-methanol (95/5 v / v ethical)]. Thus, after concentrating the fractions to dryness under reduced pressure (2.7 kPa) at 20 ° C, a pure product and 420 mg of a solid are obtained, which is purified again by means of two semi-preparative HPLC chromatographies. [Hypersil 5 µM silica, eluent: dichloromethane / methanol (95/5 ethical vol) followed by a dichloromethane / methanol gradient (97/3 and 95/5 ethical vol)]. The two batches obtained in this way were combined to obtain 390 mg of (16R) -16-deoxy-16-fluoro-14-O- [4- (4-ethylpiperazinyl-1-carbonyl) butyryl] pristinamycin II B as a colorless substance fixed hopper. 4- (4-ethylpiperazinyl-1) -4-oxobutanecarboxylic acid can be obtained as follows: 1.5 g of 1-ethylpiperazine is added under argon to 10 cm 3 of dioxane, followed by 1.5 g of glutaric anhydride. in solution in 5 cm 3 of dioxane. Stirring is continued at 25 ° C. for 19 hours and then the solvents are evaporated off under reduced pressure (2.7 kPa) to give a brown oil which is stirred in diethyl ether. The obtained solid is filtered, washed with diethyl ether and then dried at 20 ° C (90 Pa), obtaining 1.95 g of 4- (4-ethylpiperazinyl-1) acid - 4-oxobutane carboxylic acid as a hygroscopic pink solid which is used as such. Example 49 (16R) -16-Deoxy-14-O- [4- (4-ethoxycarbonylmethylpiperazinyl-1-carbonyl) butyryl] -16-fluoropristinamycin II B 1 g of (16R) is placed in a flask placed under nitrogen. -16-deoxy-16-fluoroprispinamycin II B (prepared as described in Example 1) and 30 cm 3 of dichloromethane. The mixture is heated until dissolved and then cooled. At 20 ° C, 540 mg of 4- [4- (ethoxycarbonylmethylpiperazinyl-1)] - 4-oxobutanecarboxylic acid in solution in 10 cm 3 of dichloromethane, 23 mg of 4-dimethylaminopyridine are added, followed by 390 mg of N, N'- dicyclohexylcarbodiimide. After 18 hours of stirring at 20 ° C, additional 54 mg of 4- [4- (ethoxycarbonylmethylpiperazinyl-1)] - 4-oxobutane carboxylic acid, 39 mg of N, N'-dicyclohexylcarbodiimide and 2.3 mg of 4 are added. -dimethylaminopyridine. The reaction mixture is stirred at 20 ° C. for 2 days, then filtered, rinsed with ethyl acetate and concentrated to dryness under reduced pressure (2.7 kPa). The obtained residue is stirred for 20 hours in 40 cm 3 of diethyl ether, filtered, dried at 20 ° C (90 Pa), and then purified by equilibrium chromatography [eluent: dichloromethane-methanol (98 -2 vol. Eto sabolic)]. In this way, a product is obtained, which is stirred in diethyl ether, filtered and then dried at 20 ° C (90 Pa), yielding 640 mg (16R) -16-desoxy-14-O- [ 4- (4-ethoxycarbonylmethylpiperazinyl-1-carbonyl) butyryl-16-fluoropristinamycin IIB as a white powder. To this solid, dissolved in 7 cm 3 of methyl ethyl ketone, 0.35 cm 3 of a 3M ethereal hydrochloric acid solution is added. The precipitate obtained is filtered through sintered glass No. 3, washed 3 times with 10 cm 3 of methyl ethyl ketone, and then 3 times with 15 cm 3 of diethyl ether. After drying at 20 ° C (90 Pa), 450 mg of (16R) -16-deoxy-14-O- [4- (4-ethoxycarbonylmethylpiperazinyl-1-carbonyl) butyryl] -16-fluoropristinamycin II hydrochloride are obtained. B as a colorless solid with a melting point of 156 ° C. 1 H NMR spectrum (400 MHz, (CD 3) 2 SO d 6, dp ppm): 0.88 (d, J = 6.5 Hz, 3H), 0.96 (d, J = 6.5 Hz, 3H), 1.06 (d, J = 6.5Hz, 3H), 1.27 (t, J = 7Hz, 3H), 1.57 (m, 1H), 1.70-2.35 (m, 8H), 1.79 (s, 3H), 2.37 (m, 4H), 2.78 (m, 1H), 2.90-3.50 (m, 12H), 3.65 (m, 1H), 3 , 72 (m, 1H), 3.81 (m, 1H), 3.95 (m, 1H), 4.23 (q, J = 7Hz, 2H), 4.70-4.80 (m, 2H ), 5.10 (reduced doublet, J HF = 48 Hz, 1H), 5.42 (d, J = 9 Hz, 1H), 5.66PL 203 554 B1 48 (m, 1H), 5.76 (m, 1H ), 5.82 (dd, J = 16 and 1.5Hz, 1H), 6.19 (d, J = 16Hz, 1H), 6.63 (dd, J = 16 and 4Hz, 1H), 8.03 (t, J = 6 Hz, 1H), 8.48 (s, 1H). 4- [4- (ethoxycarbonylmethylpiperazinyl-1] -4-oxobutanecarboxylic acid can be obtained as follows: 10 cm 3 of dioxane, 1.6 g of glutaric anhydride are placed in a flask maintained under argon, and then 2, 62 g of N-ethoxycarbonylmethylpiperazine in solution in 5 cm 3 of dioxane. After 2 hours of stirring at ambient temperature, the solvent is evaporated off under reduced pressure to give 3.66 g of 4- [4- (ethoxycarbonylmethylpiperazinyl-1)] - 4-oxobutane carboxylic acid as an orange oil. e as such. Example 50 (16R) -16-Deoxy-16-fluoro-14-O- {4- [4- (pyrrolidinyl-1-carbonylmethyl) piperazinyl-1-carbonyl] butyryl} pristinamycin II B Proceed as follows described in Example 46 but starting with 1.75 g of 4-oxo-4- [4- (2-oxo-2-pyrrolidinyl-1-ethyl) piperazinyl-1] butanecarboxylic acid, 2.5 g (16R) -16-deoxy-16-fluoro-pristinamycin II B (prepared as described in example 1), 1.16 g of N, N'-dicyclohexylcarbodiimide and 113 g of 4-dimethylaminopyridine in 100 cm 3 of dichloromethane are obtained after 4 hours of stirring at 20 ° C and after treatment analogous to that in Example 46, a solid which is purified by flash chromatography [eluent: dichloromethane-methanol (95/5 vol. )]. After concentrating the fraction to dryness under reduced pressure (2.7 kPa) at 20 ° C, and then stirring the solid obtained for 18 hours in diethyl ether, filtration and drying (90 Pa) at 20 ° C C, 2.46 g of (16R) -16-deoxy-16-fluoro-14-O- {4- [4- (pyrrolidinyl-1-carbonylmethyl) piperazinyl-1-carbonyl] butyryl} pristinamycin are obtained II B in the form of a light yellow powder, m.p. 135 ° C. 1H NMR spectrum (500 MHz, (CD3) 2 SO d6, dp ppm): 0.96 (d, J = 6.5Hz, 3H), 1.00 (d, J = 6.5Hz, 3H), 1.10 (d, J = 6.5Hz, 3H), 1.65-2.05 (m, 11H), 1.89 (s, 3H), 2.10-2.30 (m, 2H), 2.37 (m, 4H), 2.54 (t, J = 5Hz, 2H), 2.57 (t J = 5Hz, 2H), 2.76 (m, 1H), 2.99 (d, J = 17 and 6Hz, 1H), 3.14 (m, 1H), 3.48 (m, 7H), 3.66 (t, J = 5Hz, 2H), 3.86 (m, 1H), 4, 06 (m, 1H), 4.53 (m, 1H), 4.79 (dd, J = 10 and 2Hz, 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.10 ( reduced doublet, J HF = 48 Hz, 1H), 5.30 (d, J = 9 Hz, 1H), 5.70-5.85 (m, 3H), 6.06 (m, 1H), 6.18 ( d, J = 16 Hz, 1H), 6.52 (dd, J = 16.5 and 5 Hz, 1H), 8.12 (s, 1H). 4-oxo-4- [4- (2-oxo-2-pyrrolidinyl-1-ethyl) piperazinyl-1] butane carboxylic acid can be obtained as follows: To 10 cm 3 of dry dioxane is added 1, 52 g of glutaric anhydride followed by 2.62 g of pyrrolidinecarbonylmethylpiperazine. After stirring for 4 hours, the precipitate formed is diluted with 10 cm 3 of dioxane and then stirred for 1 hour. The insolubles were filtered through sintered glass No. 4, washed several times with diethyl ether, and then dried (90 Pa) at 20 ° C to obtain 3.26 g of 4-oxo-4- [4- ( 2-oxo-2-pyrrolidinyl-1-ethyl) piperazinyl-1] butane carboxylic acid as a colorless solid. Example 51 (16R) -16-deoxy-16-fluoro-14-O- [4- (cis-3,5-dimethylpiperazinyl-1-carbonyl) butyryl] pristinamycin hydrochloride II B Up to 680 mg (16R) - 16-deoxy-16-fluoro-14-O- [4- (cis-3,5-dimethylpiperazinyl-1-carbonyl) - butyryl] pristinamycin II B in a solution in 12 cm 3 of methyl isobutyl ketone and in the amount of ethanol appropriate to dissolve while hot, 0.58 cm 3 of a 3M ethereal hydrochloric acid solution are added at a temperature of 20 ° C. The mixture is concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C. and the precipitate formed is stirred for 1.5 hours in 10 cm 3 of diethyl ether. The solid was filtered off on sintered glass No. 4 and then dried at 20 ° C (90 Pa), yielding 650 mg of (16R) -16-deoxy-16-fluoro-14-O- [ 4- (cis-3,5-dimethylpiperazinyl-1-carbonyl) butyryl] pristinamycin IIB as a colorless solid, m.p. 205 ° C. 1 H NMR spectrum (600 MHz, (CD 3) 2 SO d 6, dp ppm): 0.87 (m, 3H), 0.95 (d, J = 6.5 Hz, 3H), 1.05 (d, J = 6.5Hz, 3H), 1.27 (d, J = 6.5Hz, 6H), 1.53 (m, 1H), 1.65-1.85 (m, 3H), 1.78 ( s, 3H), 1.85-2.00 (m, 3H), 2.11 (m, 1H), 2.21 (m, 1H), 2.25-2.50 (m, 5H), 2 .61 (m, 1H), 2.78 (m, 1H), 3.05-3.30 (m, 4H), 3.61 (broad d, J = 15Hz, 1H), 3.69 (m, 1H), 3.82 (m, 1H), 3.90-4.05 (m, 2H), 4.50 (broad d, J = 13.5Hz, 1H), 4.70-4.80 (m , 2H), 5.11 (reduced doublet, J HF = 48Hz, 1H), 5.44 (d, J = 9Hz, 1H), 5.62 (m, 1H), 5.75 (m, 1H), 5.81 (broad d, J = 15.5 Hz, 1H), 6.20 (d, J = 15 Hz, 1H), 6.63 (dd, J = 15.5 and 4 Hz, 1H), 8.17 ( t, J = 6 Hz, 1H), 8.52 (s, 1H), 9.14 (m, 1H), 9.56 (m, 1H). PL 203 554 B1 49 (16R) -16-Desoxy-16-fluoro-14-O- [4- (3,5-dimethylpiperazinyl-1-carbamoyl) butyryl] pristimycin II B can be obtained as follows aces: By following the procedure described in example 45 but starting with 470 mg of 4- (3,5-dimethylpiperazinyl-1) -4-oxobutanecarboxylic acid, 1 g of (16R) -16-deoxy-16- Fluoropristinamycin II B (prepared as described in Example 1), 430 mg of N, N'-dicyclohexylcarbodiimide, 23 mg of 4-dimethylaminopyridine, but in a mixture of 40 cm 3 of dichloromethane and 5 cm 3 of dimethylformamide, 60 each hours of stirring, 2.5 g of a brown oil is isolated which is purified by flash chromatography [eluent: dichloromethane-methanol (97/3 vol.% by volume)]. Thus, after concentrating the fraction to dryness under reduced pressure (2.7 kPa) at a temperature of 20 ° C, and then mixing the obtained solid in 10 cm 3 of diethyl ether, filtration and drying (90 Pa) at a temperature of 50 ° C, 680 mg of (16R) -16-deoxy-16-fluoro-14-O- [4- (3,5-dimethylpiperazinyl-1-carbonyl) butyryl] pristinamycin II B are obtained in the form of a colorless solid . 4- (3,5-Dimethylpiperazinyl-1) -4-oxobutanecarboxylic acid can be obtained as follows: To a mixture of 30 cm 3 of dioxane and 5 cm 3 of dichloromethane, 1.5 g of 2,6-dimethylpiperazine is added under an argon atmosphere. . After mixing, the remaining insoluble parts are filtered off and the seam is placed in a three-necked flask. Then 1.5 g of glutaric anhydride in solution in 10 cm 3 of dioxane are added dropwise, and stirring is continued at 25 ° C. for 2 hours. The solvents are evaporated off under reduced pressure (2.7 kPa) to obtain a solid, which is dissolved in 100 cm 3 of diethyl ether, filtered, washed with diethyl ether and then dried at temperature 20 ° C (90 Pa) to give 2.19 g of 4- (3,5-dimethylpyrazine-1) -4-oxobutanecarboxylic acid as a colorless solid which is used as such. Example 52 (16R) -16-deoxy-16-fluoro-14-O- {4- [4- (methylphenylcarbamoylmethyl) piperazinyl-1-carbonyl] butyryl} pristinamycin hydrochloride II B Up to 470 mg (16R) -16- deoxy-16-fluoro-14-O- {4- [4- (methylphenylcarbamoylmethyl) piperazinyl-1-carbonyl) butyryl] pristinamycin II B in solution in 5 cm 3 of methyl isobutyl ketone is added at a temperature of 4 ° C 0.3 cm 3M ethereal hydrochloric acid solution. After stirring for one hour, the precipitate formed is filtered through sintered glass No. 4 and then washed successively with a minimum amount of methyl isobutyl ketone and diethyl ether. The obtained solid is dried at 20 ° C (90 Pa) to give 463 mg of (16R) -16-deoxy-16-fluoro-14-O- {4- [4- (methylphenylcarbamoylmethyl) piperazinyl-1-carbonyl] hydrochloride. butyryl} pristinamycin II B as a colorless solid with a melting point of approximately 155 ° C. 1H NMR spectrum (500 MHz, (CD3) 2 SO d6, dp ppm): 0.87 (m, 3H), 0.95 (d, J = 6.5Hz, 3H), 1.05 (d, J = 6.5Hz, 3H), 1.53 (m, 1H), 1.65-1.85 (m, 3H), 1.77 (s, 3H), 1.85-2.05 (m, 3H), 2.11 (m, 1H), 2.19 (m, 1H), 2.34 (m, 4H), 2.78 (m, 1H), 2.85-3.55 and 3.80 -4.05 (m, total 11H), 3.26 (s, 3H), 3.60 (broad d, J = 15Hz, 1H), 3.69 (m, 1H), 3.81 (m, 1H), 3.95 (m, 1H), 4.25-4.60 (m, 1H), 4.70-4.80 (m, 2H), 5.09 (reduced doublet, J HF = 48Hz, 1H), 5.42 (d, J = 9.5Hz, 1H), 5.62 (m, 1H), 5.74 (m, 1H), 5.81 (dd, J = 16 and 2Hz, 1H) , 6.19 (d, J = 15.5 Hz, 1H), 6.63 (dd, J = 16 and 4 Hz, 1H), 7.25-7.60 (m, 5H), 8.14 (m, 1H), 8.52 (s, 1H), 10.13 (etym extension). (16R) -16-Deoxy-16-fluoro-14-O- {4- [4- (methylphenylcarbamoylmethyl) piperazinyl-1-carbonyl] butyryl} pristnamycin II B can be obtained as follows: ac as described in Example 45, but starting ac with 653 mg of 4- (4- (methylphenylcarbamoylmethyl) piperazinyl-1] -4-oxobutanecarboxylic acid, 1 g of (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in Example 1), 388 mg of N, N'-dicyclohexylcarbodiimide in solution in 10 cm 3 of dichloromethane added dropwise over 3 hours, 23 mg of 4-dimethylaminopyridine in 50 cm 3 of dichloromethane, after stirring for 22 hours, 1.49 g of a solid are obtained which is purified by flash chromatography [eluent: dichloromethane-methanol (97/3 v / v)]. Thus, after concentrating the fraction to dryness under reduced pressure (2.7 kPa) at 20 ° C, and then mixing the obtained solid in diethyl ether, filtration and drying (90 Pa) at 50 ° C, 470 mg of (16R) -16-deoxy-16-fluoro-14-O- {4- [4- (methylphenylcarbamoylmethyl) piperazinyl-1-carbonyl] butyryl} pristimycin II B are obtained as a colorless solid . 4- [4- (Methylphenylcarbamoylmethyl) piperazinyl-1] -4-oxobutanecarboxylic acid can be obtained as follows: 1.517 g of glutaric anhydride are added to 15 cm 3 of dioxane, and then 1.715 g of N - [2- (piperazinyl-1) acetyl] -N-methylaniline. After stirring for 19 hours at 25 ° C, the white precipitate formed is separated by filtration on sintered glass No. 4, washed with dioxane and then with diethyl ether, and dried at 20 ° C (90 Pa) to give 2 g of acid 4- [4- (Methylphenylcarbamoylmethyl) piperazinyl-1] -4-oxobutanecarboxylic acid as a colorless solid which is used as such a. Example 53 (16R) -16-deoxy-16-fluoro-14-O- {4- [4- (2-methoxyethyl) piperazinyl-1-carbonyl] butyryl} pristinamycin hydrochloride II B The e 1 g of tin II B (16R) -16-deoxy-16-fluoropristinamine (prepared as described in Example 1) and 40 cm 3 of dichloromethane. The mixture is heated until dissolved and then cooled. At 20 ° C, 585 mg of 4- [4- (2-methoxyethyl) piperazinyl-1] -4-oxobutanecarboxylic acid are added, followed by 45 mg of 4-dimethylaminopyridine. Finally, 388 mg of N, N'-dicyclohexylcarbodiimide in solution in 10 cm 3 of dichloromethane are added dropwise over 3 hours. After 18 hours of stirring at 20 ° C, additional 48 mg of 4- [4- (2-methoxyethyl) piperazinyl-1] -4-oxobutanecarboxylic acid and 48 mg of N, N'-dicyclohexylcarbodiimide in solution in 5 cm3 are added. 3 of dichloromethane. The reaction mixture is stirred at 20 ° C. for 3 hours, then filtered, rinsed with ethyl acetate and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa). The resulting residue is stirred for 0.5 hours in 40 cm 3 of ethyl acetate and then filtered. The insolubles are washed with ethyl acetate. It is filtered and then washed with 10 cm 3 of a saturated aqueous sodium chloride solution, dried over sodium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa). The obtained solid is first stirred for 18 hours in 40 cm 3 of diisopropyl ether, then filtered and mixed again with a mixture of 40 cm 3 of diisopropyl ether and diethyl ether. The obtained solid is separated by filtration and then purified by flash chromatography [eluent: dichloromethane-methanol (97-3 vol. Vol.%)]. Thus, a product is obtained, which is stirred in 40 cm 3 of diisopropyl ether, filtered and then dried at 30 ° C (90 Pa), yielding 815 mg of (16R) -16-deoxy-16-fluoro-14. - O {4- [4- (2-ethoxyethyl) piperazinyl-1-carbonyl] butyryl} pristinamycin IIB in the form of a white powder. To this solid, dissolved in 4 cm 3 of absolute ethanol, 0.35 cm 3 of a 3M ethereal hydrochloric acid solution is added, and then slowly 20 cm 3 of diethyl ether. The solvents are evaporated off under reduced pressure, and the obtained solid is stirred in 20 cm 3 of diethyl ether. After filtration and drying at 20 ° C (90 Pa), 800 mg of (16R) -16-deoxy-16-fluoro-14-O- {4- [4- (2-methoxyethyl) piperazinyl- 1-carbonyl] butyryl} pristinamycin II B as a colorless solid, mp 170 ° C. 1 H NMR spectrum (400 MHz, (CD 3) 2 SO d 6, dp ppm): 0.86 (d, J = 6.5 Hz, 3H), 0.95 (d, J = 6.5 Hz, 3H), 1.04 (d, J = 6.5Hz, 3H), 1.52 (m, 1H), 1.65-2.05 (m, 6H), 1.77 (s, 3H), 2.05- 2.30 (m, 2H), 2.37 (m, 4H), 2.78 (m, 1H), 2.85-3.55 (m, 13H), 3.59 (m, 1H), 3 , 65-3.75 (m, 3H), 3.81 (m, 1H), 3.90-4.10 (m, 2H), 4.42 (broad d, J = 13Hz, 1H), 4. 70-4.80 (m, 2H), 5.10 (reduced doublet, J HF = 48Hz, 1H), 5.43 (d, J = 9Hz, 1H), 5.61 (m, 1H), 5, 74 (m, 1H), 5.81 (dd, J = 16 and 1.5Hz, 1H), 6.20 (d, J = 16Hz, 1H), 6.64 (dd, J = 16 and 4Hz, 1H ), 8.18 (t, J = 6 Hz, 1H), 8.52 (s, 1H), 10.46 (m broad, 1H). 4- [4- (2-methoxyethyl) piperazinyl-1] -4-oxo-butanecarboxylic acid can be obtained as follows: 1.52 g of glutaric anhydride is added to 10 cm 3 of dioxane, and then 1, 92 g of 1- (2-methoxyethyl) piperazine in solution in 3 cm 3 of dioxane. After 5 hours of stirring at ambient temperature, an additional 300 mg of glutaric anhydride is added and stirring is continued at 20 ° C for 18 hours. The solvent is evaporated off under reduced pressure and the resulting oil is dried at 20 ° C (90 Pa) to give 3.4 g of 4- [4- (2-methoxyethyl) piperazinyl-1] -4-oxobutanecarboxylic acid in the form of orange wax which is used as such. Example 54 (16R) -16-deoxy-16-fluoro-14-O- [4- (4-propylpiperazinyl-1-carbonyl) butyryl] pristinamycin hydrochloride II B Proceed as described in Example 46, but starting with 0.5 g of 4-oxo-4- (4-propylpiperazinyl-1) butane carboxylic acid, 1 g of (16R) -16-deoxy-16-fluoropristinamycin II B (obtained as described in example Lada 1), 430 mg of N, N'-dicyclohexylcarbodiimide and 23 mg of 4-dimethylaminopyridine in 50 cm 3 of dichloromethane are obtained after 4 hours of stirring at 20 ° C, filtration and evaporation of the solvent to dryness under reduced pressure by snowfall (2.7 kPa) at 20 ° C, a solid which is purified by equilibrium chromatography [eluent: dichloromethane-methanol (97/3 v / v)]. After concentrating the fraction to dryness under reduced pressure (2.7 kPa) at 20 ° C, and then mixing the obtained solid in diethyl ether, filtration and drying (90 Pa) at 20 ° C, si e 960 mg of (16R) -16-deoxy-16-fluoro-14-O- [4- (4-propylpiperazinyl-1-carbonyl) butyryl] pristinamycin II B in the form of a white powder. To this solid, dissolved in 10 cm 3 of methyl ethyl ketone, is added 0.70 cm 3 of a 3M ethereal hydrochloric acid solution. The obtained precipitate is separated by filtration on sintered glass No. 3, washed twice with 10 cm 3 of methyl ethyl ketone, and then twice with 15 cm 3 of diethyl ether. After filtration and drying at 20 ° C (90 Pa), 700 mg of (16R) -16-deoxy-16-fluoro-14-O- [4- (4-propylpiperazinyl-1-carbonyl) butyryl] pristi hydrochloride are obtained. - namycin II B as a colorless solid with a melting point of 145 ° C. 1 H NMR spectrum (400 MHz, (CD 3) 2 SO d 6, dp ppm): 0.86 (d, J = 6.5 Hz, 3H), 0.90-1.00 (m, 6H), 1, 04 (d, J = 6.5 Hz, 3H), 1.54 (m, 1H), 1.60-2.25 (m, 10H), 1.78 (s, 3H), 2.30-2, 45 (m, 4H), 2.76 (m, 1H), 2.8-3.10 (m, 6H), 3.21 (m, 1H), 3.40-3.55 (m, 3H) , 3.60 (m, 1H), 3.68 (m, 1H), 3.82 (m, 1H), 3.90-4.10 (m, 2H), 4.45 (broad d, J = 14Hz, 1H), 4.70-4.80 (m, 2H), 5.10 (reduced doublet, J HF = 48Hz, 1H), 5.41 (d, J = 9Hz, 1H), 5.61 ( m, 1H), 5.74 (m, 1H), 5.80 (broad d, J = 16 Hz, 1H), 6.19 (d, J = 15.5 Hz, 1H), 6.62 (dd, J = 16 and 4 Hz, 1H), 8.14 (broad t, J = 5.5 Hz, 1H), 8.48 (s, 1H), 10.41 (broad m, 1H). 4-oxo-4- (4-propylpiperazinyl-1) butane carboxylic acid can be obtained as follows: 10 cm 3 of dioxane, 1.5 g of glutaric anhydride are placed in a flask maintained under nitrogen atmosphere, and then 1.66 g of N-propylpiperazine in solution in 5 cm 3 of dioxane. After 2.5 hours of stirring at ambient temperature, the solvent is evaporated off under reduced pressure, and 100 cm 3 of diethyl ether are added to the oil obtained. After stirring for one hour, the obtained solid was filtered and dried at 20 ° C (90 Pa) to obtain 2.47 g of 4-oxo-4- (4-propylpiperazinyl-1) butanecarboxylic acid in a colorless form a solid which is used as such a. Example 55 (16R) -16-Deoxy-16-fluoro-14-O- {4- [4- (3-imidazolyl-1-propyl) piperazinyl-1-carbonyl] butyryl} pristinamycin II B In a flask placed under with nitrogen are placed 1.42 g of (16R) -14-O- {4- [4- (3-chloropropyl) pyrazinyl-1-carbonyl] butyryl} -16-deoxy-16-fluoropristinamycin II B, 6 cm 3 dimethylformamide, 0.24 g imidazole and 10 mg sodium iodide. The mixture was heated at 75 ° C for 5 hours and then stirred for 60 hours at 20 ° C. Then, at 20 ° C, 0.12 g of additional imidazole is again added in solution in 2 cm 3 of DMF and stirring is continued for 4 hours at 75 ° C, and then 18 hours at 20 ° C. . Then the mixture obtained is concentrated to dryness under reduced pressure (2.7 kPa), the obtained mixture is dissolved in 50 cm 3 of dichloromethane, and the obtained solution is washed twice with 40 cm 3 of distilled water. . The organic phase is decanted, dried over magnesium sulphate, filtered, and then concentrated to dryness under reduced pressure, yielding 1.14 g of a solid, which is purified by equilibrium chromatography [eluent: dichloromethane -methanol (gradient 95/5 followed by 90/10 vol. ethical)]. In this way, a solid is obtained, which is stirred for 40 hours in diethyl ether, filtered and then dried at 20 ° C (90 Pa), yielding 290 mg (16R) -16-deoxy -16-fluoro-14-O- {4- [4- (3-imidazolyl-1-propyl) piperazinyl-1-carbonyl] butyryl} pristinamycin II B as a crushed colorless solid, mp 122 ° C . 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.45-2.05 (m, 9H), 1.88 (s, 3H), 2.10-2.30 (m, 2H), 2.29 (t , J = 7 Hz, 2H), 2.37 (m, 8H), 2.76 (m, 1H), 2.99 (m, 1H), 3.23 (m, 1H), 3.40-3, 55 (m, 3H), 3.62 (m, 2H), 3.86 (m, 1H), 4.00-4.10 (m, 1H), 4.05 (t, J = 7Hz, 2H) , 4.53 (m, 1H), 4.78 (dd, J = 10 and 2Hz, 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.12 (reduced double, J HF = 48Hz, 1H), 5.31 (d, J = 9Hz, 1H), 5.75 (m, 1H), 5.75-5.85 (m, 1H), 5.82 (dd, J = 16 and 2Hz, 1H), 6.00 (m, 1H), 6.19 (d, J = 16Hz, 1H), 6.52 (dd, J = 16 and 5Hz, 1H), 6.93 (m, 1H), 7.08 (broad s, 1H), 7.50 (broad s, 1H), 8.12 (s, 1H). (16R) -14-O- {4- [4- (3-chloropropyl) piperazinyl-1-carbonyl] butyryl} -16-deoxy-16-fluoropristimycin II B can be obtained by post according to example 46, but starting with 0.94 g of 4- [4- - (3-chloropropyl) piperazinyl-1)] - 4-oxobutanecarboxylic acid, 1.5 g of (16R) -16-deoxy- 16-fluoropristinamycin II B (prepared as described in Example 1), 460 mg of N, N'-dicyclohexylcarbodiimide and 23 mg of 4-dimethylaminopyridine in 40 ml of dichloromethane. Thus, after stirring for 23 hours at 20 ° C, a suspension is obtained and filtered. The filtrate is concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C to give a solid, which is stirred in diisopropyl ether, filtered and then dissolved in 50 cm 3 of dichloromethane. The solution obtained is washed with 30 cm 3 of distilled water, decanted, dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C, obtaining 1.42 g. (16R) -14-O- {4- [4- (3-chloropropyl) piperazinyl-1-carbonyl] butyryl} - -16-deoxy-16-fluoropristinamycin II B as yellow solid which is used e as yes a. 4- [4- (3-chloropropyl) piperazinyl-1)] - 4-oxo-butanecarboxylic acid can be obtained as follows: 15 cm 3 of dioxane, 1.5 g of anhydride are placed in a flask maintained under argon. glutaric acid, and then 2.13 g of N- (chloropropyl) piperazine in solution in 5 cm 3 of dioxane and 1 cm 3 of dichloromethane. After 2 hours of stirring at 20 ° C, the solvent is evaporated under reduced pressure (2.7 kPa) at 20 ° C to give 3.75 g of 4- [4- (3-chloropropyl) piperazinyl-1-acid. )] - 4-oxo-butane carboxylic acid yellow oil which is used as is. Example 56 (16R) -16-deoxy-16-fluoro-14-O- [4- (2-morphoolinoethoxycarbonyl)] butyryl} pristinamycin hydrochloride II B Up to 550 mg (16R) -16-deoxy-16-fluoro -14-O- [4- (2-morpholinoethoxycarbonyl)] butyryl} pristimycin II B in solution in 5.5 cm 3 of methyl isobutyl ketone is added at 4 ° C 0.42 cm 3 of a 3M ethereal hydrogen chloride solution. After stirring for 1 hour, the precipitate formed is filtered through sintered glass No. 4, washed successively with methyl isobutyl ketone and diethyl ether, and then dried at 20 ° C (90 Pa) to obtain 458 mg of hydrochloride. (16R) -16-deoxy-16-fluoro-14-O- [4- (2-morpholinoethoxycarbonyl)] butyryl} pristinamycin IIB as a colorless solid, m.p. 168 ° C. 1H NMR spectrum (500 MHz, (CD3) 2 SO d6, dp ppm): 0.85 (m, 3H), 0.94 (d, J = 6.5Hz, 3H), 1.03 (d, J = 6.5Hz, 3H), 1.50 (m, 1H), 1.70-1.85 (m, 3H), 1.77 (s, 3H), 1.85-2.05 (m, 3H), 2.09 (m, 1H), 2.19 (m, 1H), 2.38 (m, 2H), 2.42 (t, J = 7Hz, 2H), 2.77 (m, 1H ), 3.10-3.50 (m, 8H), 3.58 (broad d, J = 15Hz, 1H), 3.68 (m, 1H), 3.70-3.85 (m, 3H) , 3.90-4.00 (m, 3H), 4.39 (m, 2H), 4.70-4.80 (m, 2H), 5.09 (reduced double, J HF = 48Hz, 1H), 5.42 (d, J = 9Hz, 1H), 5.60 (m, 1H), 5.74 (m, 1H), 5.80 (broad d, J = 16Hz, 1H), 6, 19 (d, J = 16 Hz, 1H), 6.62 (dd, J = 16 and 54 Hz, 1H), 8.17 (m, 1H), 8.52 (s, 1H), 10.50 (dec strains m, 1H). (16R) -16-deoxy-16-fluoro-14-O- [4- (2-morpholinoethoxycarbonyl)] butyryl} pristinamycin II B can be obtained as follows: trace 45, but starting from 461 mg of 2-morpholinoethyl monoester of glutaric acid, 1 g of (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in example 1), 388 mg of N, N ' -dicyclohexylcarbodiimide, 23 mg of 4-dimethylaminopyridine in 40 cm 3 of dichloromethane, after 22 hours of stirring, 1.33 g of a solid is obtained, which is purified by two consecutive equilibrium chromatographies [eluent: respectively dichloromethane / methanol (97/3 vol ethical) and dichloromethane / methanol (98/2 vol ethical)]. After concentrating the fractions to dryness under reduced pressure (2.7 kPa), stirring the solids obtained in diethyl ether, filtering and drying (90 Pa) at 20 ° C, 550 mg (16R) -16-deoxy- is obtained. 16-fluoro-14-O- [4- (2-morpholinoethoxycarbonyl)] butyryl} pristinamycin IIB as a colorless solid. The 2-morpholinoethyl monoester of glutaric acid can be prepared as follows: 1.517 g of glutaric anhydride are added to 10 cm 3 of dioxane, followed by 1.61 cm 3 of N-2-hydroxyethylmorpholine. After stirring for 19 hours at 25 ° C, the solvent is evaporated and the product obtained is dried at 55 ° C (90 Pa) to give 3.18 g of 2-morpholine-4-ethyl monoester of glutaric acid in the form of br azo oil which is used as such. Example 57 (16R) -16-Deoxy-16-fluoro-14-O- {4- [4- (2-morpholinoethyl) piperazinyl-1-carbonyl] butyryl} pristinamycin II BPL 203 554 B1 53 according to example 46, but starting with 0.7 g of 4- [4- (2-morpholinoethylpiperazinyl-1)] - 4-oxobutanecarboxylic acid, 1 g of (16R) -16-deoxy-16-fluoropristinamycin (obtained as described in Example 1), 460 mg of N, N'-dicyclohexylcarbodiimide and 23 mg of 4-dimethylaminopyridine in 40 cm 3 of dichloromethane are obtained, after 4 hours of stirring at 20 ° C, a suspension is filtered and filtered. . The filtrate is concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C to obtain a beige powder which is purified by equilibrium chromatography [eluent: dichloromethane-methanol (96/4 by vol. ethoscially)]. After concentrating the fraction to dryness under reduced pressure (2.7 kPa) at 20 ° C, and then stirring the obtained solid in diisopropyl ether for 36 hours, filtration and drying (90 Pa) at 20 ° C ° C, 750 mg of a solid are obtained. This solid is stirred again for 60 hours in a mixture of 20 cm 3 of diisopropyl ether and 10 cm 3 of diethyl ether. After filtration and drying (90 Pa) at 20 ° C, the obtained solid is stirred for 1.5 hours at 60 ° C in 60 cm 3 of diisopropyl ether, then filtered and dried (90 Pa ) at 20 ° C to give 0.55 g of (16R) -16-deoxy-16-fluoro-14-O- {4- [4- (2-morpholinoethyl) piperazin-1-carbonyl] butyryl} pristinamycin II B as a yellow powder, m.p. 116 ° C. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.55-2.05 (m, 7H), 1.89 (s, 3H), 2.10-2.30 (m, 2H), 2.38 (m , 4H), 2.40-2.60 (m, 12H), 2.76 (m, 1H), 2.98 (m, 1H), 3.23 (m, 1H), 3.40-3. 55 (m, 3H), 3.61 (m, 2H), 3.72 (t, J = 5Hz, 4H), 3.86 (m, 1H), 4.06 (m, 1H), 4.54 (m, 1H), 4.79 (dd, J = 10 and 1.5Hz, 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.12 (reduced doublet, J HF = 48Hz, 1H), 5.30 (d, J = 9 Hz, 1H), 5.75 (m, 1H), 5.75-5.85 (m, 1H), 5.82 (dd, J = 17 and 1, 5Hz, 1H), 5.96 (m, 1H), 6.19 (d, J = 16Hz, 1H), 6.51 (dd, J = 17 and 5Hz, 1H), 8.12 (s, 1H) . 4- [4- (2-morpholinoethylpiperazinyl-1)] - 4-oxobutanecarboxylic acid can be obtained as follows: 10 cm 3 of dioxane, 1.5 g of glutaric anhydride are placed in a flask maintained under nitrogen atmosphere, and then 2.62 g of 1- (2-morpholinoethyl) piperazine in solution in 10 cm 3 of dioxane. After 60 hours of stirring at ambient temperature, the solvent is evaporated off under reduced pressure and 100 cm 3 of diethyl ether are added to the remaining oil. After cooling to -40 ° C, the product thickens. Then stirring is continued for 1 hour at 20 ° C, and the obtained solid is filtered, washed with diethyl ether, and then dried at 20 ° C (90 Pa), obtaining 3.57 g 4- [4- (2-morpholinoethylpiperazinyl-1)] - 4-oxobutanoic acid as a colorless solid which is used as such a. Example 58 (16R) -16-deoxy-16-fluoro-14-O - [(3RS) -3-methyl-4- (4-methylpiperazinyl-1-carbonylbutyryl] pristinamycin hydrochloride II B. Example 46, but starting from 516 mg of 2-methyl-4- (4-methylpiperazinyl-1) -4-oxobutanecarboxylic acid, 1 g (16R) -16-deoxy-16-fluoropristinamycin II B, 467 mg of N , N'-dicyclohexylcarbodiimide and 54 mg of 4-dimethylaminopyridine in 40 cm 3 of dichloromethane, 1.25 g of a solid are obtained, which is purified by flash chromatography [eluent: dichloromethane / methanol (95/5 vol. )]. After concentrating the fraction to dryness under reduced pressure (2.7 kPa) at 20 ° C, and then stirring the solid for 18 hours in diisopropyl ether, filtration and drying (90 Pa) at 20 ° C are obtained e 730 mg (16R) -16-deoxy-16-fluoro-14-O - [(3RS) -3-methyl-4- (4-methylpiperazinyl-1-carbonylbutyryl] pristinamycin II B as a colorless solid which is dissolved in 3.5 cm 3 of absolute ethanol, to which is added 0.34 cm 3 of a 3M ethereal hydrogen chloride solution. Finally, 35 ml of diethyl ether are added and the suspension obtained is stirred for 2 hours at 20 ° C. The solid is filtered, rinsed with diethyl ether and then dried at 45 ° C (90 Pa) to give 645 mg of (16R) -16-deoxy-16-fluoro-14-O- hydrochloride. [(3RS) -3-methyl-4- (4-methylpiperazinyl-1-carbonyl) butyryl] pristinamycin IIB as a colorless solid, m.p. 185 ° C. 1 H NMR spectrum (400 MHz, (CD 3) 2 SO d 6, dp ppm): 0.85 (d, J = 6.5 Hz, 3H), 0.90-1.00 (m, 6H), 1, 03 (d, J = 6.5 Hz, 3H), 1.51 (m, 1H), 1.70-2.45 (m, 11H), 1.77 (s, 3H), 2.70-3, 50 (m, 9H), 2.77 (broad s, 3H), 3.59 (m, 1H), 3.68 (m, 1H), 3.80 (m, 1H), 3.90-4, 20 (mf extension, 1H), 3.97 (m, 1H), 4.44 (mf extension, 1H), 4.70-4.80 (m, 2H), 5.09 (reduced doublet , J HF = 48Hz, 1H), 5.43 (d, J = 9Hz, 1H), 5.61 (m, 1H), 5.75 (m, 1H), 5.80 (broad d, J = 16Hz , 1H), 6.19 (d, J = 16Hz, 1H), 6.62 (dd, J = 16 and 4Hz, 1H), 8.17 (t, J = 5.5Hz, 1H), 8.52 (s, 1H), 10.49 (broad mf, 1H). PL 203 554 B1 54 (3RS) -2-methyl-4- (4-methylpiperazinyl-1) -4-xobutanecarboxylic acid can be obtained as follows: To 20 cm 3 of dioxane 1.6 g of anhydride 3 are added. -methylglutaric acid, followed by 1.48 cm3 of N-methylpiperazine. After stirring for 4 hours, an additional 320 mg of 3-methylglutaric anhydride are added. Stirring is continued at 20 [deg.] C. for 18 hours and then the solvent is evaporated off at 50 [deg.] C. under reduced pressure (2.7 kPa). The obtained oil was dried at 50 ° C (90 Pa), yielding 3.1 g of (3RS) -2-methyl-4- (4-methyl-piperazinyl-1) -4-oxobutanecarboxylic acid in the form of a yellow lake. which is used as such. Example 59 (16R) -16-Deoxy-16-fluoro-14-O - [(RR, SS) -trans-2- (4-methylpiperazinyl-1-carbonyl) -1-cyclobutanecarbonyl] pristinamycin II B ( 50/50 mixture of two diasteroisomers To 2.1 g of (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in example 1) in solution in 100 cm 3 of dichloromethane is added at a temperature of 20 ° C , under argon, 2.0 g of (RR, SS) -trans-2- (4-methylpiperazinyl-1-carbonyl) -1-cyclobutanecarboxylic acid, 1.24 g of N, N'-dicyclohexylcarbodiimide and 0.49 g 4-dimethylaminopyridine. After 24 hours of stirring, the reaction mixture is filtered to remove insoluble components. The filtrate is concentrated to dryness under reduced pressure (2.7 kPa), giving 5.2 g of a residue, which is purified by flash chromatography [eluent: dichloromethane / methanol gradient (97/3, and then 95/5 ethical vol.)]. After stirring in diisopropyl ether, 0.26 g of (16R) -16-deoxy-16-fluoro-14-O - [(RR, SS) -trans-2- (4-methylpiperazinyl-1-carbonyl) -1 is obtained. -cyclobutane carbonyl] pristinamycin II B (50/50 mixture of the two diastereomers) as a white powder. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): (2 diastereoisomers in the ratio 50-50): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6, 5Hz, 3H), 1.11 (d, J = 6.5Hz, 3H), 1.55-2.45 (m, 15H), 1.90 (s, 3H), 2.29 and 2.30 ( 2s, total 3H), 2.77 (m, 1H), 2.98 (d, J = 17 and 6 Hz, 1H), 3.23 (m, 1H), 3.30-3.75 (m, 7H), 3.86 (m, 1H), 4.06 (m, 1H), 4.55 (m, 1H), 4.75-4.85 (m, 2H), 5.11 (reduced doublet, J HF = 48Hz, 1H), 5.30 (d, J = 9Hz, 1H), 5, 70-5, 85 (m, 3H), 5.96 and 6.02 (2m, total 1H), 6 , 20 (d, J = 16 Hz, 1H), 6.52 (m, 1H), 8.12 (s, 1H). (RR, SS) -trans-2- (4-methylpiperazinyl-1-carbonyl) -1-cyclobutanecarboxylic acid can be obtained as follows: For a solution of 1.8 g of (RR, SS) -trans-1 acid dichloride The 2-cyclobutane dicarboxylic acid in 50 ml of dichloromethane is added dropwise at 25 ° C under argon to 1.1 ml of 1-methylpiperazine. After stirring for 4 hours, 10 cm 3 of distilled water are added. After stirring for 1 hour, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) to give a residue which is dissolved in 20 cm 3 of distilled water. This solution is brought to pH 10 by adding 1N aqueous sodium hydroxide solution. The solution obtained is extracted with 50 cm 3 of ethyl acetate, the pH is adjusted to 5-6 by adding 1N aqueous hydrochloric acid solution and then concentrated to dryness under reduced pressure (2.7 kPa). The remaining residue is recovered twice with 50 cm 3 of toluene and brought to dryness under reduced pressure (2.7 kPa). The residue that remains is dissolved with 50 cm 3 of ethanol at 50 ° C, the insoluble matter is removed by filtration, and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa). Thus, 2.4 g of (RR, SS) -trans-2- (4-methylpiperazinyl-1-carbonyl) -1-cyclobutanecarboxylic acid are obtained in the form of a yellow oil. Dichloride of (RR, SS) -trans-1,2-cyclobutanedicarboxylic acid can be obtained as follows: Up to 1.5 g of (RR, SS) -trans-1,2-cyclobutanedicarboxylic acid are added at a temperature of 20 ° C 2.2 cm 3 of sulfonyl chloride, and then the reaction mixture is heated for 2 hours under reflux. The reaction mixture is finally concentrated under reduced pressure (2.7 kPa). The remaining sc is recovered twice with 50 cm 3 of toluene and brought to dryness under reduced pressure (2.7 kPa). Thus, 1.8 g of (RR, SS) -trans-1,2-cyclobutane-dicarboxylic acid dichloride are obtained in the form of a yellow oil. Example 60 (16R) -16-deoxy-16-fluoro-14-O- (1-methylpiperidinyl-4-carbonyl) pristinamycin methanesulfonate II A Up to 1.06 g (16R) -16-deoxy-16-fluoropristinamycin II A (prepared as described in Example 8), 0.23 g of 1-methyl-4-piperidinecarboxylic acid, 0.123 g of 4-dimethylaminopyridine in solution in 40 cm 3 of dichloromethane are added at a temperature of 0.516 g of N, N ' - dicyclohexyl-carbodiimide. After 24 hours of stirring, the reaction mixture is washed with 50 cm 3 of water, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) to obtain a residue which is then purified. by means of flash chromatography [eluent: dichloromethane / methanol (95/5 v / v bulk)]. A product is obtained which is dissolved with 35 cm 3 of ethanol and 13.4 cm 3 of 0.1N aqueous methanesulfonic acid solution and then concentrated to dryness under reduced pressure (2.7 kPa) and stirred in with diethyl ether, filtered and concentrated to give a residue which is stirred in 25 cm 3 of dichloromethane and 10 cm 3 of a 5% aqueous solution of sodium carbonate hydrogen. The organic phase is then separated off and concentrated to dryness under reduced pressure (2.7 kPa) to obtain a residue which is dissolved in 20 cm 3 of ethanol and 10 cm 3 of 0.1N aqueous methanesulfonic acid solution. The solution is concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C to obtain 0.65 g of (16R) - -16-deoxy-16-fluoro-14-O- (1-methyl methanesulfonate) -piperidinyl-4-carbonyl) pristinamycin IIA in the form of a cream solid. 1 H NMR spectrum (400 MHz, (CD 3) 2 SO d6 at 383 K, d in ppm): 0.93 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz , 3H), 1.13 (d, J = 6.5Hz, 3H), 1.75-2.30 (m, 7H), 1.84 (s, 3H), 2.40 (s, 3H), 2.55-2.85 (m, 4H), 2.81 (s, 3H), 2.90-3.55 (m, 6H), 3.79 (broad d, J = 16.5Hz, 1H) , 3.94 (d, J = 16.5 and 6.5Hz, 1H), 4.05-4.25 (m, 2H), 4.81 (dd, J = 9 and 3Hz, 1H), 4, 99 (reduced doublet, J HF = 48 Hz, 1H), 5.33 (d, J = 9.5 Hz, 1H), 5.75 (d, J = 9.5 and 5 Hz, 1H), 5.81 (m , 1H), 5.92 (dd, J = 16 and 1.5Hz, 1H), and 6.10 (d, J = 16Hz, 1H), 6.28 (, J = 3Hz, 1H), 6.63 (dd, J = 16 and 6.5 Hz, 1H), 7.43 (m, 1H), 8.45 (s, 1H), 8.85-9.45 (very stretchy, 1H). 1-Methyl-4-piperidinecarboxylic acid can be obtained as follows: To 7.60 g of ethyl 1-methyl-4-piperidinecarboxylate in 35 cm 3 ethanol solution is added at a temperature of 20 ° C 12.5 cm 3 4N aqueous sodium hydroxide solution. After 20 hours of stirring, the reaction mixture is concentrated to a smaller volume, then neutralized with a 4N aqueous solution of hydrochloric acid, and finally dry concentrated under reduced pressure (2.7 kPa ). The residue that remains is stirred in 60 cm 3 of absolute ethanol and then filtered. The filtrate is concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C to give 6.3 g of 1-methyl-4-piperidinecarboxylic acid as a colorless solid. 1 H NMR spectrum (300 MHz, (CD 3) 2 SO d 6, dp ppm): 1.56 (m, 2H), 1.78 (m, 2H), 1.98 (d J = 11.5 and 2 , 5 Hz, 2H), 2.13 (m, 1H), 2.18 (s, 3H), 2.74 (broad d, J = 11.5 Hz, 2H). Ethyl 1-methyl-4-piperidinecarboxylate can be obtained as follows: To 9.2 g of ethyl 4-piperidinecarboxylate hydrochloride in solution in 80 cm 3 of dichloromethane is added at a temperature of 20 ° C 12.5 cm 3 of 4N aqueous sodium hydroxide solution. After stirring for 5 minutes, the organic phases are dried over magnesium sulphate, filtered and then cooled to 5 ° C. Then 7.0 cm 3 of formaldehyde and 14.2 g of sodium triacetoxyborohydride (in two portions) are added under an argon atmosphere. After 1 hour of vigorous stirring at 20 ° C., the reaction mixture is diluted with 50 cm 3 of water, made alkaline with 4N aqueous sodium hydroxide solution and then decanted. The organic phase is dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C to give 7.6 g of ethyl 1-methyl-4-piperidinecarboxylate in as a colorless oil. 1 H NMR spectrum (250 MHz, CDCl 3, dp ppm): 1.24 (t, J = 7 Hz, 3H), 1.65-2.05 (m, 6H), 2.15-2.30 (m , 1H), 2.25 (s, 3H), 2.81 (broad d, J = 11.5 Hz, 2H), 4.13 (q, J = 7 Hz, 2H). Example 61 (16R) -16-Deoxy-16-fluoro-14-O- [1- (dimethylaminoacetyl) piperidine-4-carbonyl] pristinamycin II B Up to 1.1 g (16) -16-deoxy-16 -fluoropristinamycin II B (prepared as described in Example 1) in solution in 50 cm 3 of dichloromethane is added at a temperature of 20 ° C, under an argon atmosphere, 0.51 g of 1- (dimethylaminoacetyl) piperidine-4 -carboxylic acid, 0.5 g of N, N'-dicyclohexylcarbodiimide, and 0.15 g of 4-dimethylaminopyridine. After stirring for 48 hours, additional 0.5 g of N, N'-dicyclohexylcarbodiimide and 0.5 g of 4-dimethylaminopyridine are added. After 48 hours of stirring, the reaction mixture is filtered to remove insoluble components. The filtrate is concentrated to dryness under reduced pressure (2.7 kPa) to give 1.8 g of a residue which is purified by flash chromatography [eluent: dichloromethane / methanol gradient (97/3, then 95/5 ethical vol.)]. After stirring in diethyl ether, 0.38 g of (16R) -16-deoxy-16-fluoro-14-O- [1- (dimethylaminoacetyl) piperidine-4-carbonyl] pristinamycin II B is obtained as a colorless solid. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d, J = 6.5Hz, 3H), 1.50-2.05 (m, 9H), 1.89 (s, 3H), 2.10-2.35 (m, 2H), 2.28 (s, 6H), 2.52 (m, 1H), 2.77 (m, 1H), 2.80 (m, 1H), 3.00 (dt, J = 17 and 6Hz, 1H) , 3.05-3.20 (m, 1H), 3.10 (AB, J = 14Hz, 2H), 3.25 (m, 1H), 3.50 (m, 1H), 3.85 (m , 1H), 4.00-4.10 (m, 2H), 4.38 (m, 1H), 4.53 (m, 1H), 4.78 (broad d, J = 10Hz, 1H), 4 , 82 (dd, J = 9 and 3Hz, 1H), 5.10 (reduced doublet, J HF = 48Hz, 1H), 5.29 (d, J = 9Hz, 1H), 5.70-5.90 ( m, 3H), 5.93 (m, 1H), 6.19 (d, J = 16Hz, 1H), 6.52 (dd, J = 16 and 4Hz, 1H), 8.12 (s, 1H) . 1- (dimethylaminoacetyl) piperidine-4-carboxylic acid can be obtained in the following way: To 4.5 g of ethyl 1- (dimethylaminoacetyl) piperidine-4-carboxylate in solution in 50 cm 3 of ethanol is added at a temperature of 20 ° C 25 cm 3 of 1N aqueous sodium hydroxide solution. After stirring for 16 hours at 50 ° C., the ethanol is removed under reduced pressure and the remaining aqueous phase is extracted with 50 ml of ethyl acetate. The aqueous phase is then adjusted to pH 6 by adding 1N hydrochloric acid and then concentrated to dryness under reduced pressure (2.7 kPa). The residue is recovered twice with 50 cm 3 of toluene and brought to dryness under reduced pressure (2.7 kPa). The remaining residue is dissolved with 50 cm 3 of ethanol at 50 ° C, and the insoluble matter is removed by filtration. The filtrate is concentrated under reduced pressure (2.7 kPa) to give 4.2 g of 1- (dimethylaminoacetyl) piperidine-4-carboxylic acid as a yellow oil. 1 H NMR spectrum (300 MHz, CDCl 3, dp ppm): 1.50-1.80 (m, 2H), 1.93 (m, 2H), 2.40-2.60 (m, 1H), 2.51 (s, 6H), 2.78 (m, 1H), 3.07 (m, 1H), 3.25 (d, J = 14.5Hz, 1H), 3.55 (d, J = 14.5Hz, 1H), 3.84 (broad d, J = 14Hz, 1H), 4.39 (broad d, J = 14Hz, 1H). Ethyl 1- (dimethylaminoacetyl) piperidine-4-carboxylate can be obtained as follows: To a solution of 2.3 g of N, N-dimethylglycine, 3.2 cm 3 of ethyl piperidine-4-carboxylate, 3.4 cm 3 of triethylamine and 0.27 g of hydroxybenzotriazole hydrate in 100 ml of dichloromethane were added at 20 ° C under argon, 4.6 g of N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride. After 18 hours of stirring, the reaction mixture is washed twice with 100 cm 3 of distilled water. The organic phase is dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa). 4.6 g of ethyl 1- (dimethylaminoacetyl) piperidine-4-carboxylate are obtained in the form of a yellow oil. 1 H NMR spectrum (250 MHz, (CD 3) 2 SO d6 with a few drops of CD 3 COOD d4, dp ppm): 1.22 (t, J = 7 Hz, 3H), 1.55 (m, 2H), 1.88 (m, 2H), 2.37 (s, 6H), 2.60 (m, 1H), 2.90-3.15 (m, 2H), 3.34 (s, 2H), 3 , 90-4.15 (m, 2H), 4.11 (q, J = 7 Hz, 2H). Example 62 (16R) -16-Deoxy-16-fluoro-14-O- [1- (imidazolyl-1-acetylpiperidine-4-carbonyl] pristinamycine II B Up to 0.8 g (16R) -16-deoxy 0.15 g of imidazole and 0 18 g of potassium iodide. After stirring for 16 hours, 100 cm 3 of dichloromethane are added. The mixture obtained is washed twice with 50 ml of 0.1N aqueous sodium hydroxide solution. The organic phase is decanted, dried over magnesium sulphate, filtered, and then concentrated to dryness under reduced pressure (2.7 kPa), obtaining 0.9 g of a residue, which is then cleaned by flash chromatography [eluent: dichloromethane / methanol (95/5 v / v)]. After stirring in isopropyl ether, filtering and drying (2.7 kPa) at 20 ° C, 0.38 g of (16R) -16-deoxy-16-fluoro-14-O- [1- (imidazolyl) is obtained -1-acetyl) piperidine-4-carbonyl] pristinamycin IIB in the form of a white powder. 1 H NMR spectrum (400 MHz, (CD 3) 2 SO d 6, dp ppm): 0.86 (d, J = 6.5 Hz, 3H), 0.95 (d, J = 6.5 Hz, 3H), 1.04 (d, J = 6.5Hz, 3H), 1.35-2.30 (m, 11H), 1.78 (s, 3H), 2.67 (m, 1H), 2.75- 2.85 (m, 2H), 3.10-3.35 (m, 3H), 3.61 (broad d, J = 15Hz, 1H), 3.70 (m, 1H), 3.81 (m , 2H), 3.97 (m, 1H), 4.18 (m, 1H), 4.70-4.80 (m, 2H), 4.95-5.20 (m, 1H), 5. 00 (AB limited, 2H), 5.43 (d, J = 9Hz, 1H), 5.62 (m, 1H), 5.70-5.80 (dd, J = 16 and 2Hz, 1H), 5 , 80 (dd, J = 16 and 2Hz, 1H), 6.19 (d, J = 16Hz, 1H), 6.63 (dd, J = 16 and 4Hz, 1H), 6.86 (s, 1H) , 7.05 (s, 1H), 7.52 (s, 1H), 8.13 (m, 1H), 8.52 (s, 1H). (16R) -16-Deoxy-16-fluoro-14-O- (1-chloroacetylpiperidine-4-carbonyl) pristinamycin II B can be obtained as follows: Up to 1.1 g of (16R) -16-deoxy -16-fluoropristinamycin II B (prepared as described in example 1) in solution in 50 cm 3 of dichloromethane is added at a temperature of 20 ° C, under argon, 0.62 g of 1-chloroacetylpiperidine-4-carboxylic acid, 0, 62 g of N, N'-dicyclohexylcarbimide and 0.24 g of 4-dimethylaminopyridine. After stirring for 16 hours at 20 ° C, the reaction mixture is filtered to remove insoluble components. The filtrate is concentrated to dryness under reduced pressure (2.7 kPa) to give 1.8 g of a residue which is purified by flash chromatography [eluent: dichloromethane / methanol (97/3 vol. )]. Thus, 0.25 g of (16R) -16-deoxy-16-fluoro-14-O- (1-chloroacetylpiperidine-4-carbonyl) pristinamycin IIB is obtained as a colorless solid. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.70-2.05 (m, 9H), 1.89 (s, 3H), 2.10-2.30 (m, 2H), 2.55 (m , 1H), 2.77 (m, 1H), 2.90-3.05 (m, 2H), 3.15-3.35 (m, 2H), 3.51 (m, 1H), 3. 75-3.90 (m, 2H), 4.00-4.15 (m, 1H), 4.07 (s, 2H), 4.31 (m, 1H), 4.52 (m, 1H) , 4.78 (broad d, J = 10Hz, 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.10 (reduced doublet, J HF = 48Hz, 1H), 5.29 (d, J = 9 Hz, 1H), 5.75-5.90 (m, 3H), 5.92 (m, 1H), 6.19 (d, J = 16 Hz, 1H), 6.52 (dd , J = 17 and 5 Hz, 1H), 8.12 (s, 1H). 1-Chloroacetylpiperidine-4-carboxylic acid can be obtained as follows: To 2.3 g of ethyl 1-chloroacetylpiperidine-4-carboxylate in solution in 25 cm 3 of ethanol is added at 20 ° C, under argon, 10 cm 3 of 1N aqueous sodium hydroxide solution. After stirring for 16 hours, the methanol is removed under reduced pressure (2.7 kPa). Then, 30 cm 3 of distilled water and 1N hydrochloric acid are added to the residue until the pH is 4. The solution obtained is concentrated to dryness under reduced pressure (2.7 kPa). The residue that remains is recovered twice from toluene and brought to dryness under reduced pressure (2.7 kPa). Thus, 3 g of 1-chloroacetylpiperidine-4-carboxylic acid are obtained in the form of a white paste. 1 H NMR spectrum (250 MHz, (CD 3) 2 SO d 6, dp ppm): 1.25-1.65 (m, 2H), 1.70-1.95 (m, 2H), 2.40 ( m, 1H), 2.79 (m, 1H), 3.11 (m, 1H), 3.75 (broad d, J = 14Hz, 1H), 4.05-4.25 (m, 1H), 4.36 (AB limited, J = 13 Hz, 2H). Ethyl 1-chloroacetylpiperidine-4-carboxylate can be obtained as follows: Up to 15.7 g of ethyl piperidine-4-carboxylate in solution in 200 cm 3 of dichloromethane and 14 cm 3 of triethylamine are added dropwise over 10 minutes in at 0 ° C, under argon, 8 cm 3 of chloroacetyl chloride. After 18 hours of stirring at 20 ° C., the reaction mixture is washed successively with 100 cm 3 of distilled water, 100 cm 3 of a saturated aqueous sodium hydrogen carbonate solution and 100 cm 3 of a saturated aqueous sodium chloride solution. The organic phase is dried over magnesium sulfate, filtered and then concentrated under reduced pressure (2.7 kPa) to give 22 g of ethyl 1-chloroacetylpiperidine-4-carboxylate as a yellow oil. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 1.29 (t, J = 7 Hz, 3H), 1.60-1.85 (m, 2H), 2.54 (m, 1H), 2.89 (m, 1H), 3.19 (m, 1H), 3.81 (broad d, J = 14Hz, 1H), 4.05 (AB bounded, J = 12Hz, 2H), 4.13 ( q, J = 7 Hz, 2H), 4.31 (broad d, J = 14 Hz, 1H). Example 63 (16R) -16-Desoxy-16-fluoro-14-O- [1- (4-morpholinyl-4-butyryl) piperidine-4-carbonyl] pristinamycin II B described in example 60, starting from 1.80 g of (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in example 1), 1.20 g of acid 1- (4 -morpholinyl-4-butyryl) piperidine-4-carboxylic acid, 0.24 g of 4-dimethylaminopyridine, 30 ml of dimethylformamide and 0.82 g of N, N'-dicyclohexylcarbodiimide. After workup, the crude product was purified by flash chromatography [eluent: dichloromethane / methanol (97/3 vol. Ethanol)] followed by two chromatography on a CBT1 alumina column [eluent: respectively ethyl acetate / methanol (98 / 2 vol. Ethy) and acetonitrile / diisopropyl ether (50/50 vol. Ethy)] yielding 0.12 g of (16R) -16-deoxy-16-fluoro-14-O- [1- (4-morpholinyl- 4-butyryl) piperidine-4-carbonyl] pristinamycin IIB as a colorless solid. 1 H NMR spectrum (500 MHz, (CD 3) 2 SO d 6, d in ppm). The presence of rotamers in the ratio 60-40 was observed: 0.87 (m, 3H), 0.95 (d, J = 6.5Hz, 3H), 1.04 (m, 3H), 1.20-2.30 ( m, 13H), 1.70 and 1.78 (2s, total 3H), 2.27 (t, J = 7.5Hz, 2H), 2.33 (m, 6H), 2.62 (m, 1H), 2.70-2.80 (m, 2H), 3.10 (m, 1H), 3.24 (m, 1H), 3.50-4.00 (m, 6H), 3.57 (m, 4H), 4.22 (m, 1H), 4.70-4.90 (m, 2H), 5.09 and 5.40-5.55 (correspondingly reduced doublet, J HF = 48Hz m, total 1H), 5.40-5.70 (m, 2H), 5.70-5.85 (m, 2H), 6.19 and 6.24 (2d, J = 16Hz, total 1H), 6.63 (dd, J = 16 and 4.5Hz, 1H), 8.12 and 8.22 (mit, J = 6Hz, total 1H, respectively), 8.47 and 8.51 (2 s , total 1H). 1- (4-Morpholinyl-4-butyryl) piperidine-4-carboxylic acid can be obtained as follows: Up to 1.30 g 1- (4-morpholinyl-4-butyryl) piperidine Ethyl 4-carboxylate in solution in 20 cm 3 of ethanol is added to 6.0 cm 3 of a 1N aqueous sodium hydroxide solution. After 1.5 hours of stirring at 50 ° C., the reaction mixture is concentrated to almost dryness, diluted with 20 cm 3 of water and the pH is adjusted to 5 by adding 1N aqueous hydrochloric acid solution. After concentration to dryness under reduced pressure (2.7 kPa), 1.6 g of 1- (4-morpholinyl-4-butyril) -4-piperidinecarboxylic acid are obtained in the form of an off-white paste. 1 H NMR spectrum (400 MHz, (CD 3) 2 SO d 6, dp ppm): 1.33 (m, 1H), 1.46 (m, 1H), 1.64 (m, 2H), 1.80 (m, 2H), 2.20-2.40 (m, 8H), 2.43 (m, 1H), 2.69 (m, 1H), 3.05 (m, 1H), 3.55 ( t, J = 4.5 Hz, 4H), 3.79 (broad d, J = 13.5 Hz, 1H), 4.20 (broad d, J = 13.5 Hz, 1H). Ethyl 1- (4-morpholinyl-4-butyryl) piperidine-4-carboxylate can be obtained as follows: Up to 1.0 g of 4-morpholinobutyric acid, 0.78 g of ethyl isonipecotane, 2.1 cm 3 of triethylamine and 20 mg of hydroxybenzotriazole hydrate in solution in 80 ml of dichloromethane are added at 20 ° C. 0.95 g of N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride in solution in 20 ml of dichloromethane. After stirring for 20 hours at 20 ° C, the reaction mixture is washed with 20 cm 3 of water. The organic phase is dried over magnesium sulphate, filtered and concentrated under reduced pressure (2.7 kPa) to obtain a light yellow oil which is purified by chromatography on a CBT1 alumina column [eluent: dichloromethane / methanol (97/3 vol ethical)]. Thus, 1.30 g of ethyl 1- (4-morpholinyl-4-butyryl) -4-piperidinecarboxylate are obtained in the form of a light yellow oil. 1 H NMR spectrum (300 MHz, (CD 3) 2 SO d 6, dp ppm): 1.20 (t, J = 7 Hz, 3H), 1.25-1.60 (m, 2H), 1.65 (m , 2H), 1.84 (m, 2H), 2.20-2.40 (m, 8H), 2.59 (m, 1H), 2.70 (m, 1H), 3.08 (m, 1H), 3.57 (t, J = 5Hz, 4H), 3.82 (broad d, J = 14Hz, 1H), 4.08 (q, J = 7Hz, 2H), 4.24 (broad d, J = 14 Hz, 1H). 4-morpholinobutyric acid can be obtained according to P. AND. Cruickshanka et al. , J. Amer. Chem. Soc. , 83, 2891 (1961). Example 64 (16R) -16-Deoxy-16-fluoro-14-O- [cis-A- (4-morpholinobutyrylamino) -1-cyclohexanecarbonyl] pristinamycin II B The fasting is performed analogously to the procedure described in example at any 60, but starting from 3.2 g of (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in example 1), 2.0 g of cis-4- (4-morpholinobutyrylamino) acid - 1-cyclohexanecarboxylic acid, 0.40 g of 4-dimethylaminopyridine, 75 ml of dimethylformamide and 1.50 g of N, N'-dicyclohexylcarbodiimide. After workup, the crude product is purified by chromatography on a CBT1 alumina column [eluent: dichloromethane / methanol gradient (100/0, then 98/2 v / v)] and then by chromatography. equilibrium [eluent: gradient chloromethane / methanol 100/0, 98/2, 95/5, 90/10 by volume)] and again by chromatography on a CBT1 alumina column [eluent: ethyl acetate / methanol (99/1 vol eto sabolic)]. Thus, 0.40 g of (16R) -16-deoxy-16-fluoro-14-O- [cis-4- (4-morpholine-butyrylamino) -1-cyclohexanecarbonyl] pristinamycin II B is obtained as a colorless substance fixed hopper. 1H NMR spectrum (500 MHz, (CD3) 2 SO d6, dp ppm): 0.86 (d, J = 6.5Hz, 3H), 0.94 (d, J = 6.5Hz, 3H), 1.04 (d, J = 6.5, 3H), 1.35-1.70 (m, 8H), 1.75-2.25 (s, 3H), 1.78 (s, 3H), 2.08 (t, J = 7.5 Hz, 2H), 2.22 (t, J = 7.5 Hz, 2H), 2.31 (unres. Comp, 4H), 2.48 (m, 1H), 2, 77 (m, 1H), 3.15-3.30 (m, 2H), 3.56 (t, J = 5Hz, 4H), 3.62 (broad d, J = 15Hz, 1H), 3.65 -3.75 (m, 2H), 3.82 (m, 1H), 3.95 (m, 1H), 4.70-4.80 (m, 2H), 5.09 (reduced doublet, J HF = 48Hz, 1H), 5.42 (d, J = 9.5Hz, 1H), 5.62 (m, 1H), 5.75 (m, 1H), 5.80 (broad d, J = 16Hz, 1H), 6.19 (d, J = 16Hz, 1H), 6.62 (dd, J = 16 and 5Hz, 1H), 7.65 (d, J = 7.5Hz, 1H), 8.12 ( t, J = 6 Hz, 1H), 8.51 (s, 1H). Cis-4- (4-morpholinobutyrylamino) -1-cyclohexanecarboxylic acid can be prepared as follows: 6.0 cm 3 of 1N aqueous sodium hydroxide solution. After 1.5 hours of stirring at 50 ° C., the reaction mixture is concentrated to almost dryness and finally diluted in 20 cm 3 of water and the pH is adjusted to 5 by adding 1N aqueous hydrochloric acid solution. After concentration to dryness under reduced pressure (2.7 kPa), cis-4- (4-morpholinobutyrylamino) -1-cyclohexanecarboxylic acid is obtained in the form of a white paste, which is then used as such in the next step. and. 1 H NMR spectrum (400 MHz, CDCl 3, d in ppm). 1.50-1.75 (m, 6H), 1.85-2.00 (m, 4H), 2.25 (t, J = 7.5Hz, 2H), 2.44 (m, 1H), 2.61 (t, J = 7.5 Hz, 2H), 2.72 (unres. Comp., 4H), 3.96 (m, 1H), 6.72 (d, J = 8 Hz, 1H). The methyl cis-4- (4-morpholinobutyrylamino) -1-cyclohexanecarboxylate can be obtained as follows: The procedure is analogous to that described in example 63, but starts from 4.20 g Methyl cis-4-aminocyclohexane-1-carboxylate hydrochloride, 4.0 g of 4-morpholinobutyric acid, 50 mg of hydroxybenzotriazole hydrate, 11.2 cm 3 of triethylamine, 200 cm 3 of dichloromethane and 4.2 g of N- hydrochloride (3-dimethylamino-propyl) -N'-ethylcarbodiimide. After working up analogous to that in Example 60, the crude product was purified by equilibrium chromatography [eluent: dichloromethane / methanol (95/5 vol.%)] To give 5.0 g of cis-4- ( Methyl 4-morpholinobutyrylamino) -1-cyclohexanecarboxylate as a yellow oil. 1 H NMR spectrum (400 MHz, (CD 3) 2 SO d 6, dp ppm): 1.40-2.00 (m, 10H), 2.10 (t, J = 7.5 Hz, 2H), 2, 25 (t, J = 7.5Hz, 2H), 2.34 (unres. Comp, 4H), 2.45-2.60 (m, 1H), 3.59 (t, J = 5Hz, 4H), 3, 65 (s, 3H), 3.72 (m, 1H), 7.68 (d, J = 7 Hz, 1H). Methyl cis-4-aminocyclohexane-1-carboxylate hydrochloride can be prepared as follows: To 50 cm 3 of methanol cooled to -10 ° C, 5 cm 3 of sulfonyl chloride are added dropwise. After stirring for 10 minutes at 20 ° C, 5.0 g of cis-4-aminocyclohexane-1-carboxylic acid are slowly added in portions. After 2 hours of stirring at 20 ° C, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C to obtain 7.5 g of cis-4-aminocyclohexane-1-hydrochloride. methyl carboxylate in the form of a white powder. 1 H NMR spectrum (500 MHz, (CD 3) 2 SO d 6 at 373 K, d in ppm). A mixture of diastereoisomers in the ratio of 80-20: 1.46 and 1.60-1.70 (2m, total 4H), 1.85 and 1.95-2.15 (2m, total 4H), 2, 30-2.60 (2m, total 1H), 3.00 and 3.13 (2m, total 1H), 3.64 and 3.67 (2s, total 3H), 8.12 (unresolved, 3H ). Example 65 (16R) -16-Deoxy-16-fluoro-14-O- [N- (4-methylpiperazinyl-1-carbonyl) glycinyl] pristinamycin II B Up to 3 g (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in Example 1) in solution in 100 cm 3 of dichloromethane, 1.21 g of N, N'-dicyclohexylcarbodiimide, 1.07 g of N- (4- methylpiperazinyl-1-carbonyl) glycine and 0.13 4-dimethylaminopyridine. After stirring for 24 hours at 20 ° C., 0.6 g of N, N'-dicyclohexylcarbodiimide and 0.065 g of 4-dimethylaminopyridine are added. After 25 hours of additional stirring at 20 ° C., the reaction mixture is filtered and the insoluble matter is washed with 70 cm 3 of dichloromethane. After two washing and filtration cycles, the filtrate is concentrated to dryness under reduced pressure (2.7 kPa). The remaining residue is dissolved in 50 ml of ethanol and the pH is adjusted to 2 by adding methanesulphonic acid. After concentration under reduced pressure (2.7 kPa), the residue is taken up with 50 cm 3 of water and extracted twice with 50 cm 3 of ethyl acetate. The aqueous phase is decanted, adjusted to pH 8/9 by the addition of 1N aqueous sodium hydroxide solution and then extracted 3 times with 60 cm 3 of dichloromethane. The organic phases are combined, washed with 50 cm 3 of water, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) to give 2 g of red oil which is purified by a flash chromatography [eluent: dichloromethane / methanol / acetonitrile gradient (90/5/5 to 80/10/10 v / v)]. In this way, 0.222 g of a yellow solid is obtained, which is stirred for 2 hours in 20 cm 3 of diethyl ether, obtained after filtration, washing twice with 10 cm 3 of diethyl ether and drying under water. reduced pressure (2.7 kPa) 0.181 g (16R) -16-deoxy-16-fluoro-14-O- [N- (4-methylpiperazinyl-1-carbonyl) glycinyl] pristinamycin II B as a colorless substance solid with a melting point of approximately 140 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.60-2.05 (m, 5H), 1.89 (s, 3H), 2.15 (m, 1H), 2.20-2.35 (m , 1H), 2.31 (s, 3H), 2.40 (m, 4H), 2.76 (m, 1H), 2.99 (dt, J = 17 and 6Hz, 1H), 3.23 ( m, 1H), 3.43 (m, 4H), 3.49 (m, 1H), 3.85 (m, 1H), 3.94 (dd, J = 18 and 5Hz, 1H), 4.00 -4.10 (m, 2H), 4.54 (m, 1H), 4.78 (broad d, J = 10Hz, 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 4. 91 (m, 1H), 5.13 (reduced doublet, J HF = 48Hz, 1H), 5.32 (d, J = 9Hz, 1H), 5.77 (m, 1H), 5.82 (broad d , J = 17Hz, 1H), 5.86 (m, 1H), 5.95 (m, 1H), 6.19 (d, J = 16Hz, 1H), 6.51 (dd, J = 17 and 4Hz , 1H). 8.12 (s, 1H). N- (4-Methylpiperazinyl-1-carbonyl) glycine can be prepared as follows: Up to 0.15 g of 5% palladium on charcoal, suspended in 100 cm 3 of methanol, is added at a temperature of 20 ° C under argon, 2.36 g of benzyl N- (4-methylpiperazinyl-1-carbonyl) glycinate. After stirring for 2.5 hours at 22 ° C. and under a pressure of 1.6 bar of hydrogen, 50 cm 3 of water are added and filtered over Clarcel. The dough obtained is washed 3 times at 60 ° C with 70 cm 3 of water. Finally, the filtrate is concentrated to dryness under reduced pressure (2.7 kPa) at 50 ° C. The residue that remains is dried under reduced pressure (2.7 kPa) at 50 ° C to obtain 1.5 g of N- (4-methyl-piperazinyl-1-carbonyl) glycine. 1 H NMR spectrum (400 MHz, (CD 3) 2 SO d6 with the addition of a few drops CD 3 COOD d4, dp ppm): 2.65 (s, 3H), 2.98 (m, 4H), 3.51 ( m, 4H). 3.68 (s, 2H). Benzyl N- (4-methylpiperazinyl-1-carbonyl) glycinate can be obtained as follows: To 3 g of 4-methylpiperazinyl-1-carbonyl chloride hydrochloride in solution in 150 cm 3 of tetrahydrofuran is added at a temperature of 20 ° C 4.2 cm 2 of triethylamine and 3.02 g of benzyl glycinate hydrochloride. After stirring for 16 hours at 60 ° C, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) and the residue is dissolved in 70 cm 3 of dichloromethane. The organic phase is washed successively 2 times with 100 cm 3 of an aqueous saturated solution of sodium hydrogen carbonate and 70 cm 3 of water, then dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa ) to give 1.9 g of benzyl N- (4-methylpiperazinyl-1-carbonyl) glycinate as a colorless solid. 1 H NMR spectrum (400 MHz, (CD 3) 2 SO d 6, dp ppm): 2.18 (s, 3H), 2.25 (t, J = 5 Hz, 4H), 3.30 (t, J = 5Hz, 4H), 3.80 (d, J = 6Hz, 2H), 5.13 (s, 2H), 7.02 (t, J = 6Hz, 1H), 7.30-7.45 (m, 5H). Example 66 (16R) -16-Desoxy-16-fluoro-14-O- {4 - [(3-carboxy) propyldisulfanyl] butyryl} pristinamycin II B Up to 1.75 g (16R) -16-deoxy-16- Fluoropristinamycin II B (prepared as described in Example 1) in a solution in 50 cm 3 of dichloromethane is added at a temperature of 20 ° C, under argon, 1.25 g of 4,4'-dihydro-propane carboxylic acid, 1.03 g N, N'-dicyclohexylcarbodiimide and 0.06 g of 4-dimethylaminopyridine. After 18 hours of stirring, 70 cm 3 of dichloromethane are added to the reaction mixture, and then it is filtered to remove insoluble matter. The filtrate is then concentrated to dryness under reduced pressure (2.7 kPa), obtaining 3.3 g of a residue, which is purified by two consecutive equilibrium chromatographies [eluent: dichloromethane / methanol (96/4 and 97.5 / 2.5 ethical vol)]. A residue is obtained, which is mixed with 25 cm 3 of distilled water and then dissolved by the addition of a saturated aqueous sodium carbonate solution. The aqueous phase (pH 7-8) is washed four times with 50 ml of ethyl acetate and then acidified to pH 2-3 with 1N aqueous hydrochloric acid solution. A paste-like precipitate appears which is dissolved by the addition of 250 cm 3 of dichloromethane. The organic phase is separated, dried over magnesium sulfate, filtered and then concentrated under reduced pressure (2.7 kPa) to give 0.7 g of (16R) -16-deoxy-16-fluoro. 14- -O- {4 - [(3-carboxyl) propyldisulfanyl] butyryl} pristinamycin II B as a colorless solid. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 0.99 (d, J = 6.5 Hz, 3H), 1.11 (d , J = 6.5Hz, 3H), 1.50-2.30 (m, 11H), 1.90 (s, 3H), 2.35-2.55 (m, 4H), 2.65-2 , 85 (m, 5H), 3.04 (m, 1H), 3.26 (d, J = 17 and 5Hz, 1H), 3.56 (m, 1H), 3.85 (m, 1H), 4.07 (m, 1H), 4.53 (m, 1H), 4.75-4.85 (m, 2H), 5.08 (reduced doublet, J HF = 48Hz, 1H), 5.29 ( d, J = 9 Hz, 1H), 5.75-5.90 (m, 1H), 5.79 (m, 1H), 5.88 (dd, J = 16 and 1.5 Hz, 1H), 6, 10-6.25 (m, 1H), 6.17 (d, J = 15.5 Hz, 1H), 6.58 (dd, J = 16 and 5 Hz, 1H), 8.13 (s, 1H). Example 67 (16R) -16-Desoxy-16-fluoro-14-O- {4- [3- (4-methylpiperazinyl-1-carbonyl) propyldisulfanyl] butyryl} pristinamycin II B Up to 1 g (16R) - 16-deoxy-16-fluoro-14-O- {4- [3-carboxyl) propyldisulfanyl] butyryl} pristinamy tin II B (prepared as described in example 70) in solution in 93 cm 3 of dichloromethane is added at 20 ° C under argon, 0.97 g of N, N'-dicyclohexylcarbodiimide, 0.5 ml of 1-methylpiperazine and 0.08 g of 4-dimethylaminopyridine. After 96 hours of stirring, the reaction mixture is filtered to remove insoluble matter, and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa) to give 2 g of a residue, which is then purified. by flash chromatography [eluent: dichloromethane / methanol (96/4 v / v)]. There is obtained 0.5 g of (16R) -16-deoxy-16-fluoro-14-O- {4- [3- (4-methylpiperazinyl-1-carbonyl) propyldisulfanyl] butyryl} pristinamycin II B in the form of a colorless solid. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.65-2.10 (m, 9H), 1.88 (s, 3H), 2.15 (m, 1H), 2.24 (m, 1H), 2.32 (s, 3H), 2.35-2.50 (m, 8H), 2.70-2.80 (m, 1H), 2.71 (t, J = 7.5 Hz, 2H), 2.75 (t, J = 7 Hz, 2H), 3.00 (m, 1H), 3.24 (m, 1H), PL 203 554 B1 61 3.40-3.55 (m, 3H), 3 , 64 (t, J = 5Hz, 2H), 3.86 (m, 1H), 4.06 (m, 1H), 4.55 (m, 1H), 4.78 (dd, J = 10 and 2Hz , 1H), 4.82 (dd, J = 9 and 3Hz, 1H), 5.11 (reduced doublet, J HF = 48Hz, 1H), 5.30 (d, J = 9.5Hz, 1H), 5 , 75- 5.85 (m, 1H), 5.76 (m, 1H), 5.81 (dd, J = 16 and 2Hz, 1H), 6.01 (m, 1H), 6.19 (d , J = 16 Hz, 1H), 6.52 (dd, J = 16 and 5 Hz, 1H), 8.12 (s, 1H). Example 68 (16R) -14-O- (3-Carboxylpropionyl) -16-deoxy-16-fluoropristinamycin II A A three-necked flask is placed 560 mg (16R) -16-deoxy-16-fluoropristinamycin II A (obtained from as described in Example 8) in solution in 3 ml of pyridine, and then at 20 ° C succinic anhydride and 120 mg of 4-dimethylaminopyridine are added. After stirring for 18 hours, the reaction mixture is poured onto 50 cm 3 of distilled water and 10 cm 3 of dichloromethane. Finally, sufficient amount of 0.1N hydrochloric acid is added to adjust the pH to 4. The reaction mixture is filtered through cotton to remove insoluble matter and then decanted. The aqueous phase is washed twice with 10 cm 3 of dichloromethane, the organic phases are combined and methanol is added to them to complete dissolution, dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa ) yielding 670 mg of a solid, which was purified by flash chromatography [eluent: dichloromethane-methanol (97-3 vol. vol. partial)]. In this way, 530 mg of product are obtained, which is purified again by flash chromatography [eluent: dichloromethane-methanol (95-5 vol.% By volume)]. 15 minutes in 5 cm 3 of diethyl ether, filtered and then dried at 50 ° C (90 Pa). 147 mg of (16R) -14-O- (3-carboxylpropionyl) -16-deoxy-16-fluoropristinamycin II A are obtained as a colorless solid with a melting point of approximately 156 ° C (with decomposition ). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.99 (m, 6H), 1.13 (d, J = 6.5 Hz, 3H), 1.83 (s, 3H), 1, 90-2.10 (m, 2H), 2.27 (m, 1H), 2.50-2.90 (m, 7H), 3.08 (m, 1H), 3.28 (m, 1H) , 4.00 (broad d, J = 18 Hz, 1H), 4.12 (m, 1H), 4.20 (m, 1H), 4.30 (m, 1H), 4.72 (reduced doublet, J HF = 48Hz, 1H), 4.85-5.00 (m, 2H), 5.67 (m, 1H), 5.71 (m, 1H), 5.96 (d, J = 16Hz, 1H) , 5.98 (d, J = 17 Hz, 1H), 6.18 (wide t, J = 2 Hz, 1H), 6.61 (dd, J = 17 and 7 Hz, 1H), 7.02 (m , 1H). 7.96 (s, 1H). Example 69 (16R) -16-deoxy-16-fluoro-14-O- [3- (4-methylpiperazinyl-1-carbonyl) ashnyl] pristinamycin hydrochloride II A Up to 355 mg (16R) -16-deoxy- 16-fluoro-14-O- [3- (4-methylpiperazinyl-1-carbonyl) propionyl] pristinamycin IIA dissolved in 3.5 ml of absolute ethanol is slowly added 0.167 ml of 3M ethereal hydrogen chloride solution and 7 cm 3 of diethyl ether until the product precipitates. After 15 minutes of stirring, the product is filtered, rinsed with a minimum amount of ethanol-ether mixture (1/2), and then dried at 20 ° C (90 Pa) to obtain 305 mg of hydrochloride (16R) - 16-deoxy-16-fluoro-14-O- [3- (4-methylpiperazinyl-1-carbonyl) propionyl] pristinamycin IIA as a colorless solid, m.p. 192 ° C. 1H NMR spectrum (400 MHz, (CD3) 2 SO d6, dp ppm): 0.87 (d, J = 6.5Hz, 3H), 0.96 (d, J = 6.5Hz, 3H), 1.10 (d, J = 6.5Hz, 3H), 1.78 (s, 3H), 1.93 (m, 1H), 2.02 (m, 1H), 2.18 (m, 1H) , 2.50-2.80 (m, 7H), 2.78 (s, 3H), 2.80-3.55 (m, 8H), 3.66 (broad d, J = 16Hz, 1H), 3.90-4.25 (m, 3H), 4.14 (m, 1H), 4.25-4.55 (unres., 1H), 4.77 (dd, J = 9 and 1.5Hz, 1H ), 5.05 (reduced doublet, J HF = 48Hz, 1H), 5.38 (d, J = 9.5Hz, 1H), 5.71 (m, 2H), 5.88 (d, J = 16Hz , 1H), 6.12 (d, J = 16 Hz, 1H), 6.62 (dd, J = 16 and 5.5 Hz, 1H), 8.03 (m, 1H), 8.61 (s, 1H ), 10.58 (unres. Comp., 1H). (16R) -16-Desoxy-16-fluoro-14-O- [3- (4-methylpiperazinyl-1-carbonyl) propionyl] pristinamycin II A can be obtained as follows: In a flask placed under nitrogen 848 mg of (16R) -16-deoxy-16-fluoropristimycin II A (prepared as described in Example 8), 24 cm 3 of dichloromethane and 352 mg of 4- (4-methylpiperazinyl-1) -4 acid are introduced -oxomasol. The mixture obtained is heated until dissolved, and then 360 mg of N, N'-dicyclohexylcarbodiimide and 20 mg of 4-dimethylaminopyridine are added at ambient temperature. After 18 hours of stirring at 20 ° C, additional 36 mg of N, N'-dicyclohexylcarbodiimide and 20 mg of 4-dimethylaminopyridine are added. The reaction mixture is then stirred for one week at 20 ° C., then filtered, washed with ethyl acetate and concentrated under reduced pressure (2.7 kPa). The obtained fine oil is dissolved in 15 cm 3 of ethyl acetate and 30 cm 3 of dichloromethane. The organic phase is washed 3 times with 30 cm 3 of distilled water, decanted, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa) at 20 ° C. 1.05 g of a yellow oil which is purified by flash chromatography [eluent: dichloromethane-methanol (95-5 vol / vol)]. Thus, 840 mg of the product is obtained, which is stirred for 18 hours in 16 cm 3 of diethyl ether, filtered and then dried at 20 ° C (90 Pa), yielding 640 mg (16R) -16- deoxy-16-fluoro-14-O- [3- (4-methylpiperazinyl-1-carbonyl) propionyl] pristinamycin IIA as a colorless solid, m.p. 130 ° C. 4- (4-Methylpiperazinyl-1) -4-oxobutyric acid can be obtained as follows: 1.17 g of succinic anhydride is added to 20 cm 3 of dioxane, and then 1.19 cm 3 of N-me - tylopiperazine. After 18 hours of stirring at ambient temperature, the precipitate obtained is filtered off, rinsed with a minimum amount of dioxane and then successively twice with 10 cm 3 of acetone and 10 cm 3 of diethyl ether. After drying under reduced pressure (2.7 kPa) at 20 ° C, 1.09 g of 4- (4-methylpiperazinyl-1) -4-oxobutyric acid is obtained as a colorless solid, mp 114 ° C. C. Example 70 (16R) -14-O- (4-Carboxylbutyryl) -16-deoxy-16-fluoropristinamycin II A Up to 1.05 g (16R) -16-deoxy-16-fluoropristinamycin II A (prepared as described in Example 8) in a solution in 5.5 cm 3 of pyridine are added at a temperature of 20 ° C under argon, 0.68 mg of glutaric anhydride and 0.24 g of 4-dimethylaminopyridine. After stirring for 24 hours, the reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) to give a residue which is mixed with 110 cm 3 of ethyl acetate and 55 cm 3 of distilled water. The organic phase is decanted, washed successively twice with 55 cm3 of distilled water, 55 cm3 of 0.1N aqueous hydrochloric acid solution, twice with 55 cm3 of distilled water, and twice with a an aqueous saturated sodium chloride solution. After drying over magnesium sulphate, the organic phase is concentrated to dryness under reduced pressure (2.7 kPa). 0.95 g of a residue is obtained, which is dissolved in 100 cm 3 of dichloromethane and extracted with 100 cm 3 of 1% aqueous sodium hydrogen carbonate solution. 500 cm 3 of ethyl acetate are added to the emulsion obtained to allow decantation. Then the aqueous phase is separated off, washed again three times with 100 ml of ethyl acetate, acidified with 1N aqueous hydrochloric acid until the pH is approximately 2, then extracted three times with with the aid of dichloromethane (100, 100 and 100 cm 3). The organic phases are combined, dried over magnesium sulfate, filtered and then concentrated under reduced pressure (2.7 kPa). Thus, 0.33 g of (16R) -14-O- (4-carboxylbutyryl) -16-deoxy-16-fluoropristinamycin IIA is obtained as a beige solid, m.p. 116 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.98 (m, SR), 1.12 (d, J = 6.5 Hz, 3H), 1.80-2.10 (m, 4H ), 1.82 (s, 3H), 2.15-2.45 (m, 5H), 2.65-2.90 (m, 3H), 3.08 (m, 1H), 3.26 ( dt, J = 16 and 3.5Hz, 1H), 3.99 (broad d, J = 18Hz, 1H), 4.05-4.35 (m, 3H), 4.71 (reduced doublet, J HF = 48Hz, 1H), 4.85-5.00 (m, 2H), 5.60-5.75 (m, 2H), 5.96 (d, J = 16Hz, 1H), 5.98 (broad d , J = 16Hz, 1H), 6.18 (t, J = 3Hz, 1H), 6.61 (dd, J = 16 and 7Hz, 1H), 7.09 (t, J = 5.5Hz, 1H) , 7.95 (s, 1H). Example 71 (16R) -16-Desoxy-16-fluoro-14-O- [4- (4-methylpiperazinyl-1-carbonyl) butyrylristinamycin II A Up to 1 g (16R) -16-deoxy-16-fluoropristinamycin II A (prepared as described in Example 8) in a solution in 30 cm 3 of dichloromethane, 0.48 g of 4- (4-methylpiperazinyl-1-carbonyl) acid is added at a temperature of 20 ° C under an argon atmosphere. lolic acid, 0.48 g of N, N'-dicyclohexylcarbodiimide, and 0.14 g of 4-dimethylaminopyridine. After stirring for 20 hours at 20 ° C, the reaction mixture is poured onto 50 cm 3 of distilled water and 10 cm 3 of dichloromethane. The resulting mixture is filtered to remove insoluble components. The organic phase is decanted and the aqueous phase is extracted twice with 10 cm 3 of dichloromethane. The organic phases are combined, dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure (2.7 kPa), giving 1.6 g of a residue, which is purified by two steps. successive flash chromatographies [eluent: dichloromethane / methanol (95/5 v / v)]. After stirring in diethyl ether, filtering and drying (2.7 kPa), 0.6 g of (16R) -16-deoxy-16-fluoro-14-O- [4- (4-methylpiperazinyl-1-carbonyl) is obtained. ) butyryl] pristinamycin as a solid paste with a melting point of 120 ° C. 1 H NMR spectrum (500 MHz, CDCl 3, dp ppm): 0.99 (m, 6H), 1.13 (d, J = 6.5 Hz, 3H), 1.84 (s, 3H), 1. 90-2.10 (m, 2H), 1.92 (m, 2H), 2.15-2.45 (m, 9H), 2.30 (s, 3H), 2.65-2.90 ( m, 3H), 3.07 (m, 1H), 3.27 (dt, J = 15 and 3.5Hz, 1H), 3.46 (m, 2H), 3.63 (m, 2H), 3 .99 (broad d, J = 17.5Hz, 1H), 4.10-4.25 (m, 2H), 4.30 (m, 1H), 4.71 (reduced doublet, J HF = 48Hz, 1H ), 4.90 (d, J = 9.5Hz, 1H), 4.95 (dd, J = 10 and 2Hz, PL 203 554 B1 63 1H), 5.65 (dt, J = 9.5 and 4Hz , 1H), 5.72 (m, 1H), 5.96 (d, J = 16Hz, 1H), 5.98 (broad d, J = 16.5Hz, 1H), 6.17 (t, J = 3 Hz, 1H), 6.60 (dd, J = 16.5 and 7 Hz, 1H), 7.02 (t, J = 5.5 Hz, 1H), 7.94 (s, 1H). 4- (4-methylpiperazinyl-1-carbonyl) butyric acid can be obtained according to the German patent description DE 782851953. Example 72 (16R) -16-Deoxy-16-fluoro-14-O - {(1R, 2R) - [2- (4-methylpiperazinyl-1-carbonyl] cyclohexanone carbonyl} pristinamycin II B analogous to the method described in example 60, but starting with 0.83 g of (16R) -16-deoxy-16-fluoropristinamycin II B (prepared as described in example 1), 0.40 g of the acid (1R, 2R ) -2 - [(4-methylpiperazinyl-1) carbonyl] -1-cyclohexanecarboxylic acid, 0.10 g of 4-dimethylaminopyridine, 30 ml of dichloromethane and 0.40 g of N, N'-dicyclohexylcarbodiimide. After working up analogously to that of Example 60, the crude product is purified by flash chromatography [eluent: dichloromethane / acetonitrile / methanol (90/5/5 v / v)] and then by chromatography on an oxide column. aluminum CBT1 [eluent: ethyl acetate / methanol (98/2 v / v)] to give 0.40 g of (16R) -16-deoxy-16-fluoro-14-O - {(1R, 2R) - [ 2- (4-methylpiperazinyl-1-carbonyl] cyclohexanecarbonyl} pristinamycin IIB as a colorless solid. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.95 (d, J = 6.5 Hz, 3H), 0.99 (d, J = 6.5 Hz, 3H), 1.09 (d , J = 6.5Hz, 3H), 1.20-1.45 (m, 4H), 1.55-2.45 (m, 17H), 1.83 (s, 3H), 2.50 (m , 1H), 2.70-2.85 (m, 3H), 3.00 (m, 1H), 3.22 (m, 1H), 3.44 (m, 1H), 3.45-3. 65 (m, 4H), 3.88 (m, 1H), 4.04 (m, 1H), 4.53 (m, 1H), 4.70-4.85 (m, 2H), 5.10 (reduced doublet, J HF = 48Hz, 1H), 5.29 (d, J = 10Hz, 1H), 5.65-5.80 (m, 2H), 5.81 (broad d, J = 16Hz, 1H ), 6.02 (m, 1H), 6.18 (d, J = 16 Hz, 1H), 6.50 (dd, J = 16 and 4 Hz, 1H), 8.12 (s, 1H). (1R, 2R) -2 - [(4-methylpiperazinyl-1) carbonyl] -1-cyclohexanecarboxylic acid can be obtained as follows: Up to 0.50 g of (-) - trans-1,2- anhydride The cyclohexanedicarboxylic acid in solution in 20 cm 3 of dioxane is added at -15 ° C under argon to 0.37 cm 3 of N-methylpiperazine in solution in 5 cm 3 of dioxane. After 1.25 hours of stirring at 20 ° C, the reaction mixture is filtered, the solid is washed with 20 cm 3 of diethyl ether, dehydrated and then dried under reduced pressure (2.7 kPa) under reduced pressure (2.7 kPa). at 20 ° C to give 0.65 g of (1R, 2R) -2 - [(4-methylpiperazinyl-1) carbonyl] -1-cyclohexanecarboxylic acid as a colorless solid. 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 1.20-1.60 (m, 4H), 1.65-1.90 (m, 3H), 2.05-2.35 (m , 3H), 2.37 (s, 3H), 2.70-2.95 (m, 5H), 3.43 (m, 1H), 3.84 (broad d, J = 13.5Hz, 1H) , 4.30 (d, J = 12.5 Hz, 1H). Example 73 (16R) -16-Azido-16-deoxypristinamycin II B Following the same procedure as in example 4, but starting from tetra-n-butylammonium nitride, we get (16R) -16-azido -16-deoxypristinamycin II B as a colorless solid with a melting point of approximately 135 ° C (with decomposition). 1 H NMR spectrum (400 MHz, CDCl 3, dp ppm): 0.96 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.10 (d , J = 6.5Hz, 3H), 1.50-1.65 (m, 1H), 1.75-2.05 (m, 5H), 1.88 (s, 3H), 2.15 (m , 1H), 2.77 (m, 1H), 2.90 (dd, J = 17 and 6 Hz, 1H), 3.15 (dd, J = 17 and 7 Hz, 1H), 3.49 (m, 1H ), 3.88 (m, 1H), 3.95-4.15 (m, 2H), 4.54 (m, 1H), 4.70-4.80 (m, 2H), 4.83 ( dd, J = 9 and 3Hz, 1H), 5.37 (d, J = 9.5Hz, 1H), 5.75 (m, 1H), 5.82 (dd, J = 17 and 1.5Hz, 1H ), 5.97 (m, 1H), 6.22 (d, J = 16 Hz, 1H), 6.52 (dd, J = 17 and 5 Hz, 1H), 8.15 (s, 1H). The pharmaceutical compositions according to the present invention contain at least one streptogramin derivative according to the invention, in a pure state, associated with at least one group B streptogramin derivative, if appropriate in the form of a salt, and optionally in the form of a derivative of the present invention. association forms with one or more compatible and pharmaceutically acceptable solvents or adjuvants. The compositions according to the invention may be administered orally, parenterally, topically, rectally or in aerosols. As solid compositions for oral administration, tablets, pills, capsules, powders or granules can be used. In such compositions, the active product according to the invention, generally in the form of association, is mixed with one or more neutral diluents or adjuvants, such as sucrose, lactose or amidone. These compositions may contain substances other than diluents, for example, a lubricant such as magnesium stearate, or a controlled release coating. As liquid compositions for oral administration, pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs containing neutral diluents, such as water or paraffin oil, can be used. These compositions may also include substances other than diluents, for example, wetting agents, sweeteners and fragrances. Compositions for parenteral administration can be sterile solutions or emulsions. As a solvent or carrier, propylene glycol, polyethylene glycol, vegetable oils, especially olive oil, organic esters for injection, for example ethyl oleate, can be used. These compositions may also contain adjuvants, especially moisturizing, isotonic, emulsifying, dispersing and stabilizing agents. Sterilization can be carried out in many ways, for example by a bacteriological filter, by irradiation or by heating. They may also be formulated as sterile solid compositions which can be dissolved upon use in sterile water or any other sterile injectable medium. Compositions for topical administration can be, for example, creams, ointments, lotions or sprays. Compositions for rectal administration are rectal suppositories or capsules which contain, in addition to the main ingredient, excipients such as cocoa butter, semi-synthetic glycerides or polyethylene glycols. Compositions may also be with aerosols. When used in the form of a liquid aerosol, the compositions can be stable sterile solutions or solid compositions that are dissolved on the time of use in pyrogen-free sterile water, in serum or in any other pharmaceutically acceptable excipient. When used in the form of dry aerosols intended for direct inhalation, the main ingredient is finely divided and bound to a diluent or a solid water-soluble excipient with a granulation of 30 to 80 µ, such as, for example, dextran, mannitol or lactose. For human therapy, the novel streptogramin derivatives according to the invention are particularly useful in the treatment of infections of bacterial origin. The doses depend on the anticipated effect and duration of treatment. The physician will determine the dosage of the drugs he judges as most appropriate depending on the treatment, age, weight, degree of infection, and other factors relevant to the art of treatment. Dosages will generally range from 0.5 to 3 g of active product when administered 2 or 3 times a day, either orally or parenterally for adults. The composition according to the invention is illustrated by the following example. Example In accordance with the usual technique, tablets are prepared containing 250 mg of active product, with the following composition: - (16R) -16-deoxy-16-fluoropristinamycin II B 175 mg - pristinamycin IB 75 mg excipient: amidone , hydrated silica, dextrin, gelatin, magnesium stearate: 500 mg

Claims (14)

1. Claims 1. A streptogramin derivative from group A of the general formula: in which: - R 1 represents a thiocyanate halogen atom, - R 2 represents a hydrogen atom or a methyl or ethyl radical, - R 3 represents a hydrogen atom or a radical R 3 ' -CO, in which R 3 'is phenyl or phenylalkyl unsubstituted or substituted on the phenyl radical (by one or more radicals selected from alkyl, which optionally contains the radical NR'R ", in which the radicals R' and R" identical or different may be hydrogen atoms or alkyl radicals which may form, together with the nitrogen atom to which they are attached, a saturated or unsaturated 3 to 8 membered heterocyclyl radical, optionally containing another heteroatom selected from oxygen, sulfur or nitrogen, said heterocycle being itself substituted by one or more radicals (saturated or unsaturated alkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonylalkyl, aryl, heterocyclyl, heterocyclylalkyl) of 3 to 8 members or -CH 2 -CO-NR'R ") or R 'and / or R" may be a hydroxyalkyl, phenyl, heterocyclylalkyl, saturated or unsaturated radical, -CO -NR'R "" where NR'R "is either an alkyl or acyl substituted with NR'R" as defined above) or R 3 'may be selected from the phenyl or phenylalkyl radicals substituted on the radical phenyl by one or more radicals (selected from alkyl, which may be substituted with an alkoxy or alkylthio radical, which may itself optionally contain a carboxy radical or a radical NR'R "as defined above, or selected from the acyloxy radical, which may be substituted with NR'R ", defined as above), or R 3 'may be selected from an alkyl or cycloalkyl radical, optionally substituted (by a carboxylic radical , carboxyalkyldisulfanyl or via the radical NR'R ", -CH 2 -NR'R", -CO-NR'R ", or via the radical alkoxycarbonyl, alk oxy or alkyldisulfanyl optionally substituted with NR'R "or -CO-NR'R" "where NR'R" is defined as before) or R 3 'may be selected from among heterocyclyl radicals , saturated or unsaturated, with 3 to 8 moieties optionally substituted (by alkyl or acyl optionally substituted by NR'R ") and the bond - - - denotes a single bond (stereochemistry 27R) or a double bond, as well as with its acid addition salts. 2. A derivative according to claim A group according to claim 1, characterized in that - R 1 is a fluorine, chlorine, bromine or iodine atom or an azide or thiocyanate radical, - R 2 is a methyl radical, - R 3 is a hydrogen atom or a R 3 '-CO radical, in which R 3' is a phenyl or phenylalkyl unsubstituted or substituted on the phenyl radical (by one or more radicals selected from alkyl optionally containing the radical NR'R ", in which the radicals R 'and R", identical or different, may a being hydrogen atoms or alkyl radicals which can form together with the nitrogen atom to which they are bound a heterocyclyl radical, saturated or unsaturated, of 3 to 8 members, possibly containing another heteroatom selected from oxygen, sulfur or nitrogen, said heterocycle being itself substituted with one or more radicals (alkyl, hydroxyalkyl, alkoxyalkyl, alkoxycalrbonylalkyl, aryl, heterocyclyl, heterocyclylalkyl, saturated or unsaturated, 3 to 8 members or -CH 2 -CO-NR'R ''), or R 'and optionally R' 'hydroxyalkyl, phenyl, heterocyclylalkyl, 3 to 8 membered saturated or unsaturated, -CO-NR'R' ', where NR'R' 'is as previously defined, either alkyl or acyl substituted with NR'R ", as defined above, or R 3 'may be a phenyl radical substituted with one or more radicals (selected from alkyl which may be substituted with an alkoxy radical) or an alkylthio itself containing a carboxyl radical or a radical NR'R "as defined above, or selected from acyloxy radicals which may be substituted with NR'R" as defined above, or R 3 'may be selected from among alkyl or cycloalkyl radicals, optionally substituted (by a carboxylic, carboxylalkyldisulfanyl radical or by the radical NR'R ", CH 2 -R'R", -CO-NR'R "or by an alkoxycarbonyl radical , alkoxy or alkyldisulfanyl, optionally substituted with NR'R "or -CO-NR'R", wherein NR'R '' is defined as before) or R3 'may be selected from heterocyclyl radicals, saturated or unsaturated, with 3 to 8 members optionally substituted (by alkyl or acyl optionally substituted with NR itself) 'R'), it is understood that heterocycles are selected from among pyrrolidinyl, imidazolyl, pyridyl, piperidinyl, piperazinyl or morpholyl, and - a bond - - - denotes a single bond (27R stereochemistry) or wi double order. as well as their acid addition salts. 3. A derivative according to claim A compound according to claim 1 or 2, characterized in that it is (16R) -16-deoxy-16-fluoro-pristinamycin IIB. 4. A derivative according to claim A composition according to claim 1 or 2, characterized in that it is (16R) -16-deoxy-16-thiocyanatopristinamycin IIB. 5. A derivative according to claim 1 A compound according to claim 1 or 2, characterized in that it is (16R) -16-deoxy-16-chloropristinamycin IIB. 6. A derivative according to claim A compound according to claim 1 or 2, characterized in that it is (16R) -16-azido-16-deoxy-pristinamycin IIB. 7. A derivative according to claim A compound according to claim 1 or 2, characterized in that it is (16R) -16-deoxy-16-fluoro pristinamycin IIA. 8. A process for the preparation of a streptogramin derivative from group A as defined in claim 1, 1, characterized in that it is halogenated, converted into azide or converted into a thiocyanate derivative of streptotramine of the general formula: where R2 is defined as before, the bond - - - denotes a single bond ( the stereochemistry 27R) or a double bond, the hydroxyl function of which in position 14 has previously been protected and then removes the protecting radical and where appropriate to obtain a streptogramin derivative from group A as defined in claim 1. Where R 3 is other than hydrogen, introduces a residue e of an aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic or heterocyclyl aliphatic ester, which may be substituted with (R 3), and transformed into acid addition salt. 9. The method according to claim Process according to claim 8, characterized in that the operation is carried out in the presence of sulfur trifluoride or in the presence of sulfur tetrafluoride with a reagent such as a tetraalkylammonium halide, nitride or thiocyanate, trialkylbenzylammonium or trialkylphenylammonium or with a halide, nitride or alkali metal, which has been optionally added with a cyclic ether. 10. The method according to claim 8. The method of claim 8, characterized in that the fluorination process employs a fluorinating agent selected from sulfur fluoride, hexafluoropropyl diethylamine or N- (chloro-2-trifluoro-1,1,2-ethyl) diethylamine. 11. The method according to claim A process according to claim 8, 9 or 10, characterized in that the esterification is carried out by reaction of an acid or a reactive acid derivative in the presence or absence of a coupling agent such as a carbodiimide, and a tertiary amine, and optionally a catalyst such as 4-N-dimethylaminopyridine at a temperature of -40 to + 80 ° C in an organic solvent such as an amide, pyridine, halogenated solvent or ether. 12. The method according to claim The process according to claim 8, 9 or 11, characterized in that the aminosulfur trifluoride can be selected from diethylaminosulfur trifluoride, bis (2-methoxyethyl) aminosulfur trifluoride or morpholino sulfur trifluoride. 13. A pharmaceutical composition comprising a group A streptogramin derivative as defined in claim 1; 1, pure or in combination with at least one derivative of a group B streptogramin, if appropriate in the form of a salt, and / or in combination with one or more compatible and pharmaceutically acceptable diluents or adjuvants. 14. A composition according to claim 1 13, characterized in that the streptogramin derivative from group B is selected from among the natural ingredients: pristinamycin IA, pristinamycin IB, pristinamycin IC, pristinamycin ID, pristinamycin IE, pristinamycin IF, pristinamycin IG, virginiamycin S1, vernamycin S1, vernamycin S1, S3 B or C, ethamycins or among the semi-synthetic derivatives of the general formula: in which: 1) Rb, Rc, Re and Rf are hydrogen atoms, Rd is a hydrogen atom or a dimethylamino radical, and Ra is a radical of the structure -CH 2 R'a, where R'a is a pyrrolidinyl-3-thio, piperidyl-3 (or -4) -thio radical, which may be substituted with alkyl, alkyl substituted with 1 or 2 hydroxysulfonyl, alkylamino groups, dialkylamino (which themselves may be optionally substituted with mercapto or dialkylamino) or substituted with 1 or 2 optionally substituted piperazine, morpholine, thiomorpholine, piperidine, pyrrolidinyl-1, piperidyl-2, -3 rings, or -4 or a pyrrolide ynyl-2 or -3 (which may be substituted by alkyl) or Ra is a radical of structure = CHR'a where R'a is a group a pyrrolidinyl-3-amino, piperidinyl-3 (or -4) amino, pyrrolidinyl-3-oxy, piperidyl-3 (or -4) -oxy, piperidyl-3 (or -4) -thio which may be substituted with alkyl, or R'a is an alkylamino group a, alkoxy or alkylthio, substituted by 1 or 2 hydroxysulfonyl, alkylamino, dialkylamino groups (themselves optionally substituted by dialkylamino) or by trialkylammonium, imidazolyl-4 or -5, or by 1 or 2 optionally substituted piperazine rings, morpholino, thiomorpholine, piperidine, pyrrolidinyl-1, piperidinyl-1, -3 or -4, or pyrrolidinyl-2 or -3 (which may be alkyl substituted), or Ra is a quinuclidinyl-3 (or -4) thiomethyl radical or 2) Ra is a hydrogen atom, aa) or Rb, Re and Rf are hydrogen atoms, Rd is -NHCH 3 or -N (CH 3) 2 and Rc isa chlorine or bromine atom or is an alkenyl radical containing from 3 to 5 carbon atoms (if Rd is -N (CH 3) 2), b) or Rb, Rd, Re and Rf are a hydrogen and Rc is halogen or amino monoalkyl, aminodualkyl, alkoxy, trifluoromethyloxy, thioalkyl, C 1 -C 3 -alkyl or trihalomethyl radical, c) or Rb, Rc, Re and Rf are hydrogen and Rd is halogen or ethylamine, diethylamine or methylethylamine radical, alkoxy or trifluoromethyloxy, thioalkyl, C 1 -C 6 -alkyl, aryl or trihalomethyl, d) or Rb, Re and Rf mean a hydrogen atom, and Rc is a halogen or a radical amino monoalkyl or aminodualkyl, alkoxy or trifluoromethyloxy, thioalkyl, C 1 -C 3 -alkyl, and Rd is halogen or amino, amino monoalkyl or amino dialkyl, alkoxy or trifluoromethyloxy, thioalkyl, C 1 -C 6 -chloroalkyl or tri-chloro alkyl or Rc, Re and Rf are denoted by is a hydrogen atom, and Rb and Rd represent a methyl radical, or moreover, among semisynthetic derivatives of the general formula: in which: Y is a nitrogen atom or a radical = CR 3 -, R 1 is a hydrogen atom, 1 to 8 carbon atoms) alkenyl (2 to 8 carbon atoms), cycloalkyl (3 to 8 carbon atoms), saturated or unsaturated heterocyclyl (3 to 8 carbon atoms) ), phenyl, phenyl substituted (by one or more halogen atoms or by hydroxyl, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, alkylamino or dialkylamino radicals) or NR'R '', where R 'and R' ', identical or different, may be hydrogen atoms or alkyl radicals (containing from 1 to 3 carbon atoms) or may form, together with the nitrogen atom to which they are attached, a heterocyclic ring of 3 to 8 members, optionally containing another heteroatom selected from oxygen, sulfur or e manually substituted nitrogen (via an alkyl radical, alkenyl (containing from 2 to 8 carbon atoms), cycloalkyl (containing from 3 to 6 carbon atoms), saturated or unsaturated heterocyclyl (4 to 6 members), benzyl, phenyl or a substituted phenyl as defined above for R 1), or when Y is the radical = CR 3 -, R 1 may also be halo methyl, hydroxymethyl, alkoxymethyl, alkylthiomethyl in which the alkyl portion is optionally substituted with NR'R ", alkylsulfinylmethyl, alkylsulfonylmethyl, acyloxymethyl, benzoyloxymethyl, cyclopropylaminomethyl or - (CH 2) nNR'R" (where n is an integer from 1 to 4 and R 'and R '' are defined as above), or if R 3 is a hydrogen atom then R 1 can be either formyl, carboxyl, alkoxycarbonyl or -CONR'R '', where R 'and R' 'are as defined above, or when Y is a nitrogen atom, Ri may also be the radical -XR °, where X is an oxygen or sulfur atom, a sulfinyl radical A radical or sulfonyl radical or an NH radical, and R ° is an alkyl radical (containing from 1 to 8 carbon atoms), cycloalkyl (containing from 3 to 6 carbon atoms), saturated or unsaturated heterocyclyl (containing 3 to 8 members) , heterocyclylmethyl (3 to 8 members), in which the heterocyclyl part is attached to the methyl radical via a carbon atom, phenyl, phenyl substituted by one or more halogen atoms or by hydroxyl, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amine, alkylamino or dialkylamino) or the radical - (CH 2) n NR'R '' where R 'and R' 'are defined as above, and n is the number that an integer from 2 to 4, or if X is NH, then R ° may also be c a hydrogen atom, R 2 is a hydrogen atom or an alkyl radical (containing from 1 to 3 carbon atoms), R 3 represents a hydrogen atom or an alkyl, carboxy, alkoxycarbonyl or carbamoyl radical of the structure -CO-NR'R '', wherein R 'and R '' are defined as before, Ra is a methyl or ethyl radical, and Rb, Rc and Rd have the following meanings: 1) Rb and Rc are hydrogen atoms and Rd is a hydrogen atom or a methylamino or dimethylamino radical, 2 ) Rb is hydrogen, Rc is hydrogen, chlorine or bromine or is alkenyl (containing from 3 to 5 C atoms), and Rd is -NMe-R "", where R "" is alkyl, hydroxyalkyl (containing from 2 to 4C) or alkenyl (containing from 2 to 8C) optionally substituted with phenyl, cycloalkylmethyl (containing from 3 to 6C in the cycloalkyl group), benzyl, benzyl (with one or more halogen atoms or hydroxy, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amine, alkylamine or dialkylamino radicals), heterocyclylmethyl or heterocyclylethyl, in which some of the heterocyclyl are saturated or unsaturated and contain from 5 to 6 parts or 2 heteroats ohms selected from sulfur, oxygen or nitrogen optionally substituted with an alkyl, alkenyl radical (containing from 2 to 8 carbon atoms), cycloalkyl (containing from 3 to 6 carbon atoms), saturated or unsaturated heterocyclyl (containing 4 to 6 units), phenyl, substituted phenyl as previously defined for R 1, or benzyl), or R "" "is cyanomethyl or -CH 2 CORe, where either Re is OR'e, with wherein R'e is hydrogen, alkyl (2 to 6 carbon atoms), benzyl or heterocyclylmethyl wherein the heterocyclyl portion is 5 or 6 members and 1 or 2 heteroatoms selected from sulfur, oxygen or nitrogen, or Re is an alkylamino, alkylmethylamino, heterocyclylamino or heterocyclylmethylamino radical in which the heterocyclyl moiety is saturated and contains 5 or 6 units and 1 or 2 heteroatoms selected from sulfur, oxygen or nitrogen optionally substituted with an alkyl radical. benzyl or alkoxycarbonyl, 3) Rb is a hydrogen atom, Rd is a -NHCH 3 or N (CH 3) 2 radical, and Rc is a chlorine or bromine atom or is an alkenyl radical (containing from 3 to 5C) (if Rd is - N (CH 3) 2), 4) Rb and Rd are hydrogen atoms, and Rc is halogen, or alkylamino or dialkylamino, alkoxy, trifluoromethoxy, thioalkyl, alkyl (containing 1 to 6C) or trichloromethyl, 5 ) Rb and Rc are hydrogen atoms, and Rd is halogen or ethylamino, diethylamino or methylethylamino, alkoxy or trifluoromethoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkyl (containing aces from 1 to 6C), phenyl or trihalomethyl, 6) Rb is a hydrogen atom and Rc is a halogen atom, or an alkylamino or di-alkylamino, alkoxy or trifluoromethoxy, thioalkyl, alkyl (containing from 1 to 3C) radical, and Rd is a halogen atom or an amine, alkylamino or dialkylamino, alkoxy radical or trifle uoromethoxy, thioalkyl, alkyl (containing from 1 to 6C) or trihalomethyl, 7) Rc is a hydrogen atom, and Rb and Rd denote a methyl radical, as well as their salts. 6.00 from PL PL PL